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Overview {#bph14749-sec-0003}
--------

Ion channels are pore‐forming proteins that allow the flow of ions across membranes, either plasma membranes, or the membranes of intracellular organelles \[<http://www.ncbi.nlm.nih.gov/pubmed/2452140?dopt=AbstractPlus>\]. Many ion channels (such as most Na, K, Ca and some Cl channels) are gated by voltage but others (such as certain K and Cl channels, TRP channels, ryanodine receptors and IP~3~ receptors) are relatively voltage‐insensitive and are gated by second messengers and other intracellular and/or extracellular mediators. As such, there is some blurring of the boundaries between "ion channels" and "ligand‐gated channels" which are compiled separately in the Guide. Resolution of ion channel structures, beginning with K channels \[<http://www.ncbi.nlm.nih.gov/pubmed/9525859?dopt=AbstractPlus>\] then Cl channels \[<http://www.ncbi.nlm.nih.gov/pubmed/11796999?dopt=AbstractPlus>\] and most recently Na channels \[<http://www.ncbi.nlm.nih.gov/pubmed/21743477?dopt=AbstractPlus>\] has greatly improved understanding of the structural basis behind ion channel function. Many ion channels (*e.g.*, K, Na, Ca, HCN and TRP channels) share several structural similarities. These channels are thought to have evolved from a common ancestor and have been classfied together as the "voltage‐gated‐like (VGL) ion channel chanome" (see \[<http://www.ncbi.nlm.nih.gov/pubmed/16382097?dopt=AbstractPlus>\]). Other ion channels, however, such as Cl channels, aquaporins and connexins, have completely different structural properties to the VGL channels, having evolved quite separately.

Currently, ion channels (including ligand‐gated ion channels) represent the second largest target for existing drugs after G protein‐coupled receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus>\]. However, the advent of novel, faster screening techniques for compounds acting on ion channels \[<http://www.ncbi.nlm.nih.gov/pubmed/18356919?dopt=AbstractPlus>\] suggests that these proteins represent promising targets for the development of additional, novel therapeutic agents for the near future.

Family structure {#bph14749-sec-0004}
----------------

[S143 Ligand‐gated ion channels](#bph14749-sec-0005){ref-type="sec"}

[S144 5‐HT~3~ receptors](#bph14749-sec-0007){ref-type="sec"}

[S146 Acid‐sensing (proton‐gated) ion channels (ASICs)](#bph14749-sec-0012){ref-type="sec"}

[S148 Epithelial sodium channel (ENaC)](#bph14749-sec-0016){ref-type="sec"}

[S149 GABA~A~ receptors](#bph14749-sec-0020){ref-type="sec"}

[S155 Glycine receptors](#bph14749-sec-0024){ref-type="sec"}

[S158 Ionotropic glutamate receptors](#bph14749-sec-0028){ref-type="sec"}

[S164 IP~3~ receptor](#bph14749-sec-0036){ref-type="sec"}

[S165 Nicotinic acetylcholine receptors](#bph14749-sec-0040){ref-type="sec"}

[S168 P2X receptors](#bph14749-sec-0044){ref-type="sec"}

[S170 ZAC](#bph14749-sec-0048){ref-type="sec"}

[S171 Voltage‐gated ion channels](#bph14749-sec-0052){ref-type="sec"}

[S171 CatSper and Two‐Pore channels](#bph14749-sec-0055){ref-type="sec"}

[S173 Cyclic nucleotide‐regulated channels](#bph14749-sec-0059){ref-type="sec"}

[S175 Potassium channels](#bph14749-sec-0065){ref-type="sec"}

[S175 Calcium‐ and sodium‐activated potassium channels](#bph14749-sec-0067){ref-type="sec"}

[S178 Inwardly rectifying potassium channels](#bph14749-sec-0070){ref-type="sec"}

[S182 Two P domain potassium channels](#bph14749-sec-0072){ref-type="sec"}

[S185 Voltage‐gated potassium channels](#bph14749-sec-0075){ref-type="sec"}

[S189 Ryanodine receptors](#bph14749-sec-0078){ref-type="sec"}

[S190 Transient Receptor Potential channels](#bph14749-sec-0082){ref-type="sec"}

[S204 Voltage‐gated calcium channels](#bph14749-sec-0105){ref-type="sec"}

[S207 Voltage‐gated proton channel](#bph14749-sec-0109){ref-type="sec"}

[S208 Voltage‐gated sodium channels](#bph14749-sec-0113){ref-type="sec"}

[S210 Other ion channels](#bph14749-sec-0117){ref-type="sec"}

[S210 Aquaporins](#bph14749-sec-0118){ref-type="sec"}

[S212 Chloride channels](#bph14749-sec-0121){ref-type="sec"}

[S213 ClC family](#bph14749-sec-0123){ref-type="sec"}

[S215 CFTR](#bph14749-sec-0126){ref-type="sec"}

[S216 Calcium activated chloride channel](#bph14749-sec-0129){ref-type="sec"}

[S217 Maxi chloride channel](#bph14749-sec-0132){ref-type="sec"}

[S218 Volume regulated chloride channels](#bph14749-sec-0135){ref-type="sec"}

[S219 Connexins and Pannexins](#bph14749-sec-0140){ref-type="sec"}

[S221 Piezo channels](#bph14749-sec-0144){ref-type="sec"}

[S222 Sodium leak channel, non‐selective](#bph14749-sec-0148){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=976>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=977>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=697> {#bph14749-sec-0005}
===========================================================================

Overview {#bph14749-sec-0006}
--------

Ligand‐gated ion channels (LGICs) are integral membrane proteins that contain a pore which allows the regulated flow of selected ions across the plasma membrane. Ion flux is passive and driven by the electrochemical gradient for the permeant ions. These channels are open, or gated, by the binding of a neurotransmitter to an orthosteric site(s) that triggers a conformational change that results in the conducting state. Modulation of gating can occur by the binding of endogenous, or exogenous, modulators to allosteric sites. LGICs mediate fast synaptic transmission, on a millisecond time scale, in the nervous system and at the somatic neuromuscular junction. Such transmission involves the release of a neurotransmitter from a pre‐synaptic neurone and the subsequent activation of post‐synaptically located receptors that mediate a rapid, phasic, electrical signal (the excitatory, or inhibitory, post‐synaptic potential). However, in addition to their traditional role in phasic neurotransmission, it is now established that some LGICs mediate a tonic form of neuronal regulation that results from the activation of extra‐synaptic receptors by ambient levels of neurotransmitter. The expression of some LGICs by nonexcitable cells is suggestive of additional functions.

By convention, the LGICs comprise the excitatory, cationselective, nicotinic acetylcholine \[<http://www.ncbi.nlm.nih.gov/pubmed/20055696?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\], 5‐HT3 \[<http://www.ncbi.nlm.nih.gov/pubmed/18761359?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20621123?dopt=AbstractPlus>\], ionotropic glutamate \[<http://www.ncbi.nlm.nih.gov/pubmed/18765242?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\] and P2X receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18657557?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18851707?dopt=AbstractPlus>\] and the inhibitory, anion‐selective, GABAA \[<http://www.ncbi.nlm.nih.gov/pubmed/19828786?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>\] and glycine receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18721822?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21557733?dopt=AbstractPlus>\]. The nicotinic acetylcholine, 5‐HT~3~, GABA~A~ and glycine receptors (and an additional zinc‐activated channel) are pentameric structures and are frequently referred to as the Cysloop receptors due to the presence of a defining loop of residues formed by a disulphide bond in the extracellular domain of their constituent subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/20096941?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20849671?dopt=AbstractPlus>\]. However, the prokaryotic ancestors of these receptors contain no such loop and the term pentameric ligand‐gated ion channel (pLGIC) is gaining acceptance in the literature \[<http://www.ncbi.nlm.nih.gov/pubmed/19646860?dopt=AbstractPlus>\]. The ionotropic glutamate and P2X receptors are tetrameric and trimeric structures, respectively. Multiple genes encode the subunits of LGICs and the majority of these receptors are heteromultimers. Such combinational diversity results, within eachclass of LGIC,in a widerangeof receptors withdiffering pharmacological and biophysical properties and varying patternsof expression within the nervous system and other tissues. The LGICs thus present attractive targets for new therapeutic agents with improved discrimination between receptor isoforms and a reduced propensity for off‐target effects. The development of novel, faster screening techniques for compounds acting on LGICs \[<http://www.ncbi.nlm.nih.gov/pubmed/18356919?dopt=AbstractPlus>\] will greatly aid in the development of such agents.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=68> {#bph14749-sec-0007}
==========================================================================

Overview {#bph14749-sec-0008}
--------

The 5‐HT~3~ receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on 5‐Hydroxytryptamine (serotonin) receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/7938165?dopt=AbstractPlus>\]) is a ligand‐gated ion channel of the Cys‐loop family that includes the zinc‐activated channels, nicotinic acetylcholine, GABA~A~ and strychnine‐sensitive glycine receptors. The receptor exists as a pentamer of 4TM subunits that form an intrinsic cation selective channel \[<http://www.ncbi.nlm.nih.gov/pubmed/18761359?dopt=AbstractPlus>\]. Five human 5‐HT~3~ receptor subunits have been cloned and homo‐oligomeric assemblies of 5‐HT~3~A and hetero‐oligomeric assemblies of 5‐HT~3~A and 5‐HT~3~B subunits have been characterised in detail. The 5‐HT~3~C ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24003](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24003), <http://www.uniprot.org/uniprot/Q8WXA8>), 5‐HT~3~D ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24004](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24004), <http://www.uniprot.org/uniprot/Q70Z44>) and 5‐HT~3~E ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24005](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24005), <http://www.uniprot.org/uniprot/A5X5Y0>) subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/14597179?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12801637?dopt=AbstractPlus>\], like the 5‐HT~3~B subunit, do not form functional homomers, but are reported to assemble with the 5‐HT~3~A subunit to influence its functional expression rather than pharmacological profile \[<http://www.ncbi.nlm.nih.gov/pubmed/19012743?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17392525?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20522555?dopt=AbstractPlus>\]. 5‐HT~3~A, ‐C, ‐D, and ‐E subunits also interact with the chaperone RIC‐3 which predominantly enhances the surface expression of homomeric 5‐HT~3~A receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/20522555?dopt=AbstractPlus>\]. The co‐expression of 5‐HT~3~A and 5‐HT~3~C‐E subunits has been demonstrated in human colon \[<http://www.ncbi.nlm.nih.gov/pubmed/21192076?dopt=AbstractPlus>\]. A recombinant hetero‐oligomeric 5‐HT~3~AB receptor has been reported to contain two copies of the 5‐HT~3~A subunit and three copies of the 5‐HT~3~B subunit in theorderB‐B‐A‐B‐A\[<http://www.ncbi.nlm.nih.gov/pubmed/16116092?dopt=AbstractPlus>\], butthis is inconsistent with recent reports which show at least one A‐A interface \[<http://www.ncbi.nlm.nih.gov/pubmed/20409468?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21708905?dopt=AbstractPlus>\]. The 5‐HT~3~B subunit imparts distinctive biophysical properties upon hetero‐oligomeric 5‐HT~3~AB versus homo‐oligomeric 5‐HT~3~A recombinant receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/9950429?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10521471?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10854267?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18597859?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12867984?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16194573?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12623220?dopt=AbstractPlus>\], influences the potency of channel blockers, but generally has only a modest effect upon the apparent affinity of agonists, or the affinity of antagonists (\[<http://www.ncbi.nlm.nih.gov/pubmed/11489465?dopt=AbstractPlus>\], but see \[<http://www.ncbi.nlm.nih.gov/pubmed/14625088?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19131665?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10521471?dopt=AbstractPlus>\]) which may be explained by the orthosteric binding site residing at an interface formed between 5‐HT~3~A subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/20409468?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21708905?dopt=AbstractPlus>\]. However, 5‐HT~3~A and 5‐HT~3~AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles \[<http://www.ncbi.nlm.nih.gov/pubmed/18187416?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17360702?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16081679?dopt=AbstractPlus>\]. The potential diversity of 5‐HT~3~ receptors is increased by alternative splicing of the genes HTR3A and E \[<http://www.ncbi.nlm.nih.gov/pubmed/11111833?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7683998?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21345729?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18466097?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17392525?dopt=AbstractPlus>\]. In addition, the use of tissue‐specific promoters driving expression from differenttranscriptional start sites has beenreported for the*HTR3A, HTR3B,HTR3D* and *HTR3E* genes, which could result in 5‐HT~3~ subunits harbouring different N‐termini \[<http://www.ncbi.nlm.nih.gov/pubmed/18597859?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21345729?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17010535?dopt=AbstractPlus>\]. To date, inclusion of the 5‐HT~3~A subunit appears imperative for 5‐HT~3~ receptor function.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=378><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=379>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=373>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=374><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=373>Selective agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2287>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2287> \[<http://www.ncbi.nlm.nih.gov/pubmed/8848005?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9950429?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9463477?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10204690?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=218> \[<http://www.ncbi.nlm.nih.gov/pubmed/8848005?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9950429?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9463477?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4316> \[<http://www.ncbi.nlm.nih.gov/pubmed/8891244?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2284> \[<http://www.ncbi.nlm.nih.gov/pubmed/8848005?dopt=AbstractPlus>\]Antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=241> (p*K* ~i~ 6--6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11489465?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8818349?dopt=AbstractPlus>\]Selective antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7486> (p*K* ~i~ 10.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20724042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2296> (p*K* ~i~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17652911?dopt=AbstractPlus>\], (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2289> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11489465?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2300> (p*K* ~i~ ∼8.6--8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8818349?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> (p*K* ~i~ 8.5--8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9463477?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2290> (p*K* ~i~ ∼7.8--8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11489465?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8818349?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (pIC~50~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21059362?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (pIC~50~ 2.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21059362?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (pIC~50~ 2.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/21059362?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (pIC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21505038?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4323> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10381768?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21505038?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (pIC~50~ 3.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21505038?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (pIC~50~ 3.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/21505038?dopt=AbstractPlus>\]Labelled ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2305> (Antagonist) (p*K* ~d~ 9.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2303> (Antagonist) (p*K* ~d~ 8.6--9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/17652911?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9463477?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2292> (Antagonist) (p*K* ~d~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11489465?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8818349?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4074> (Antagonist) (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8994113?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4087> (Antagonist) (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8419547?dopt=AbstractPlus>\]Functional Characteristicsγ= 0.4‐0.8 pS \[+ 5‐HT3B, γ= 16 pS\]; inwardly rectifying current \[+ 5‐HT3B, rectification reduced\]; n~H~ 2‐3 \[+ 5‐HT3B 1‐2\]; relative permeability to divalent cations reduced by co‐expression of the 5‐HT3B subunitγ= 0.4‐0.8 pS \[+ 5‐HT3B, γ= 16 pS\]; inwardly rectifying current \[+ 5‐HT3B, rectification reduced\]; n~H~ 2‐3 \[+ 5‐HT3B 1‐2\]; relative permeability to divalent cations reduced by co‐expression of the 5‐HT3B subunit

Subunits {#bph14749-sec-0009}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=373><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=374><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=375><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=376><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=377>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5297](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5297), <http://www.uniprot.org/uniprot/P46098>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5298](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5298), <http://www.uniprot.org/uniprot/O95264>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24003](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24003), <http://www.uniprot.org/uniprot/Q8WXA8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24004](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24004), <http://www.uniprot.org/uniprot/Q70Z44>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24005](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24005), <http://www.uniprot.org/uniprot/A5X5Y0>Functional Characteristicsγ= 0.4‐0.8 pS \[+ 5‐HT~3~B, γ= 16 pS\]; inwardly rectifying current \[+ 5‐HT~3~B, rectification reduced\]; nH 2‐3 \[+ 5‐HT~3~B 1‐2\]; relative permeability to divalent cations reduced by co‐expression of the 5‐HT3B subunitγ= 0.4‐0.8 pS \[+ 5‐HT~3~B, γ= 16 pS\]; inwardly rectifying current \[+ 5‐HT~3~B, rectification reduced\]; nH 2‐3 \[+ 5‐HT~3~B 1‐2\]; relative permeability to divalent cations reduced by co‐expression of the 5‐HT3B subunit------

Comments {#bph14749-sec-0010}
--------

Quantitative data in the table refer to homooligomeric assemblies of the human 5‐HT~3~A subunit, or the receptor native to human tissues. Significant changes introduced by co‐expression of the 5‐HT~3~B subunit are indicated in parenthesis. Although not a selective antagonist, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5458> displays multimodal and subunit‐dependent antagonism of 5‐HT~3~ receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/19131665?dopt=AbstractPlus>\]. Similarly, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4323>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> are not selective for 5‐HT~3~ receptors (*e.g.*\[<http://www.ncbi.nlm.nih.gov/pubmed/21059362?dopt=AbstractPlus>\]). The anti‐malarial drugs <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4252>and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510> exerta modestly more potent block of 5‐HT~3~A versus 5‐HT~3~AB receptor‐mediated responses \[<http://www.ncbi.nlm.nih.gov/pubmed/18311193?dopt=AbstractPlus>\]. Knownbetterasa partial agonistof nicotinic acetylcholine α4β2 receptors, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5459> is also an agonist of the 5‐HT~3~A receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/21775477?dopt=AbstractPlus>\]. Human \[<http://www.ncbi.nlm.nih.gov/pubmed/8848005?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7565620?dopt=AbstractPlus>\], rat \[<http://www.ncbi.nlm.nih.gov/pubmed/7509203?dopt=AbstractPlus>\], mouse \[<http://www.ncbi.nlm.nih.gov/pubmed/1718042?dopt=AbstractPlus>\], guinea‐pig \[<http://www.ncbi.nlm.nih.gov/pubmed/9463477?dopt=AbstractPlus>\] ferret \[<http://www.ncbi.nlm.nih.gov/pubmed/10884508?dopt=AbstractPlus>\] and canine \[<http://www.ncbi.nlm.nih.gov/pubmed/16647053?dopt=AbstractPlus>\] orthologues of the 5‐HT~3~A receptor subunit have been cloned that exhibit intraspecies variations in receptor pharmacology. Notably, most ligands display significantly reduced affinities at the guinea‐pig 5‐HT~3~ receptor in comparison with other species. In addition to the agents listed in the table, native and recombinant 5‐HT~3~ receptors are subject to allosteric modulation by extracellular divalent cations, alcohols, several general anaesthetics and 5‐hydroxy‐ and halidesubstituted indoles (see reviews \[<http://www.ncbi.nlm.nih.gov/pubmed/8936343?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17073663?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17373882?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20621123?dopt=AbstractPlus>\]).
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=118> {#bph14749-sec-0012}
===========================================================================

Overview {#bph14749-sec-0013}
--------

Acid‐sensing ion channels (ASICs, **nomenclatureas agreed by [NC‐IUPHAR]{.ul}** \[<http://www.ncbi.nlm.nih.gov/pubmed/25287517?dopt=AbstractPlus>\]) are members of a Na^+^ channel superfamily that includes the epithelial Na^+^ channel (ENaC), the FMRF‐amide activated channel (FaNaC) of invertebrates, the degenerins (DEG) of *Caenorhabitis elegans*, channels in *Drosophila melanogaster* and 'orphan' channels that include BLINaC \[<http://www.ncbi.nlm.nih.gov/pubmed/10457052?dopt=AbstractPlus>\] and INaC \[<http://www.ncbi.nlm.nih.gov/pubmed/10767424?dopt=AbstractPlus>\] that have also been named BASICs, for bile acidactivated ion channels \[<http://www.ncbi.nlm.nih.gov/pubmed/24365967?dopt=AbstractPlus>\]. ASIC subunits contain two TM domains and assemble as homo‐ or hetero‐trimers \[<http://www.ncbi.nlm.nih.gov/pubmed/24507937?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19641589?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17882215?dopt=AbstractPlus>\] to form proton‐gated, voltage‐insensitive, Na^+^ permeable, channels (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/25585135?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23783197?dopt=AbstractPlus>\]). Splice variants of ASIC1 \[termed ASIC1a (ASIC, ASICα, BNaC2α) \[<http://www.ncbi.nlm.nih.gov/pubmed/9062189?dopt=AbstractPlus>\], ASIC1b (ASICβ, BNaC2β) \[<http://www.ncbi.nlm.nih.gov/pubmed/9707631?dopt=AbstractPlus>\] and ASIC1b2 (ASICβ2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11588592?dopt=AbstractPlus>\]; note that ASIC1a is also permeable to Ca^2+^\] and ASIC2 \[termed ASIC2a (MDEG1, BNaC1α, BNC1α) \[<http://www.ncbi.nlm.nih.gov/pubmed/9037075?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8626462?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8631835?dopt=AbstractPlus>\] and ASIC2b (MDEG2, BNaC1β) \[<http://www.ncbi.nlm.nih.gov/pubmed/9368048?dopt=AbstractPlus>\]\] have been cloned. Unlike ASIC2a (listed in table), heterologous expression of ASIC2b alone does not support H^+^‐gated currents. A third member, ASIC3 (DRASIC, TNaC1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9261094?dopt=AbstractPlus>\], has been identified. A fourth mammalian member of the family (ASIC4/SPASIC) does not support a proton‐gated channel in heterologous expression systems and is reported to downregulate the expression of ASIC1a and ASIC3 \[<http://www.ncbi.nlm.nih.gov/pubmed/10923674?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18662336?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10852210?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25828470?dopt=AbstractPlus>\]. ASIC channels are primarily expressed in central and peripheral neurons including nociceptors where they participate in neuronal sensitivity to acidosis. They have also been detected in taste receptor cells (ASIC13), photoreceptors and retinal cells (ASIC1‐3), cochlear hair cells (ASIC1b), testis (hASIC3), pituitary gland (ASIC4), lung epithelial cells (ASIC1a and ‐3), urothelial cells, adipose cells (ASIC3), vascular smooth muscle cells (ASIC1‐3), immune cells (ASIC1,‐3 and ‐4) and bone (ASIC1‐3). A neurotransmitter‐like function of protons has been suggested, involving postsynaptically located ASICs of the CNS in functions such as learning and fear perception \[<http://www.ncbi.nlm.nih.gov/pubmed/24889629?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24952644?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19945383?dopt=AbstractPlus>\], responses to focal ischemia \[<http://www.ncbi.nlm.nih.gov/pubmed/17127388?dopt=AbstractPlus>\] and to axonal degeneration in autoimmune inflammation in a mouse model of multiple sclerosis \[<http://www.ncbi.nlm.nih.gov/pubmed/17994101?dopt=AbstractPlus>\], as well as seizures \[<http://www.ncbi.nlm.nih.gov/pubmed/18536711?dopt=AbstractPlus>\] and pain \[<http://www.ncbi.nlm.nih.gov/pubmed/22094702?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21508231?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18923424?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23034652?dopt=AbstractPlus>\]. Heterologously expressed heteromultimers form ion channels with differences in kinetics, ion selectivity, pH‐ sensitivity and sensitivity to blockers that resemble some of the native proton activated currents recorded from neurones \[<http://www.ncbi.nlm.nih.gov/pubmed/10842183?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18256271?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10829030?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9368048?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=684><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=685>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:100](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:100), <http://www.uniprot.org/uniprot/P78348>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:99](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:99), <http://www.uniprot.org/uniprot/Q16515>Endogenous activatorsExtracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ (ASIC1a) (pEC~50~ ∼6.2--6.8), Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ (ASIC1b) (pEC~50~ ∼5.1--6.2)Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ (pEC~50~ ∼4.1--5)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10306> (ASIC1a) (pIC~50~ ∼9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/28320947?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4292> (ASIC1a) (pIC~50~ 9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10305> (ASIC1a) (pIC~50~ ∼8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/28327374?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (ASIC1a) (pIC~50~ ∼8.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10308> (ASIC1a) (pIC~50~ ∼7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/23034652?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10308> (ASIC1b) (pIC~50~ ∼7) \[<http://www.ncbi.nlm.nih.gov/pubmed/23624383?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10307> (ASIC1a & ASIC1b) (pIC~50~ ∼6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/29134638?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2525> (ASIC1b) (pIC~50~ ∼5.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4116> (ASIC1a) (pIC~50~ ∼5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16061325?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2525> (ASIC1a) (pIC~50~ ∼5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (ASIC1a) (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145> (ASIC1a) (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186> (ASIC1a) (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (ASIC1a) (pIC~50~ ∼4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (ASIC1b) (pIC~50~ 4.6--4.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194> (ASIC1a) (pIC~50~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11588175?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713> (ASIC1a) (pIC~50~ ∼3.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (ASIC1a) (pIC~50~ ∼3.2)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10307> (pIC~50~ ∼6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/29134638?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (pIC~50~ 4.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4116> (pIC~50~ ∼4.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (pIC~50~ ∼4.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (pIC~50~ ∼3)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4073> (ASIC1a) (p*K* ~d~ 9.7)--Functional Characteristics**ASIC1a**: γ= 14pS P~Na~/P~K~ = 5‐13, P~Na~/P~Ca~ =2.5 rapid activation rate (5.8‐13.7 ms), rapid inactivation rate (1.2‐4 s) @ pH 6.0, slow recovery (5.3‐13s) @ pH 7.4 **ASIC1b**: γ= 19 pS P~Na~/P~K~ =14.0, P~Na~ PCa rapid activation rate (9.9 ms), rapid inactivation rate (0.9‐1.7 s) @ pH 6.0, slow recovery (4.4‐7.7 s) @ pH 7.4= γ10.4‐13.4 pS P~Na~/PK =10, P~Na~/PCa = 20 rapid activation rate, moderate inactivation rate (3.3‐5.5 s) @ pH 5CommentsASIC1a and ASIC1b are activated by the heteromeric Texas coral snake toxin MitTx, with pEC~50~ values of 8 and 7.6 respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/22094702?dopt=AbstractPlus>\].ASIC2 is also blocked by diarylamidines

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:101](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:101), <http://www.uniprot.org/uniprot/Q9UHC3>Endogenous activatorsExtracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ (transient component) (pEC~50~ ∼6.2--6.7), Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ (sustained component) (pEC~50~ ∼3.5--4.3)Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4203> (largly non‐desensitizing; at pH 7.4) (pEC~50~ ∼3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4137> (at pH 7.4) (pEC~50~ ∼2.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127> (at pH 7.4) (pEC~50~ ∼2)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4135> (transient component only) (pIC~50~ 7.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10307> (pIC~50~ ∼6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/29134638?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4116> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22778804?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (transient component) (pIC~50~ ∼5.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (transient component only ‐ sustained component enhanced by 200*μ*M amiloride at pH 4) (pIC~50~ 4.2--4.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (pIC~50~ 4.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ 4.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139> (sustained component) (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11588175?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714> (sustained component) (pIC~50~ 4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4306> (sustained component) (pIC~50~ 3.6)Functional Characteristicsγ= 13‐15 pS; biphasic response consisting of rapidly inactivating transient and sustained components; very rapid activation (\<5 ms) and inactivation (0.4 s); fast recovery (0.4‐0.6 s) @ pH 7.4, transient component partially inactivated at pH 7.2CommentsASIC3 is activated by Mit‐Toxin (pEC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22094702?dopt=AbstractPlus>\].

Comments {#bph14749-sec-0014}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4292> (PcTx1) inhibits ASIC1a by increasing the affinity toH+and promoting channel desensitization \[<http://www.ncbi.nlm.nih.gov/pubmed/15955877?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10829030?dopt=AbstractPlus>\]. PcTx1 has little effect on ASIC2a, ASIC3 or ASIC1a expressed as a heteromultimer with either ASIC2a, or ASIC3 but does inhibit ASIC1a expressed as a heteromultimer with ASIC2b \[<http://www.ncbi.nlm.nih.gov/pubmed/21715637?dopt=AbstractPlus>\]. PcTx1 and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10305> potentiate ASIC1b currents \[<http://www.ncbi.nlm.nih.gov/pubmed/16505147?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28327374?dopt=AbstractPlus>\]. ASIC1containing homo‐ and heteromers are inhibited by Mambalgins, toxins contained in the black mamba venom, which induce in ASIC1a an acidic shift of the pH dependence of activation \[<http://www.ncbi.nlm.nih.gov/pubmed/23034652?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10306> is highly selective for ASIC1a with very little activity at ASIC1b. It inhibits channel activation and is very slowly reversible \[<http://www.ncbi.nlm.nih.gov/pubmed/28320941?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4135> most potently blocks homomeric ASIC3 channels, but also ASIC2b+ASIC3, ASIC1b+ASIC3, and ASIC1a+ASIC3 heteromeric channels with IC~50~ values of 117 nM, 900 nM and 2 *μ*M, respectively. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4135> has no effect on ASIC1a or ASIC2a+ASIC3, however, it does potentiate ASIC1b and ASIC2a homomers in the low micromolar range(1‐10*μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/15044953?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17113616?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29134638?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4135>however also inhibits voltage‐gated Na^+^ channels \[<http://www.ncbi.nlm.nih.gov/pubmed/21943094?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22972919?dopt=AbstractPlus>\]. IC~50~ value for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4116> was determined using high throughput electrophysiology on human ASIC3 expressed in HEK293 cells \[<http://www.ncbi.nlm.nih.gov/pubmed/22778804?dopt=AbstractPlus>\]. The pEC~50~ values for proton activation of ASIC channels are influenced by numerous factors including extracellular di‐ and poly‐valent ions, Zn^2+^, protein kinase C and serine proteases (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/25287517?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23783197?dopt=AbstractPlus>\]). Rapid acidification is required for activation of ASIC1 and ASIC3 due to fast inactivation/desensitization. pEC~50~ values for H^+^‐activation of either transient, or sustained, currents mediated by ASIC3 vary in the literature and may reflect species and/or methodological differences \[<http://www.ncbi.nlm.nih.gov/pubmed/9886053?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9744806?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9261094?dopt=AbstractPlus>\]. The transient ASIC current component is Na^+^‐selective (PNa/PK of about 10) \[<http://www.ncbi.nlm.nih.gov/pubmed/9261094?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25114023?dopt=AbstractPlus>\] whereas the sustained current component that is observed with ASIC3 and some ASIC heteromers is non‐selective between Na^+^ and K^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/9744806?dopt=AbstractPlus>\]. The reducing agents dithiothreitol (DTT) and glutathione (GSH) increase ASIC1a currents expressed in CHO cells and ASIC‐like currents in sensory ganglia and central neurons \[<http://www.ncbi.nlm.nih.gov/pubmed/16085050?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16707785?dopt=AbstractPlus>\] whereas oxidation, through the formation of intersubunit disulphide bonds, reduces currents mediated by ASIC1a \[<http://www.ncbi.nlm.nih.gov/pubmed/19218436?dopt=AbstractPlus>\]. ASIC1a is also irreversibly modulated by extracellular serine proteases, such as trypsin, through proteolytic cleavage \[<http://www.ncbi.nlm.nih.gov/pubmed/16282326?dopt=AbstractPlus>\]. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are direct inhibitors of ASIC currents (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/25613302?dopt=AbstractPlus>\]). Extracellular Zn^2+^ potentiates proton activation of homomeric and heteromeric channels incorporating ASIC2a, but not homomeric ASIC1a or ASIC3 channels \[<http://www.ncbi.nlm.nih.gov/pubmed/11457851?dopt=AbstractPlus>\]. However, removal of contaminating Zn^2+^ by chelation reveals a high affinity block of homomeric ASIC1a and heteromeric ASIC1a+ASIC2 channels by Zn^2+^ indicating complex biphasic actions of the divalent \[<http://www.ncbi.nlm.nih.gov/pubmed/15470133?dopt=AbstractPlus>\]. Nitric oxide potentiates submaximal currents activated by H^+^ mediated by ASIC1a, ASIC1b, ASIC2a and ASIC3 \[<http://www.ncbi.nlm.nih.gov/pubmed/18045919?dopt=AbstractPlus>\]. Ammonium ions activate ASIC channels (most likely ASIC1a) in midbrain dopaminergic neurones: that may be relevant to neuronal disorders associated with hyperammonemia \[<http://www.ncbi.nlm.nih.gov/pubmed/16847263?dopt=AbstractPlus>\]. The positive modulation of homomeric, heteromeric and native ASIC channels by the peptide <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4195> and related substances, such as neuropeptides FF and SF, is reviewed in detail in \[<http://www.ncbi.nlm.nih.gov/pubmed/25592215?dopt=AbstractPlus>\]. Inflammatory conditions and particular pro‐inflammatory mediators such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> induce overexpression of ASIC‐encoding genes and enhance ASIC currents \[<http://www.ncbi.nlm.nih.gov/pubmed/18923424?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12486159?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17258862?dopt=AbstractPlus>\]. The sustained current component mediated by ASIC3 is potentiated by hypertonic solutions in a manner that is synergistic with the effect of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> \[<http://www.ncbi.nlm.nih.gov/pubmed/18923424?dopt=AbstractPlus>\]. ASIC3 is partially activated by the lipids lysophosphatidylcholine (LPC) and arachidonic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/26772186?dopt=AbstractPlus>\]. Mit‐Toxin, which is contained in the venom of the Texas coral snake, activates several ASIC subtypes \[<http://www.ncbi.nlm.nih.gov/pubmed/22094702?dopt=AbstractPlus>\]. Selective activation of ASIC3 by GMQ at a site separate from the proton binding site is potentiated by mild acidosis and reduced extracellular Ca^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/20920791?dopt=AbstractPlus>\].

Further reading on Acid‐sensing (proton‐gated) ion channels (ASICs) {#bph14749-sec-0015}
-------------------------------------------------------------------

Baron A *et al.* (2015) Pharmacology of acid‐sensing ion channels ‐ Physiological and therapeutical perspectives. *Neuropharmacology* **94**: 19‐35 <https://www.ncbi.nlm.nih.gov/pubmed/25613302?dopt=AbstractPlus>

Boscardin E *et al.* (2016) The function and regulation of acid‐sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19. *Br. J. Pharmacol.* **173**: 2671‐701 <https://www.ncbi.nlm.nih.gov/pubmed/27278329?dopt=AbstractPlus>

Cristofori‐Armstrong B *et al.* (2017) Acid‐sensing ion channel (ASIC) structure and function: Insights from spider, snake and sea anemone venoms. *Neuropharmacology* **127**: 173‐184 <https://www.ncbi.nlm.nih.gov/pubmed/28457973?dopt=AbstractPlus>

Gründer S *et al.* (2015) Biophysical properties of acid‐sensing ion channels (ASICs). *Neuropharmacology* **94**: 9‐18 <https://www.ncbi.nlm.nih.gov/pubmed/25585135?dopt=AbstractPlus>

Hanukoglu I. (2017) ASIC and ENaC type sodium channels: conformational states and the structures of the ion selectivity filters. *FEBS J.* **284**: 525‐545 <https://www.ncbi.nlm.nih.gov/pubmed/27580245?dopt=AbstractPlus>

Kellenberger S *et al.* (2015) International Union of Basic and Clinical Pharmacology. XCI. structure, function, and pharmacology of acid‐sensing ion channels and the epithelial Na+ channel. *Pharmacol. Rev.* **67**: 1‐35 <https://www.ncbi.nlm.nih.gov/pubmed/25287517?dopt=AbstractPlus>

Rash LD. (2017) Acid‐Sensing Ion Channel Pharmacology, Past, Present, and Future .... *Adv. Pharmacol.* **79**: 35‐66 <https://www.ncbi.nlm.nih.gov/pubmed/28528673?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=122> {#bph14749-sec-0016}
===========================================================================

Overview {#bph14749-sec-0017}
--------

The epithelial sodium channels (ENaC) are located on the apical membrane of epithelial cells in the distal kidney tubules, lung, respiratory tract, male and female reproductive tracts, sweat and salivary glands, placenta, colon and some other organs \[<http://www.ncbi.nlm.nih.gov/pubmed/7810611?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7806569?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26772908?dopt=AbstractPlus>\]. In these epithelia, ENaC allows flow of Na^+^ ions from the extracellular fluid in the lumen into the epithelial cell. Na^+^ ions are then pumped out of the cytoplasm into the interstitial fluid by the Na^+^/K^+^ ATPase located on the basolateral membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/16139686?dopt=AbstractPlus>\]. As Na^+^ is one of the major electrolytes in the extracellular fluid (ECF), osmolarity change initiated by the Na^+^ flow is accompanied by a flow of water accompanying Na^+^ ions \[<http://www.ncbi.nlm.nih.gov/pubmed/18509340?dopt=AbstractPlus>\]. Thus, ENaC has a central role in the regulation of ECF volume and blood pressure, especially via its function in the kidney \[<http://www.ncbi.nlm.nih.gov/pubmed/25287517?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25540145?dopt=AbstractPlus>\]. The expression of ENaC subunits, hence its activity, is regulated by the renin‐angotensin‐aldosterone system, and other factors that are involved in electrolyte homeostasis \[<http://www.ncbi.nlm.nih.gov/pubmed/8770001?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22038262?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25540145?dopt=AbstractPlus>\]. In the respiratory tract and female reproductive tract large segments of the tracts are covered by multi‐ciliated cells. In these cells ENaC has been shown to be located along the entire length of the cilia \[<http://www.ncbi.nlm.nih.gov/pubmed/22207244?dopt=AbstractPlus>\]. Cilial location greatly increases ENaC density per cell surface and allows ENaC to serve as a sensitive regulator of osmolarity of the periciliary fluid throughout the whole depth of the fluid bathing the cilia \[<http://www.ncbi.nlm.nih.gov/pubmed/22207244?dopt=AbstractPlus>\]. In contrast to ENaC, CFTR that is defective in cystic fibrosis is not located on non‐cilial cell‐surface \[<http://www.ncbi.nlm.nih.gov/pubmed/22207244?dopt=AbstractPlus>\]. Thus, ENaC function is also essential for the clearance of respiratory airways, transport of germ cells, fertilization, implantation and cell migration \[<http://www.ncbi.nlm.nih.gov/pubmed/22207244?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8389146?dopt=AbstractPlus>\]. ENaC has beenrecently localized in the germinal epithelium of the testis, Sertoli cells, spermatozoa, along the epididymis ducts, and smooth muscle cells \[<http://www.ncbi.nlm.nih.gov/pubmed/29453757?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/30659401?dopt=AbstractPlus>\]. Evidence has been provided that rare mutations in ENaC are associated with female infertility \[<http://www.ncbi.nlm.nih.gov/pubmed/29885352?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=742>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=739>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=738>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=741>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4305> (pEC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18326490?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4280> (pIC~50~ 8.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145> (pIC~50~ ∼8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (pIC~50~ 6.7--7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4329> (pIC~50~ ∼5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8107805?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14500741?dopt=AbstractPlus>\]

Subunits {#bph14749-sec-0018}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=738><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=739><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=741><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=740>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10599](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10599), <http://www.uniprot.org/uniprot/P37088>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10600](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10600), <http://www.uniprot.org/uniprot/P51168>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10602](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10602), <http://www.uniprot.org/uniprot/P51170>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10601](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10601), <http://www.uniprot.org/uniprot/P51172>

Further reading on Epithelial sodium channel (ENaC) {#bph14749-sec-0019}
---------------------------------------------------
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Hanukoglu I. (2017) ASIC and ENaC type sodium channels: conformational states and the structures of the ion selectivity filters. *FEBS J.* **284**: 525‐545 <https://www.ncbi.nlm.nih.gov/pubmed/27580245?dopt=AbstractPlus>
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=72> {#bph14749-sec-0020}
==========================================================================

Overview {#bph14749-sec-0021}
--------

The GABA~A~ receptor is a ligand‐gated ion channel of the Cys‐loop family that includes the nicotinic acetylcholine, 5‐HT~3~ and strychnine‐sensitive glycine receptors. GABA~A~ receptor‐mediated inhibition within the CNS occurs by fast synaptic transmission, sustained tonic inhibition and temporally intermediate events that have been termed 'GABA~A~, slow' \[<http://www.ncbi.nlm.nih.gov/pubmed/21145601?dopt=AbstractPlus>\]. GABA~A~ receptors exist as pentamers of 4TM subunits that form an intrinsic anion selective channel. Sequences of six α, three β, three γ, one *δ*, three *ρ*, one*∈*, one *π* and one ϑ GABA~A~ receptor subunits have been reported in mammals \[<http://www.ncbi.nlm.nih.gov/pubmed/18760291?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17175817?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23038269?dopt=AbstractPlus>\]. The *π*‐subunit is restricted to reproductive tissue. Alternatively spliced versions of many subunits exist (e.g. α4‐ and α6‐ (both not functional) α5‐, β2‐, β3‐ and γ2), along with RNA editing of the α3 subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/19909284?dopt=AbstractPlus>\]. The three *ρ*‐subunits, (*ρ*1‐3) function as either homo‐or hetero‐oligomeric assemblies \[<http://www.ncbi.nlm.nih.gov/pubmed/15566397?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11239575?dopt=AbstractPlus>\]. Receptors formed from *ρ*‐subunits, because of their distinctive pharmacology that includes insensitivity tobicuculline, benzodiazepines and barbiturates, have sometimes been termed GABA~C~ receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/11239575?dopt=AbstractPlus>\], **but they are classified as GABA~A~ receptors by [NC‐IUPHAR]{.ul} on the basis of structural and functional criteria** \[<http://www.ncbi.nlm.nih.gov/pubmed/9647870?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18760291?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>\].

Many GABA~A~ receptor subtypes contain α‐, β‐ and γ‐subunits with the likely stoichiometry 2α.2β.1γ\[<http://www.ncbi.nlm.nih.gov/pubmed/12126658?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>\]. It is thought that the majority of GABA~A~ receptors harbour a single type of α‐ and β ‐subunit variant. The α1β2γ2 hetero‐oligomer constitutes the largest population of GABA~A~ receptors in the CNS, followed by the α2β3γ2 and α3β3γ2 isoforms. Receptors that incorporate the α4‐ α5‐or α6‐subunit, or the β1‐, γ1‐, γ3‐, *δ*‐, *∈*‐ and ϑ‐subunits, are less numerous, but they may nonetheless serve important functions. For example, extrasynaptically located receptors that contain α6‐ and *δ*‐subunits in cerebellar granule cells, or an α4‐ and *δ*‐subunit in dentate gyrus granule cells and thalamic neurones, mediate a tonic current that is important for neuronal excitability in response to ambient concentrations of GABA \[<http://www.ncbi.nlm.nih.gov/pubmed/19828786?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15738957?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15331240?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15111008?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24027497?dopt=AbstractPlus>\]. GABA binding occurs at the β+/α‐ subunit interface and the homologous γ+/α‐ subunits interface creates the benzodiazepinesite. A second site for benzodiazepine binding hasrecently been postulated to occur at the α+/β‐ interface (\[<http://www.ncbi.nlm.nih.gov/pubmed/21248110?dopt=AbstractPlus>\]; reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/21189125?dopt=AbstractPlus>\]). The particular α‐and γ‐subunit isoforms exhibit marked effects on recognition and/or efficacy at the benzodiazepine site. Thus, receptors incorporating either α4‐ or α6‐subunits are not recognised by 'classical' benzodiazepines, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> (but see \[<http://www.ncbi.nlm.nih.gov/pubmed/20638393?dopt=AbstractPlus>\]). The trafficking, cell surface expression, internalisation and function of GABA~A~ receptors and their subunits are discussed in detail in several recent reviews \[<http://www.ncbi.nlm.nih.gov/pubmed/17083446?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18382465?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21555068?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21742794?dopt=AbstractPlus>\] but one point worthy of note is that receptors incorporating the γ2 subunit (except when associated with α5) cluster at the postsynaptic membrane (but may distribute dynamically between synaptic and extrasynaptic locations), whereas as those incorporating the d subunit appear to be exclusively extrasynaptic.

[**NC‐IUPHAR**]{.ul} \[<http://www.ncbi.nlm.nih.gov/pubmed/9647870?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>\] class the GABA~A~ receptors according to their subunit structure, pharmacology and receptor function. Currently, eleven native GABA~A~ receptors are classed as conclusively identified (*i.e*., α1β2γ2, α1βγ2, α3βγ2, α4βγ2, α4β2*δ*, α4β3*δ*, α5βγ2, α6βγ2, α6β2*δ*, α6β3*δ* and *ρ*) with further receptor isoforms occurring with high probability, or only tentatively \[<http://www.ncbi.nlm.nih.gov/pubmed/18760291?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>\]. It is beyond the scope of this Guide to discuss the pharmacology of individual GABA~A~ receptor isoforms in detail; such information can be gleaned in the reviews \[<http://www.ncbi.nlm.nih.gov/pubmed/9647870?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12171573?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15974965?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12126658?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12469353?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17394533?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18760291?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18790874?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17175817?dopt=AbstractPlus>\] and \[<http://www.ncbi.nlm.nih.gov/pubmed/21309116?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18482097?dopt=AbstractPlus>\]. Agents that discriminate between α‐subunit isoforms are noted in the table and additional agents that demonstrate selectivity between receptor isoforms, for example via β‐subunit selectivity, are indicated in the text below. The distinctive agonist and antagonist pharmacology of *ρ* receptors is summarised in the table and additional aspects are reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/15566397?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20963487?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21428815?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11239575?dopt=AbstractPlus>\].

Several high‐resolution cryo‐electron microscopy structures have been described in which the full‐length human α1β3γ2L GABA~A~ receptor in lipid nanodiscs is bound to the channel‐blocker picrotoxin, the competitive antagonist bicuculline, the agonist GABA (γ‐aminobutyric acid), and the classical benzodiazepines alprazolam and diazepam \[<http://www.ncbi.nlm.nih.gov/pubmed/30602790?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=404><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4075](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4075), <http://www.uniprot.org/uniprot/P14867>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4076](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4076), <http://www.uniprot.org/uniprot/P47869>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Endogenous allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4192> \[benzodiazepine site\] (Antagonist) (p*K* ~i~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9767648?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6963> (Positive) (p*K* ~i~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> \[benzodiazepine site\] (Positive) (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8632757?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364> \[benzodiazepine site\] (Positive) (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7111> \[benzodiazepine site\] (Positive) (pEC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/12408715?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4094> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4095> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4179> \[benzodiazepine site\] (Inverse agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4192> \[benzodiazepine site\] (Antagonist) (p*K* ~i~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9767648?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6963> (Positive) (p*K* ~i~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> \[benzodiazepine site\] (Positive) (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8632757?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7111> \[benzodiazepine site\] (Positive) (pEC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12408715?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364> \[benzodiazepine site\] (Positive) (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4094> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4095> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4179> \[benzodiazepine site\] (Inverse agonist)Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4348> (Positive) (p*K* ~i~ 7.4--7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8719414?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8813598?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241> \[benzodiazepine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4347> \[benzodiazepine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4221> \[benzodiazepine site\] (Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4277> \[benzodiazepine site\] (Full agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241> \[benzodiazepine site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4327> \[benzodiazepine site\] (Partial agonist)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4360> \[benzodiazepine site\] (Allosteric modulator, Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4362> \[benzodiazepine site\] (Allosteric modulator, Positive)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4360> \[benzodiazepine site\] (Allosteric modulator, Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist)Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=407>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4077](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4077), <http://www.uniprot.org/uniprot/P34903>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4078](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4078), <http://www.uniprot.org/uniprot/P48169>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\] (low efficacy)Selective agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\] (relatively high efficacy)Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Endogenous allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4192> \[benzodiazepine site\] (Antagonist) (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9767648?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6963> (Positive) (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> \[benzodiazepine site\] (Positive) (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8632757?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364> \[benzodiazepine site\] (Positive) (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2551039?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7111> \[benzodiazepine site\] (Positive) (pEC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12408715?dopt=AbstractPlus>\]^,^ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4095> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4179> \[benzodiazepine site\] (Inverse agonist)--Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4094> \[benzodiazepine site\] (higher affinity), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241> \[benzodiazepine site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4297> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4326> \[benzodiazepine site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4327> \[benzodiazepine site\] (Partial agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296> \[benzodiazepine site\] (Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146> \[benzodiazepine site\] (Full agonist)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4360> \[benzodiazepine site\] (Allosteric modulator, Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4365> \[benzodiazepine site\] (Allosteric modulator, Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist)Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> are not active at this subunit. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4365> selectively labels α4‐subunit‐containing receptors in the presence of a saturating concentration of a 'classical' benzodiazepine (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364>)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=409>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4079](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4079), <http://www.uniprot.org/uniprot/P31644>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4080](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4080), <http://www.uniprot.org/uniprot/Q16445>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\] (low efficacy)Selective agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\] (relatively high efficacy)Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> \[GABA site\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Endogenous allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4321> (Potentiation)Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4192> \[benzodiazepine site\] (Antagonist) (p*K* ~i~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9767648?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> \[benzodiazepine site\] (Positive) (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8632757?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7111> \[benzodiazepine site\] (Positive) (pEC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12408715?dopt=AbstractPlus>\]^,^ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4094> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4179> \[benzodiazepine site\] (Inverse agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4192> \[benzodiazepine site\] (Partial agonist) (p*K* ~i~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9767648?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4146> \[benzodiazepine site\] (Full agonist)Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4095> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4238> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4241> \[benzodiazepine site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4257> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4299> \[benzodiazepine site\] (Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4301> \[benzodiazepine site\] (Inverse agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4296> \[benzodiazepine site\] (Full agonist)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4364> \[benzodiazepine site\] (Selective Binding) (p*K* ~d~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9353361?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4363> \[benzodiazepine site\] (Allosteric modulator, Inverse agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4360> \[benzodiazepine site\] (Allosteric modulator, Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4367> \[benzodiazepine site\] (Allosteric modulator, Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4368> \[benzodiazepine site\] (Allosteric modulator, Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4369> \[anion channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4366> \[benzodiazepine site\] (Allosteric modulator, Mixed), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4365> \[benzodiazepine site\] (Allosteric modulator, Full agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4083> \[GABA site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4090> \[GABA site\] (Agonist)Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193> are not active at this subunit. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4365> selectively labels α6‐subunit‐containing receptors in the presence of a saturating concentration of a 'classical' benzodiazepine (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364>)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=410><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=411><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=412>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4081](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4081), <http://www.uniprot.org/uniprot/P18505>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4082](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4082), <http://www.uniprot.org/uniprot/P47870>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4083](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4083), <http://www.uniprot.org/uniprot/P28472>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Allosteric modulators----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7336> (Binding) (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8773466?dopt=AbstractPlus>\]Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=413><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=414><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4086](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4086), <http://www.uniprot.org/uniprot/Q8N1C3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4087](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4087), <http://www.uniprot.org/uniprot/P18507>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4088](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4088), <http://www.uniprot.org/uniprot/Q99928>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/9508826?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=416><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=417><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=418><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=419>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4084](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4084), <http://www.uniprot.org/uniprot/O14764>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4085](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4085), <http://www.uniprot.org/uniprot/P78334>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14454](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14454), <http://www.uniprot.org/uniprot/Q9UN88>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4089](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4089), <http://www.uniprot.org/uniprot/O00591>Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\]------Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits, incorporation of a *δ* or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4090](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4090), <http://www.uniprot.org/uniprot/P24046>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4091](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4091), <http://www.uniprot.org/uniprot/P28476>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17969](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17969), <http://www.uniprot.org/uniprot/A8MPY1>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\] (Partial agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\] (Partial agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4226> \[GABA site\] (Partial agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> \[GABA site\] (Partial agonist)Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4067> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4107> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4067> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4107> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4067> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4107> \[GABA site\]Antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4227> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4287> \[GABA site\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4096> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4099> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4328> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4143> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4096> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4099> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4328> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4143> \[GABA site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4096> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4099> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4328> \[GABA site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4143> \[GABA site\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4320>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051>Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> is not active at this subunit<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> is not active at this subunit<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> is not active at this subunit

Comments {#bph14749-sec-0022}
--------

The potency and efficacy of many GABA agonists vary between GABA~A~ receptor isoforms \[<http://www.ncbi.nlm.nih.gov/pubmed/12171573?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23385381?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12469353?dopt=AbstractPlus>\]. For example, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4322> is a partial agonist at receptors with the subunit composition α4β3γ2, but elicits currents in excess of those evoked by GABA at the α4β3*δ* receptor where GABA itself is a low efficacy agonist \[<http://www.ncbi.nlm.nih.gov/pubmed/14645489?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12145096?dopt=AbstractPlus>\]. The antagonists <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2312> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4197> differ in their ability to suppress spontaneous openings of the GABA~A~ receptor, the former being more effective \[<http://www.ncbi.nlm.nih.gov/pubmed/10455284?dopt=AbstractPlus>\]. The presence of the γ subunit within the heterotrimeric complex reduces the potency and efficacy of agonists \[<http://www.ncbi.nlm.nih.gov/pubmed/16272218?dopt=AbstractPlus>\]. The GABA~A~ receptor contains distinct allosteric sites that bind barbiturates and endogenous (*e.g.*, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108>) and synthetic (*e.g.*, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5461>) neuroactive steroids in a diastereo‐ or enantio‐selective manner \[<http://www.ncbi.nlm.nih.gov/pubmed/15959466?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17531325?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17560657?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19199916?dopt=AbstractPlus>\]. Picrotoxinin and TBPS act at an allosteric site within the chloride channel pore to negatively regulate channel activity; negative allosteric regulation by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5462> derivatives also involves the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> site, whereas positive allosteric regulation by such compounds is proposed to occur at a distinct locus. Many intravenous (*e.g.*, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5463>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5464>) and inhalational (*e.g*., <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2505>) anaesthetics and alcohols also exert a regulatory influence upon GABA~A~ receptor activity \[<http://www.ncbi.nlm.nih.gov/pubmed/18201756?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21194017?dopt=AbstractPlus>\]. Specific amino acid residues within GABA~A~ receptor α‐ and β‐subunits that influence allosteric regulation by anaesthetic and non‐anaesthetic compounds havebeen identified \[<http://www.ncbi.nlm.nih.gov/pubmed/16126282?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17560657?dopt=AbstractPlus>\]. Photoaffinity labelling of distinct amino acid residues within purified GABA~A~ receptors by the etomidate derivative, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5404>, has also been demonstrated \[<http://www.ncbi.nlm.nih.gov/pubmed/17093081?dopt=AbstractPlus>\] and this binding subject to positive allosteric regulation by anaesthetic steroids \[<http://www.ncbi.nlm.nih.gov/pubmed/19282280?dopt=AbstractPlus>\]. An array of natural products including flavonoid and terpenoid compounds exert varied actions at GABA~A~ receptors (reviewed in detail in \[<http://www.ncbi.nlm.nih.gov/pubmed/15974965?dopt=AbstractPlus>\]).

In addition to the agents listed in the table, modulators of GABA~A~ receptor activity that exhibit subunit dependent activity include: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5465> \[negative allosteric modulator selective for β1‐ versus β2‐, or β3‐subunit‐containing receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/15100159?dopt=AbstractPlus>\]\]; fragrent dioxane derivatives \[positive allosteric modulators selective for β1‐ versus β2‐, or β3‐subunit‐containing receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/20511229?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5466>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5463>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5467>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2593>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5468>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5469>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5470> \[positive allosteric modulators with selectivity for β2/β3‐ over β1‐subunit‐containing receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18585399?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20718740?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12126658?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5467> \[intrinsic efficacy, *i.e*., potentiation, or inhibition, is dependent upon the identity of the γ1‐3‐, *δ*‐, or *∈*‐subunit co‐assembed with α1‐ and β1‐subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/12367611?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> \[selective blockade of receptors containing an α6‐subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/12021393?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4839> \[selective blockade of receptors containing an α6subunit co‐assembled with β2/β3‐, but not β1‐subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/12126658?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> \[potentiates responses mediated by α1β3γ2L receptors, weakly inhibits α6β3γ2L receptors, and strongly blocks α6β3*δ* and α4β3*δ* receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/12145096?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9203639?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2299> \[selectively potentiates responses mediated by α4β3*δ* and α6β3*δ* receptors versus receptors in which β2 replaces β3, or γ replaces *δ* \[<http://www.ncbi.nlm.nih.gov/pubmed/16814864?dopt=AbstractPlus>\], but see also \[<http://www.ncbi.nlm.nih.gov/pubmed/17591542?dopt=AbstractPlus>\]\]; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4183> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4184> \[selectively potentiate responses mediated by *δ*‐subunitcontaining receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18762200?dopt=AbstractPlus>\]\]. It should be noted that the apparent selectivity of some positive allosteric modulators (*e.g*., neurosteroids such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4108> for *δ*‐subunit‐containing receptors (*e.g.*, α1β3*δ*) may be a consequence of the unusually low efficacy of GABA at this receptor isoform \[<http://www.ncbi.nlm.nih.gov/pubmed/19828786?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14645489?dopt=AbstractPlus>\].

Further reading on GABA~A~ receptors {#bph14749-sec-0023}
------------------------------------
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Braat S *et al.* (2015) The GABA~A~ Receptor as a Therapeutic Target for Neurodevelopmental Disorders. *Neuron* **86**: 1119‐30 <https://www.ncbi.nlm.nih.gov/pubmed/26050032?dopt=AbstractPlus>
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=73> {#bph14749-sec-0024}
==========================================================================

Overview {#bph14749-sec-0025}
--------

The inhibitory glycine receptor (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Glycine Receptors**) is a member of the Cys‐loop superfamily of transmittergated ion channels that includes the zinc activated channels, GABA~A~, nicotinic acetylcholine and 5‐HT~3~ receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18721822?dopt=AbstractPlus>\]. The receptor is expressed either as a homo‐pentamer of α subunits, or a complex now thought to harbour 2α and 3β subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/16805771?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15748848?dopt=AbstractPlus>\], that contain an intrinsic anion channel. Four differentially expressed isoforms of the α‐subunit (α1‐α4) and one variant of the β‐subunit (β1, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4329](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4329), <http://www.uniprot.org/uniprot/P48167>) have been identified by genomic and cDNA cloning. Further diversity originates from alternative splicing of the primary gene transcripts for α1 (α1^INS^ and α1^del^), α2 (α2A and α2B), α3 (α3S and α3L) and β (βΔ7) subunits and by mRNA editing of the α2 and α3 subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/19210758?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15895087?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17145751?dopt=AbstractPlus>\]. Both α2 splicing and α3 mRNA editing can produce subunits (*i.e.*, α2B and α3P185L) with enhanced agonist sensitivity. Predominantly, the mature form of the receptor contains α1 (or α3) and β subunits while the immature form is mostly composed of only α2 subunits. RNA transcripts encoding the α4‐subunit have not been detected in adult humans. The N‐terminal domain of the α‐subunit contains both the agonist and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> binding sites that consist of several discontinuous regions of amino acids. Inclusion of the β‐subunit in the pentameric glycine receptor contributes to agonist binding, reduces single channel conductance and alters pharmacology. The β‐subunit also anchors the receptor, via an amphipathic sequence within the large intracellular loop region, to gephyrin. The latter is a cytoskeletal attachment protein that binds to a number of subsynaptic proteins involved in cytoskeletal structure and thus clusters and anchors hetero‐oligomeric receptors to the synapse \[<http://www.ncbi.nlm.nih.gov/pubmed/16807723?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17504238?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11283747?dopt=AbstractPlus>\]. G‐protein βγ subunits enhance the open state probability of native and recombinant glycine receptors by association with domains within the large intracellular loop \[<http://www.ncbi.nlm.nih.gov/pubmed/17040914?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12858180?dopt=AbstractPlus>\]. Intracellular chloride concentration modulates the kinetics of native and recombinant glycine receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/18987182?dopt=AbstractPlus>\]. Intracellular Ca^2+^ appears to increase native and recombinant glycine receptor affinity, prolonging channel open events, by a mechanism that does not involve phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/11144365?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=423><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=424><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=426>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4326](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4326), <http://www.uniprot.org/uniprot/P23415>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4327](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4327), <http://www.uniprot.org/uniprot/P23416>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4328](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4328), <http://www.uniprot.org/uniprot/O75311>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:31715](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31715), <http://www.uniprot.org/uniprot/Q5JXX5>Selective agonists (potency order)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2379><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2379><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2379>--Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4201> (pIC~50~ 6.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> (p*K* ~i~ 5.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (pIC~50~ 5.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (pIC~50~ 4.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> (p*K* ~i~ 4.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367> (pIC~50~ 3.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=746> (weak inhibition), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4289>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731> (pIC~50~ 7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733> (pIC~50~ 6.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=746> (pIC~50~ 6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4201> (pIC~50~ 5.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> (p*K* ~i~ 5.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (pIC~50~ 5.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> (p*K* ~i~ 4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367> (pIC~50~ 4.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2361> (pIC~50~ 3.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4289>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731> (pIC~50~ 7.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=746> (pIC~50~ 7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733> (pIC~50~ 7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4072> (pIC~50~ 5.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (pIC~50~ 4.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347>--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (pIC~50~ 5.1--6.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2368> (pIC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/8090751?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286> (pIC~50~ 5.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (pIC~50~ 5.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> (pIC~50~ 5.2)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (pIC~50~ 6.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> (pIC~50~ 5.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (pIC~50~ 4.9--5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286> (pIC~50~ 4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2368> (pIC~50~ \>4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8090751?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (pIC~50~ 6.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (pIC~50~ 5.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286> (pIC~50~ 5.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> (block is weaker when β subunit is co‐expressed)--Endogenous allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Potentiation) (pEC~50~ 7.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> (Inhibition) (pIC~50~ 4.8--5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition) (pIC~50~ 4.8), Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> (Inhibition)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Potentiation) (pEC~50~ 6.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> (Inhibition) (pIC~50~ 4.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition) (pIC~50~ 3.4)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> (Inhibition) (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition) (pIC~50~ 3.8)--Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> (Potentiation) (pEC~50~ 7.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731> (Potentiation) (pEC~50~ 6.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> (Potentiation) (pEC~50~ ∼5.5)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> (Potentiation) (pEC~50~ ∼6)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> (Potentiation) (pEC~50~ ∼5.3)--Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2360> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2360> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2360> (Antagonist)--Functional Characteristicsγ = 86 pS (main state); (+ β = 44 pS)γ = 111 pS (main state); (+ β = 54 pS)γ = 105 pS (main state); (+ β = 48)--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4329](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4329), <http://www.uniprot.org/uniprot/P48167>Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (when co‐expressed with the α1 subunit) (pIC~50~ 5.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> (when co‐expressed with the α1 subunit) (p*K* ~i~ 5.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> (when co‐expressed with the α2 subunit) (p*K* ~i~ 5.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> (when co‐expressed with the α2 subunit) (p*K* ~i~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (when co‐expressed with the α3 subunit) (pIC~50~ 4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (when co‐expressed with the α2 subunit) (pIC~50~ 4.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2366> (when co‐expressed with the α1 subunit) (pIC~50~ 3.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4201> (when co‐expressed with the α1 subunit) (pIC~50~ \>3.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4201> (when co‐expressed with the α2 subunit) (pIC~50~ \>3.5)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (when co‐expressed with the α2 subunit) (pIC~50~ 6.1--6.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (when co‐expressed with the α1 subunit) (pIC~50~ 5.6--6.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1862> (when co‐expressed with the α3 subunit) (pIC~50~ 6.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2368> (when co‐expressed with the human α1 subunit) (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/8090751?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2368> (when co‐expressed with the human α2 subunit) (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8090751?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (when co‐expressed with the α3 subunit) (pIC~50~ 5.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286> (when co‐expressed with the α1 subunit) (pIC~50~ 4.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286> (when co‐expressed with the α3 subunit) (pIC~50~ 4.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> (when co‐expressed with the α1 subunit) (pIC~50~ 4.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> (when co‐expressed with the α2 subunit) (pIC~50~ 4.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> (when co‐expressed with the α1 subunit) (pIC~50~ 3.7)Endogenous allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition) (pIC~50~ 4.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (Inhibition) (pIC~50~ 3.7)CommentsLigand interaction data for hetero‐oligomer receptors containing the β subunit are also listed under the α subunit

Comments {#bph14749-sec-0026}
--------

Data in the table refer to homo‐oligomeric assemblies of the α‐subunit, significant changes introduced by coexpression of the β1 subunit are indicated in parenthesis. Not all glycine receptor ligands are listed within the table, but some that may be useful in distinguishing between glycine receptor isoforms are indicated (see detailed view pages for each subunit: <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=423&familyId=73&familyType=IC>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=424&familyId=73&familyType=IC>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425&familyId=73&familyType=IC>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=426&familyId=73&familyType=IC>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427&familyId=73&familyType=IC>). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367>, for example, although not selective antagonists of glycine receptors, are included for this purpose. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> is a potent and selective competitive glycine receptor antagonist with affinities in the range 5--15 nM. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2378> demonstrates comparable potency, but additionally blocks GABA~A~ receptors. There are conflicting reports concerning the ability of cannabinoids to inhibit \[<http://www.ncbi.nlm.nih.gov/pubmed/16107637?dopt=AbstractPlus>\], or potentiate and at high concentrations activate \[<http://www.ncbi.nlm.nih.gov/pubmed/19204413?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19307742?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16332990?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21460829?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18755158?dopt=AbstractPlus>\] glycine receptors. Nonetheless, cannabinoid analogues may hold promise in distinguishing between glycine receptor subtypes \[<http://www.ncbi.nlm.nih.gov/pubmed/18755158?dopt=AbstractPlus>\]. In addition, potentiation of glycine receptor activity by cannabinoids has been claimed to contribute to cannabis‐induced analgesia relying on Ser296/307 (α1/α3) in M3 \[<http://www.ncbi.nlm.nih.gov/pubmed/21460829?dopt=AbstractPlus>\]. Several analogues of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4259> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5477> act as agonists and antagonists of both glycine and GABA~A~ receptors. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4051> acts as an allosteric inhibitor that appears to bind within the pore, and shows strong selectivity towards homomeric receptors. While its components, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4286>, have equal potencies at α1 receptors, their potencies at α2 and α3 receptors differ modestly and may allow some distinction between different receptor types \[<http://www.ncbi.nlm.nih.gov/pubmed/17714449?dopt=AbstractPlus>\]. Binding of picrotoxin within the pore has been demonstrated in the crystal structure of the related *C. elegans* GluCl Cys‐loop receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/21572436?dopt=AbstractPlus>\]. In addition to the compounds listed in the table, numerous agents act as allosteric regulators of glycine receptors (comprehensively reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/12413807?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15383648?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17692006?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21557733?dopt=AbstractPlus>\]). Zn^2+^ acts through distinct binding sites of high‐ and low‐affinity to allosterically enhance channel function at low (\<10 *μ*M) concentrations and inhibits responses at higher concentrations in a subunit selective manner \[<http://www.ncbi.nlm.nih.gov/pubmed/15905212?dopt=AbstractPlus>\]. The effect of Zn^2+^ is somewhat mimicked by Ni^2+^. Endogenous Zn^2+^ is essential for normal glycinergic neurotransmission mediated by α1 subunit‐containing receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/17114051?dopt=AbstractPlus>\]. Elevation of intracellular Ca^2+^ produces fast potentiation of glycine receptor‐mediated responses. Dideoxyforskolin (4 *μ*M) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> (0.2--5 *μ*M) both potentiate responses to low glycine concentrations (15 *μ*M), but act as inhibitors at higher glycine concentrations (100 *μ*M). Additional modulatory agents that enhance glycine receptor function include inhalational, and several intravenous general anaesthetics (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5478>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5464> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5480>) and certain neurosteroids. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2299> and higher order n‐alcohols also enhance glycine receptor function although whether this occurs by a direct allosteric action at the receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/10908659?dopt=AbstractPlus>\], or through βγ subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/20647311?dopt=AbstractPlus>\] is debated. Recent crystal structures of the bacterial homologue, GLIC, have identified transmembrane binding pockets for both anaesthetics \[<http://www.ncbi.nlm.nih.gov/pubmed/21248852?dopt=AbstractPlus>\] and alcohols \[<http://www.ncbi.nlm.nih.gov/pubmed/21730162?dopt=AbstractPlus>\]. Solvents inhaled as drugs of abuse (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5481>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5482>) may act at sites that overlap with those recognising alcohols and volatile anaesthetics to produce potentiation of glycine receptor function. The function of glycine receptors formed as homomeric complexes of α1 or α2 subunits, or hetero‐oligomers of α1/β or α2/β subunits, is differentially affected by the 5‐HT~3~ receptor antagonist tropisetron (ICS 205‐930) which may evoke potentiation (which may occur within the femtomolar range at the homomeric glycine α1 receptor), or inhibition, depending upon the subunit composition of the receptor and the concentrations of the modulator and glycine employed. Potentiation and inhibition by tropeines involves different binding modes \[<http://www.ncbi.nlm.nih.gov/pubmed/19383091?dopt=AbstractPlus>\]. Additional tropeines, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320>, modulate glycine receptor activity.

Further reading on Glycine receptors {#bph14749-sec-0027}
------------------------------------

Burgos CF *et al*. (2016) Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors. *Mol. Pharmacol*. **90**: 318‐25 <https://www.ncbi.nlm.nih.gov/pubmed/27401877?dopt=AbstractPlus>

Dutertre S *et al*. (2012) Inhibitory glycine receptors: an update. *J. Biol. Chem*. **287**: 40216‐23 <https://www.ncbi.nlm.nih.gov/pubmed/23038260?dopt=AbstractPlus>

Lynch JW. (2004) Molecular structure and function of the glycine receptor chloride channel. *Physiol. Rev.* **84**: 1051‐95 <https://www.ncbi.nlm.nih.gov/pubmed/15383648?dopt=AbstractPlus>

Perkins DI *et al*. (2010) Molecular targets and mechanisms for ethanol action in glycine receptors. *Pharmacol. Ther*. **127**: 53‐65 <https://www.ncbi.nlm.nih.gov/pubmed/20399807?dopt=AbstractPlus>

Yevenes GE *et al*. (2011) Allosteric modulation of glycine receptors. *Br. J. Pharmacol*. **164**: 224‐36 <https://www.ncbi.nlm.nih.gov/pubmed/21557733?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=75> {#bph14749-sec-0028}
==========================================================================

Overview {#bph14749-sec-0029}
--------

The ionotropic glutamate receptors comprise members of the NMDA (N‐methyl‐D‐aspartate), AMPA (α‐amino3‐hydroxy‐5‐methyl‐4‐isoxazoleproprionic acid) and kainate receptor classes, named originally according to their preferred, synthetic, agonist \[<http://www.ncbi.nlm.nih.gov/pubmed/10049997?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18765242?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\]. Receptor heterogeneity within each class arises from the homo‐oligomeric, or hetero‐oligomeric, assembly of distinct subunits into cation‐selective tetramers. Each subunit of the tetrameric complex comprises an extracellular amino terminal domain (ATD), an extracellular ligand binding domain (LBD), three transmembrane domains composed of three membrane spans (M1, M3 and M4), a channel lining re‐entrant 'p‐loop' (M2) located between M1 and M3 and an intracellular carboxy‐ terminal domain (CTD) \[<http://www.ncbi.nlm.nih.gov/pubmed/20491632?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22974439?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16554805?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21080238?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\]. The X‐ray structure of a homomeric ionotropic glutamate receptor (GluA2 -- see below) has recently been solved at 3.6Å resolution \[<http://www.ncbi.nlm.nih.gov/pubmed/19946266?dopt=AbstractPlus>\] and although providing the most complete structural information current available may not representative of the subunit arrangement of, for example, the heteromeric NMDA receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/21677647?dopt=AbstractPlus>\]. It is beyond the scope of this supplement to discuss the pharmacology of individual ionotropic glutamate receptor isoforms in detail; such information can be gleaned from \[<http://www.ncbi.nlm.nih.gov/pubmed/17962328?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15494561?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10049997?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17622578?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18793656?dopt=AbstractPlus>, 434, <http://www.ncbi.nlm.nih.gov/pubmed/15731895?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21395862?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23686171?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17088105?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23376022?dopt=AbstractPlus>\]. Agents that discriminate between subunit isoforms are, where appropriate, noted in the tables and additional compounds that distinguish between receptor isoforms are indicated in the text below.

**The classification of glutamate receptor subunits has been re‐addressed by [NC‐IUPHAR]{.ul}** \[<http://www.ncbi.nlm.nih.gov/pubmed/18655795?dopt=AbstractPlus>\]. The scheme developed recommends a nomenclature for ionotropic glutamate receptor subunits that is adopted here.

AMPA and Kainate receptors {#bph14749-sec-0030}
--------------------------

AMPA receptors assemble as homomers, or heteromers, that may be drawn from GluA1, GluA2, GluA3 and GluA4 subunits. Transmembrane AMPA receptor regulatory proteins (TARPs) of class I (i.e. γ2, γ3, γ4 and γ8) act, with variable stoichiometry, as auxiliary subunits to AMPA receptors and influence their trafficking, single channel conductance gating and pharmacology (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/18026130?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21521608?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18514334?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20134027?dopt=AbstractPlus>\]). Functional kainate receptors can be expressed as homomers of GluK1, GluK2 or GluK3 subunits. GluK1‐3 subunits are also capable of assembling into heterotetramers (*e.g*. GluK1/K2; \[<http://www.ncbi.nlm.nih.gov/pubmed/16361114?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20850188?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16847640?dopt=AbstractPlus>\]). Two additional kainate receptor subunits, GluK4 and GluK5, when expressed individually, form high affinity binding sites for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231>, but lack function, but can form heteromers when expressed with GluK1‐3 subunits (*e.g*. GluK2/K5; reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/18793656?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20850188?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16847640?dopt=AbstractPlus>\]). Kainate receptors may also exhibit 'metabotropic' functions \[<http://www.ncbi.nlm.nih.gov/pubmed/16361114?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17981346?dopt=AbstractPlus>\]. As found for AMPA receptors, kainate receptors are modulated by auxiliary subunits (Neto proteins, \[<http://www.ncbi.nlm.nih.gov/pubmed/21709676?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20850188?dopt=AbstractPlus>\]). An important function difference between AMPA and kainate receptors is that the latter require extracellular Na+ and Cl‐ for their activation \[<http://www.ncbi.nlm.nih.gov/pubmed/19822544?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21713670?dopt=AbstractPlus>\]. RNA encoding the GluA2 subunit undergoes extensive RNA editing in which the codon encoding a p‐loop glutamine residue (Q) is converted to one encoding arginine (R). This Q/R site strongly influences the biophysical properties of the receptor. Recombinant AMPA receptors lacking RNA edited GluA2 subunits are: (1) permeable to Ca^2+^; (2) blocked by intracellular polyamines at depolarized potentials causing inward rectification (the latter being reduced by TARPs); (3) blocked by extracellular argiotoxin and Joro spider toxins and (4) demonstrate higher channel conductances than receptors containing the edited form of GluA2 \[<http://www.ncbi.nlm.nih.gov/pubmed/17582328?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12850211?dopt=AbstractPlus>\]. GluK1 and GluK2, but not other kainate receptor subunits, are similarly edited and broadly similar functional characteristics apply to kainate receptors lacking either an RNA edited GluK1, or GluK2, subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/16361114?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20850188?dopt=AbstractPlus>\]. Native AMPA and kainate receptors displaying differential channel conductances, Ca^2+^ permeabilites and sensitivity to block by intracellular polyamines have been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/16713244?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17582328?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17275103?dopt=AbstractPlus>\]. GluA1‐4 can exist as two variants generated by alternative splicing (termed 'flip' and 'flop') that differ in their desensitization kinetics and their desensitization in the presence of cyclothiazide which stabilises the nondesensitized state. TARPs also stabilise the non‐desensitized conformation of AMPA receptors and facilitate the action of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167> \[<http://www.ncbi.nlm.nih.gov/pubmed/18514334?dopt=AbstractPlus>\]. Splice variants of GluK1‐3 also exist which affects their trafficking \[<http://www.ncbi.nlm.nih.gov/pubmed/16361114?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20850188?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4571](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4571), <http://www.uniprot.org/uniprot/P42261>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4572](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4572), <http://www.uniprot.org/uniprot/P42262>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4573](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4573), <http://www.uniprot.org/uniprot/P42263>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4574](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4574), <http://www.uniprot.org/uniprot/P48058>Agonists(<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4070>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4131>(<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4070>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4131>(<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4070>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4131>(<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4070>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4131>Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4209>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210> (active isomer, non‐competitive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4209>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210> (active isomer, non‐competitive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4209>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210> (active isomer, non‐competitive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4209>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4210> (active isomer, non‐competitive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245>Channel blockersextracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4138>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4229> (selective for channels lacking GluA2)extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4138>extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4138>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4229> (selective for channels lacking GluA2)extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4138>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4229> (selective for channels lacking GluA2)Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4248> (Positive) (pEC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249> (Positive) (pEC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167> (Positive) (pEC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4166> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288> (Positive)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249> (Positive) (pEC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4248> (Positive) (pEC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167> (Positive) (pEC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4166> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288> (Positive)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249> (Positive) (pEC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4248> (Positive) (pEC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167> (Positive) (pEC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4166> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288> (Positive)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4248> (Positive) (pEC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249> (Positive) (pEC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167> (Positive) (pEC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11406188?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4166> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133> (Positive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288> (Positive)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4077> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4077> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4077>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4077> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4081>Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4288> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4133> are examples of pyrrolidinones. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4167>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4304>, and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4219> are examples of benzothiadiazides. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4165> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4166> are examples of benzylpiperidines. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4248>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4249> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251> are examples of biarylpropylsulfonamides. Also blocked by intracellular polyamines.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=448><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=449>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4575](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4575), <http://www.uniprot.org/uniprot/Q9ULK0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4576](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4576), <http://www.uniprot.org/uniprot/O43424>

Comments {#bph14749-sec-0031}
--------

GluD1 and GluD2 comprise, on the basis of sequence homology, an 'orphan' class of ionotropic glutamate receptor subunit. They do not form a functional receptor when expressed solely, or in combination with other ionotropic glutamate receptor subunits, in transfected cells \[<http://www.ncbi.nlm.nih.gov/pubmed/12725908?dopt=AbstractPlus>\]. However, GluD2 subunits bind <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> and GluD2 subunits carrying the mutation A654T form a spontaneously open channel that is closed by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> \[<http://www.ncbi.nlm.nih.gov/pubmed/17715062?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4579](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4579), <http://www.uniprot.org/uniprot/P39086>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4580](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4580), <http://www.uniprot.org/uniprot/Q13002>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4581](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4581), <http://www.uniprot.org/uniprot/Q13003>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4582](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4582), <http://www.uniprot.org/uniprot/Q16099>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4583](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4583), <http://www.uniprot.org/uniprot/Q16478>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4185> \[<http://www.ncbi.nlm.nih.gov/pubmed/11160654?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317> \[<http://www.ncbi.nlm.nih.gov/pubmed/10821708?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231> \[<http://www.ncbi.nlm.nih.gov/pubmed/9849663?dopt=AbstractPlus>\], (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4069>, (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4071>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4112>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4140>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4185> \[<http://www.ncbi.nlm.nih.gov/pubmed/11160654?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181> \[<http://www.ncbi.nlm.nih.gov/pubmed/8809152?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317> \[<http://www.ncbi.nlm.nih.gov/pubmed/8996224?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231> \[<http://www.ncbi.nlm.nih.gov/pubmed/8809152?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9849663?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317> \[<http://www.ncbi.nlm.nih.gov/pubmed/18578478?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231> (low potency) \[<http://www.ncbi.nlm.nih.gov/pubmed/18578478?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4185><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4185>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4185>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231>Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4246> \[<http://www.ncbi.nlm.nih.gov/pubmed/9849663?dopt=AbstractPlus>\]--------Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4102>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4123>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4247>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4250>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4258>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4274> (non‐competitive), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4333>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4334><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4102>------Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4162> (Positive)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4162> (Positive)------Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4092> (Antagonist) (p*K* ~d~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20837679?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4085> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4085> (Agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/8996224?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4092> (Antagonist) (p*K* ~d~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20837679?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4085> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4085> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4075> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4085> (Agonist)Comments--Intracellular polyamines are subtype selective channel blockers (GluK3 ≫ GluK2)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4162> are inactive at the GluK3 subunit. Intracellular polyamines are subtype selective channel blockers (GluK3 ≫ GluK2)----

Comments {#bph14749-sec-0032}
--------

All AMPA receptors are additionally activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4231> (and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4181>) with relatively low potency, (EC~50~ 100 *μ*M). Inclusion of TARPs within the receptor complex increases the potency and maximal effect of kainate \[<http://www.ncbi.nlm.nih.gov/pubmed/21521608?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18514334?dopt=AbstractPlus>\]. AMPA is weak partial agonist at GluK1 and at heteromeric assemblies of GluK1/GluK2, GluK1/GluK5 and GluK2/GluK5 \[<http://www.ncbi.nlm.nih.gov/pubmed/18793656?dopt=AbstractPlus>\]. Quinoxalinediones such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5475> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4264> show limited selectivity between AMPA and kainate receptors. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4245> also has kainate (GluK1) receptor activity as has <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4209> (GluK3 and GluK2/GluK3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18793656?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141> is a potent competitive antagonist of AMPA receptors, has a weaker antagonist action at kainate receptors comprising GluK1 subunits, butis devoid of activity at kainate receptors formed from GluK2 or GluK2/GluK5 subunits. The pharmacological activity of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4141> resides with the (S)‐enantiomer. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4123> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4334> may block GluK3, in addition to GluK1 \[<http://www.ncbi.nlm.nih.gov/pubmed/20837679?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18761361?dopt=AbstractPlus>\]. (2S,4R)‐4‐methylglutamate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4317>) is equipotent in activating (and desensitising) GluK1 and GluK2 receptor isoforms and, via the induction of desensitisation at low concentrations, has beenused as a functional antagonist of kainate receptors. Both (2*S*,4*R*)‐4‐methylglutamate and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4246> have agonist activity at NMDA receptors. (2S,4R)‐4‐methylglutamate is also an inhibitor of the glutamate transporters EAAT1 and EAAT2.

NMDA receptors {#bph14749-sec-0033}
--------------

NMDA receptors assemble as obligate heteromers that may be drawn from GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A and GluN3B subunits. Alternative splicing can generate eight isoforms of GluN1 with differing pharmacological properties. Various splice variants of GluN2B, 2C, 2D and GluN3A have also been reported. Activation of NMDA receptors containing GluN1 and GluN2 subunits requires the binding of two agonists, glutamate to the S1 and S2 regions of the GluN2 subunit and glycine to S1 and S2 regions of the GluN1 subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/16474411?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15701057?dopt=AbstractPlus>\]. The minimal requirement for efficient functional expression of NMDA receptors *in vitro* is a di‐heteromeric assembly of GluN1 and at least one GluN2 subunit variant, as a dimer of heterodimers arrangement in the extracellular domain \[<http://www.ncbi.nlm.nih.gov/pubmed/16281028?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21677647?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16554805?dopt=AbstractPlus>\]. However, more complex tri‐heteromeric assemblies, incorporating multiple subtypes of GluN2 subunit, or GluN3 subunits, can be generated*in vitro* and occur*in vivo*. The NMDA receptor channel commonly has a high relative permeability to Ca^2+^ and is blocked, in a voltage‐dependent manner, by Mg^2+^ such that at resting potentials the response is substantially inhibited.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4584](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4584), <http://www.uniprot.org/uniprot/Q05586>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4585](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4585), <http://www.uniprot.org/uniprot/Q12879>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4586](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4586), <http://www.uniprot.org/uniprot/Q13224>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[glycine site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511> \[glutamate site\] (GluN2D \> GluN2C = GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> \[glycine site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> \[glutamate site\] (GluN2D = GluN2B \> GluN2C = GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[glycine site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A)Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4066> \[glycine site\] (Partial agonist), (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216> \[glutamate site\] (Partial agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4066> \[glycine site\] (Partial agonist), (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068> \[glutamate site\] (GluN2D \> GluN2C = GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268> \[glutamate site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216> \[glutamate site\] (GluN2B ≥ GluN2A ≥ GluN2D \> GluN2C; partial agonist at GluN2A and GluN2C)Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240> \[glycine site\] (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8182696?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4208> \[glycine site\] (p*K* ~i~ 8.1--8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10780999?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239> \[glycine site\] (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/1534584?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2361> \[glycine site\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2361> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4208> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4243> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4276> \[glutamate site\] (GluN2A \> GluN2B (human), but weakly selective for rat GluN2A versus GluN2B) \[<http://www.ncbi.nlm.nih.gov/pubmed/11909726?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14718249?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16778008?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16452656?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4332> \[glutamate site\] (GluN2D ≥ GluN2C \> GluN2A ≥ GluN2B) \[<http://www.ncbi.nlm.nih.gov/pubmed/15801853?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4161> \[glutamate site\] (GluN2B \> GluN2D = GluN2C = GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4168> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170> \[glutamate site\] (GluN2A = GluN2B \> GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155> \[glutamate site\]Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (GluN2A = GluN2B \> GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4260> (GluN2A = GluN2B ≫ GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128> (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2403>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4233>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4282>Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4088> \[glycine site\] (Antagonist) (p*K* ~d~ ∼8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9721050?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4078> \[glutamate site\] (Selective Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4079> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4080> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082> \[glutamate site\] (Selective Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4086> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4089> \[cation channel\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4084> \[glycine site\] (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4078> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4079> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4080> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4086> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4088> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4089> \[cation channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4084> \[glycine site\] (Agonist)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4587](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4587), <http://www.uniprot.org/uniprot/Q14957>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4588](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4588), <http://www.uniprot.org/uniprot/O15399>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6511> \[glutamate site\] (GluN2D \> GluN2C = GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4171> \[glycine site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> \[glutamate site\] (GluN2D = GluN2B \> GluN2C = GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> \[glycine site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A)Agonists(<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4068> \[glutamate site\] (GluN2D \> GluN2C = GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268> \[glutamate site\] (GluN2D \> GluN2C \> GluN2B \> GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4216> \[glutamate site\] (GluN2B ≥ GluN2A ≥ GluN2D \> GluN2C; partial agonist at GluN2A and GluN2C)Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2361> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4154> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4208> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4239> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4240> \[glycine site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4243> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4332> \[glutamate site\] (GluN2D ≥ GluN2C \> GluN2A ≥ GluN2B) \[<http://www.ncbi.nlm.nih.gov/pubmed/15801853?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4161> \[glutamate site\] (GluN2B \> GluN2D = GluN2C = GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4168> \[glutamate site\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4170> \[glutamate site\] (GluN2A = GluN2B \> GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4155> \[glutamate site\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4282> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17303642?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4233> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17303642?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128> (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A) (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17303642?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (GluN2A = GluN2B \> GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4260> (GluN2A = GluN2B ≫ GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2403><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (GluN2A = GluN2B \> GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4260> (GluN2A = GluN2B ≫ GluN2C = GluN2D), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4128> (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2403>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4233>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4282>Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4078> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4079> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4080> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4086> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4088> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4089> \[cation channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4084> \[glycine site\] (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4078> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4079> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4080> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4082> \[glutamate site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4086> \[glycine site\] (Selective Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4088> \[glycine site\] (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4089> \[cation channel\] (Channel blocker), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4084> \[glycine site\] (Agonist)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=460><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=461>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16767](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16767), <http://www.uniprot.org/uniprot/Q8TCU5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16768](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16768), <http://www.uniprot.org/uniprot/O60391>CommentsSee the main comments section below for information on the pharmacology of GluN3A and GluN3B subunits

Comments {#bph14749-sec-0034}
--------

Potency orders unreferenced in the table are from \[<http://www.ncbi.nlm.nih.gov/pubmed/17962328?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17303642?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17622578?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8642401?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17088105?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\]. In addition to the glutamate and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> binding sites documented in the table, physiologically important inhibitory modulatory sites exist for Mg^2+^, Zn^2+^, and protons \[<http://www.ncbi.nlm.nih.gov/pubmed/15494561?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10049997?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\]. Voltage‐independent inhibition by Zn^2+^ binding with high affinity within the ATD is highly subunit selective (GluN2A ≫ GluN2B \> GluN2C ≥ GluN2D; \[<http://www.ncbi.nlm.nih.gov/pubmed/17088105?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716669?dopt=AbstractPlus>\]). The receptor is also allosterically modulated, in both positive and negative directions, by endogenous neuroactive steroids in a subunit dependent manner \[<http://www.ncbi.nlm.nih.gov/pubmed/16257494?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11861317?dopt=AbstractPlus>\]. Tonic proton blockade of NMDA receptor function is alleviated by polyamines and the inclusion of exon 5 within GluN1 subunit splice variants, whereas the non‐competitive antagonists <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5472> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4163> increase the fraction of receptors blocked by protons at ambient concentration. Inclusion of exon 5 also abolishes potentiation by polyamines and inhibition by Zn^2+^ that occurs through binding in the ATD \[<http://www.ncbi.nlm.nih.gov/pubmed/9698310?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5472>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4163>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5473> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4300> discriminate between recombinant NMDA receptors assembled from GluN1 and either GluN2A, or GluN2B, subunits by acting as selective, non‐competitive, antagonists of heterooligomers incorporating GluN2B through a binding site at the ATD GluN1/GluN2B subunit interface \[<http://www.ncbi.nlm.nih.gov/pubmed/21677647?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4244> is a competitive antagonist that also displays selectivity for GluN2B over GluN2A subunit‐containing receptors. Similarly, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5474> is a photoaffinity label that interacts selectively with receptors incorporating GluN2B versus GluN2A, GluN2D and, to a lesser extent, GluN2C subunits. TCN 201 and TCN 213 have recently been shown to block GluN2A NMDA receptors selectively by a mechanism that involves allosteric inhibition of glycine binding to the GluN1 site \[<http://www.ncbi.nlm.nih.gov/pubmed/20810618?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22579927?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22553026?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22022974?dopt=AbstractPlus>\]. In addition to influencing the pharmacological profile of the NMDA receptor, the identity of the GluN2 subunit co‐assembled with GluN1 is an important determinant of biophysical properties that include sensitivity to block by Mg^2+^, single‐channel conductance and maximal open probablity and channel deactivation time \[<http://www.ncbi.nlm.nih.gov/pubmed/15494561?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15701057?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19404260?dopt=AbstractPlus>\]. Incorporation of the GluN3A subunit into tri‐heteromers containing GluN1 and GluN2 subunits is associated with decreased single‐channel conductance, reduced permeability to Ca^2+^ and decreased susceptibility to block by Mg^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/18654865?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20097255?dopt=AbstractPlus>\]. Reduced permeability to Ca^2+^ has also been observed following the inclusion of GluN3B in tri‐heteromers. The expression of GluN3A, or GluN3B, with GluN1 alone forms, in *Xenopus laevis* oocytes, a cation channel with unique properties that include activation by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> (but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4268>), lack of permeation by Ca^2+^ and resistance to blockade by Mg^2+^ and NMDA receptor antagonists \[<http://www.ncbi.nlm.nih.gov/pubmed/11823786?dopt=AbstractPlus>\]. The function of heteromers composed of GluN1 and GluN3A is enhanced by Zn^2+^, or glycine site antagonists, binding to the GluN1 subunit \[<http://www.ncbi.nlm.nih.gov/pubmed/18711142?dopt=AbstractPlus>\]. Zn^2+^ also directly activates such complexes. The co‐expression of GluN1, GluN3A and GluN3B appears to be required to form glycine‐activated receptors in mammalian cell hosts \[<http://www.ncbi.nlm.nih.gov/pubmed/17502428?dopt=AbstractPlus>\].
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Zhou HX *et al.* (2017) Advancing NMDA Receptor Physiology by Integrating Multiple Approaches. *Trends Neurosci.* **40**: 129‐137 <https://www.ncbi.nlm.nih.gov/pubmed/28187950?dopt=AbstractPlus>

Zhuo M. (2017) Ionotropic glutamate receptors contribute to pain transmission and chronic pain. *Neuropharmacology* **112**: 228‐234 <https://www.ncbi.nlm.nih.gov/pubmed/27543416?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=123> {#bph14749-sec-0036}
===========================================================================

Overview {#bph14749-sec-0037}
--------

The inositol 1,4,5‐trisphosphate receptors (IP~3~R) are ligand‐gated Ca^2+^‐release channels on intracellular Ca^2^+ store sites (such as the endoplasmic reticulum). They are responsible for the mobilization of intracellular Ca^2+^ stores and play an important role in intracellular Ca^2+^ signalling in a wide variety of cell types. Three different gene products (types I‐III) have been isolated, which assemble as large tetrameric structures. IP~3~Rs are closely associated with certain proteins: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>) and FKBP (and calcineurin via FKBP). They are phosphorylated by PKA, PKC, PKG and CaMKII.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=744><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=745>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6180](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6180), <http://www.uniprot.org/uniprot/Q14643>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6181](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6181), <http://www.uniprot.org/uniprot/Q14571>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6182](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6182), <http://www.uniprot.org/uniprot/Q14573>Endogenous activatorscytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> (\< mM range), cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> Concentration range: \<7.5×10^−4^M, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> (endogenous; nM ‐ *μ*M range)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (nM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> (endogenous; nM ‐ *μ*M range)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (nM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> (endogenous; nM ‐ *μ*M range)Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4124> (pharmacological; nM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4223> (pharmacological; also activated by other InsP~3~ analogues)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4124> (pharmacological; nM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4223> (pharmacological; also activated by other InsP~3~ analogues)--Antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> (*μ*M range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407> (mM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2459> (*μ*M range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4344> (*μ*M range)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2459> (*μ*M range)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2459> (*μ*M range)Functional CharacteristicsCa^2+^: (P~Ba~/P~K~ 6) single‐channel conductance 70 pS (50 mM Ca^2+^)Ca^2+^: single‐channel conductance 70 pS (50 mM Ca^2+^) 390 pS (220 mM Cs^+^)Ca^2+^: single‐channel conductance 88 pS (55 mM Ba^2+^)CommentsIP~3~R1 is also antagonised by calmodulin at high cytosolic Ca^2+^ concentrations----

Comments {#bph14749-sec-0038}
--------

The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect.

Further reading on IP~3~ receptors {#bph14749-sec-0039}
----------------------------------

Berridge MJ. (2016) The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease. *Physiol. Rev.* **96**: 1261‐96 <https://www.ncbi.nlm.nih.gov/pubmed/27512009?dopt=AbstractPlus>

Garcia MI *et al.* (2017) Cardiac inositol 1,4,5‐trisphosphate receptors. *Biochim. Biophys. Acta* **1864**: 907‐914 <https://www.ncbi.nlm.nih.gov/pubmed/27884701?dopt=AbstractPlus>

Mak DO *et al.* (2015) Inositol 1,4,5‐trisphosphate receptors in the endoplasmic reticulum: A single‐channel point of view. *Cell Calcium* **58**: 67‐78 <https://www.ncbi.nlm.nih.gov/pubmed/25555684?dopt=AbstractPlus>

Rossi AM *et al.* (2018) IP_3 receptors ‐ lessons from analyses *ex cellula*. *J. Cell. Sci.* **132**: <https://www.ncbi.nlm.nih.gov/pubmed/30552138?dopt=AbstractPlus>

Seo MD *et al.* (2015) Structural insights into endoplasmic reticulum stored calcium regulation by inositol 1,4,5‐trisphosphate and ryanodine receptors. *Biochim. Biophys. Acta* **1853**: 1980‐91 <https://www.ncbi.nlm.nih.gov/pubmed/25461839?dopt=AbstractPlus>

Thillaiappan NB *et al.* (2019) IP_3 receptors and Ca^2+^ entry. *Biochim Biophys Acta Mol Cell Res* **1866**: 1092‐1100 <https://www.ncbi.nlm.nih.gov/pubmed/30448464?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76> {#bph14749-sec-0040}
==========================================================================

Overview {#bph14749-sec-0041}
--------

Nicotinic acetylcholine receptors are members of the Cys‐loop family of transmitter‐gated ion channels that includes the GABA~A~, strychnine‐sensitive glycine and 5‐HT~3~ receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/19126755?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16554804?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19721446?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21787755?dopt=AbstractPlus>\]. All nicotinic receptors are pentamers in which each of the five subunits contains four α‐helical transmembrane domains. Genes encoding a total of 17 subunits (α1‐10, β1‐4, γ, *δ* and *ϵ*) have been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/17651090?dopt=AbstractPlus>\]. All subunits with the exception of α8 (present in avian species) have been identified in mammals. All α subunits possess two tandem cysteine residues near to the site involved in acetylcholine binding, and subunits not named α lack these residues \[<http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\]. The orthosteric ligand binding site is formed by residues within at least three peptide domains on the α subunit (principal component), and three on the adjacent subunit (complementary component). nAChRs contain several allosteric modulatory sites. One such site, for positive allosteric modulators (PAMs) and allosteric agonists, has been proposed to reside within an intrasubunit cavity between the four transmembrane domains \[<http://www.ncbi.nlm.nih.gov/pubmed/21436053?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18791069?dopt=AbstractPlus>\]; see also \[<http://www.ncbi.nlm.nih.gov/pubmed/21572436?dopt=AbstractPlus>\]). The high resolution crystal structure of the molluscan acetylcholine binding protein, a structural homologue of the extracellular binding domain of a nicotinic receptor pentamer, in complex with several nicotinic receptor ligands (*e.g.*\[<http://www.ncbi.nlm.nih.gov/pubmed/15046723?dopt=AbstractPlus>\]) and the crystal structure of the extracellular domain of the α1 subunit bound to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> at 1.94 Å resolution \[<http://www.ncbi.nlm.nih.gov/pubmed/17643119?dopt=AbstractPlus>\], has revealed the orthosteric binding site in detail (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/18262468?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17651090?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19576182?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16554804?dopt=AbstractPlus>\]). Nicotinic receptors at the somatic neuromuscular junction of adult animals have the stoichiometry (α1)~2~β1*δϵ*, whereas an extrajunctional (α1)~2~β1γ*δ* receptor predominates in embryonic and denervated skeletal muscle and other pathological states. Other nicotinic receptors are assembled as combinations of α(2‐6) and β(2‐4) subunits. For α2, α3, α4 and β2 and β4 subunits, pairwise combinations of α and β (*e.g.* α3β4 and α4β2) are sufficient to form a functional receptor *in vitro*, but far more complex isoforms may exist *in vivo* (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/19481063?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16876883?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\]). There is strong evidence that the pairwise assembly of some α and β subunits can occur with variable stoichiometry \[*e.g.* (α4)~2~(β2)~2~ or (α4)~3~(β2)~2~\] which influences the biophysical and pharmacological properties of the receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\]. α5 and β3 subunits lack function when expressed alone, or pairwise, but participate in the formation of functional hetero‐oligomeric receptors when expressed as a third subunit with another α and β pair \[e.g. α4α5αβ2, α4αβ2β3, α5α6β2, see \[<http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\] for further examples\]. The α6 subunit can form a functional receptor when co‐expressed with β4 *in vitro*, but more efficient expression ensues from incorporation of a third partner, such as β3 \[<http://www.ncbi.nlm.nih.gov/pubmed/19498417?dopt=AbstractPlus>\]. The α7, α8, and α9 subunits form functional homo‐oligomers, but can also combine with a second subunit to constitute a hetero‐oligomeric assembly (*e.g.* α7β2 and α9α10). For functional expression of the α10 subunit, co‐assembly with α9 is necessary. The latter, along with the α10 subunit, appears to be largely confined to cochlear and vestibular hair cells. Comprehensive listings of nicotinic receptor subunit combinations identified from recombinant expression systems, or *in vivo*, are given in \[<http://www.ncbi.nlm.nih.gov/pubmed/18723036?dopt=AbstractPlus>\]. In addition, numerous proteins interact with nicotinic ACh receptors modifying their assembly, trafficking to and from the cell surface, and activation by ACh (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/20346921?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20674046?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18246096?dopt=AbstractPlus>\]).

The nicotinic receptor Subcommittee of [**NC‐IUPHAR**]{.ul} has recommended a nomenclature and classification scheme for nicotinic acetylcholine (nACh) receptors based on the subunit composition of known, naturally‐ and/or heterologously‐expressed nACh receptor subtypes \[<http://www.ncbi.nlm.nih.gov/pubmed/10353988?dopt=AbstractPlus>\]. Headings for this table reflect abbreviations designating nACh receptor subtypes based on the predominant α subunit contained in that receptor subtype. An asterisk following the indicated α subunit denotes that other subunits are known to, or may, assemble with the indicated α subunit to form the designated nACh receptor subtype(s). Where subunit stoichiometries within a specific nACh receptor subtype are known, numbers of a particular subunit larger than 1 are indicated by a subscript following the subunit (enclosed in parentheses -- see also \[<http://www.ncbi.nlm.nih.gov/pubmed/18655795?dopt=AbstractPlus>\]).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=462><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=463><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=464><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1955](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1955), <http://www.uniprot.org/uniprot/P02708>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1956](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1956), <http://www.uniprot.org/uniprot/Q15822>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1957](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1957), <http://www.uniprot.org/uniprot/P32297>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1958](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1958), <http://www.uniprot.org/uniprot/P43681>Commonly used antagonists(α1)~2~β1γ*δ* and (α1)~2~β1*δϵ*: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4001> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4002> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4003> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (IC~50~ = 43 ‐ 82 nM)α2β2: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 0.9 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 1.4 *μ*M); α2β4: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 3.6 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 4.2 *μ*M)α3β2: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 1.6 *μ*M, IC~50~ = 2.0 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 2.4 *μ*M); α3β4: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 19 *μ*M, IC~50~ = 26 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 2.2 *μ*M)α4β2: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 0.1 *μ*M; IC~50~ = 0.08 ‐ 0.9 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 3.2 *μ*M, IC~50~ = 34 *μ*M); α4β4: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (*K~B~* = 0.01 *μ*M, IC~50~ = 0.19 -- 1.2 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (*K~B~* = 0.2 *μ*M, IC~50~ = 50 *μ*M)Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4004> (selective for (α1)~2~β1γ*δ*)----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5459> \[<http://www.ncbi.nlm.nih.gov/pubmed/16171993?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3994> \[<http://www.ncbi.nlm.nih.gov/pubmed/14698195?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3987> (α4β2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12871651?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3983>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3999>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4001>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3984> (selective for (α1)~2~β1*δϵ*)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3973> (α3β4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3970> (α3β2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3982> (α3β2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4011>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4011> (α3β2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4009>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4009> (α3β2)--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356> ((α1)~2~β1γ*δ* and (α1)~2~β1*δϵ*) (pIC~50~ ∼6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> ((α1)~2~β1*δ*) (pIC~50~ ∼5.8)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> (α3β4) (pIC~50~ 6.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> (α3β2) (pIC~50~ 5.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986> (α3β4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19389923?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4000> (α3β4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17625074?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963> (α3β2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963> (α3β4)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> (α4β4) (pIC~50~ 5.3--6.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> (α4β2) (pIC~50~ 5.4--5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963> (α4β2) (pIC~50~ 4.5--5.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963> (α4β4) (pIC~50~ 4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986> (α4β2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19389923?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4000> (α4β2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17625074?dopt=AbstractPlus>\]Allosteric modulators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3992> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/16738207?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3992> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/16738207?dopt=AbstractPlus>\]Selective allosteric modulators------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3993> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/21763685?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3972> (Selective Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3981> (Selective Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3976> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3979> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3976> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3976> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3979> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3976> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3979> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3976> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist) -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3979> (Agonist)Functional Characteristics(α1)~2~βγ*δ*: P~Ca~/P~Na~ = 0.16 ‐ 0.2, *P* ~f~ = 2.1 -- 2.9%; (α1)~2~β*δϵ*: P~Ca~/P~Na~ = 0.65 -- 1.38, *P* ~f~ = 4.1 -- 7.2%α2β2: P~Ca~/P~Na~ 1.5α3β2: P~Ca~/P~Na~ = 1.5; α3β4: P~Ca~/P~Na~ = 0.78 ‐ 1.1, *P* ~f~ = 2.7 -- 4.6%α4β2: P~Ca~/P~Na~ = 1.65, *P* ~f~ = 2.6 -- 2.9%; α4β4: *P* ~f~ = 1.5 -- 3.0 %

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=466><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1959](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1959), <http://www.uniprot.org/uniprot/P30532>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15963](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15963), <http://www.uniprot.org/uniprot/Q15825>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1960](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1960), <http://www.uniprot.org/uniprot/P36544>Commonly used antagonists--α6/α3β2β3 chimera: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (IC~50~ = 1.1 *μ*M)(α7)5: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4006> (IC~50~ = 8 ‐ 20 *μ*M); (α7)5: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (IC~50~ = 3.1 *μ*M)Selective agonists----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6926> (Partial agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/21919481?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15293871?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7371> (\[125I\]α‐ bungarotoxin binding assay) \[[411](#bph14749-bib-0411){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3962> (allosteric) \[<http://www.ncbi.nlm.nih.gov/pubmed/21436053?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3995> ((α7)~5~) \[<http://www.ncbi.nlm.nih.gov/pubmed/17898229?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3998> ((α7)~5~) \[<http://www.ncbi.nlm.nih.gov/pubmed/16821801?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3997> ((α7)~5~) \[<http://www.ncbi.nlm.nih.gov/pubmed/18490160?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3988> ((α7)~5~) \[<http://www.ncbi.nlm.nih.gov/pubmed/15715459?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3969> ((α7)~5~) \[<http://www.ncbi.nlm.nih.gov/pubmed/19482012?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3970>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3982>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4011>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4009><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3970> (α6β2\*), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4010> (α6β2β3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3985> (α6/α3β2β3 chimera)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> ((α7)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4007> ((α7)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3965> ((α7)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4005> ((α7)~5~)Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> (α6/α3β2β3 chimera) (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3963> (α6/α3β2β3 chimera) (pIC~50~ 4)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3990> ((α7)~5~) (pIC~50~ 4.8)Allosteric modulators----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3986> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/19389923?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3992> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/16738207?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4000> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/17625074?dopt=AbstractPlus>\]Selective allosteric modulators----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3966> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/21084390?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3991> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/15858066?dopt=AbstractPlus>\]Labelled ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist) -- Chicken, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3975>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3975> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> (Agonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3974> (Agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/17959745?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3971> (Agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/20674564?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3972> (Selective Antagonist) (p*K* ~d~ 8.3--9.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3981> (Selective Antagonist) (p*K* ~d~ 8.3--9.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3980> (Antagonist) (p*K* ~d~ 8.7) -- RatFunctional Characteristics----P~Ca~/P~Na~ = 6.6‐20, *P* ~f~ = 8.8 ‐ 11.4%

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=752><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=469><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=470>HGNC, UniProt--[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14079](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14079), <http://www.uniprot.org/uniprot/Q9UGM1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13800](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13800), <http://www.uniprot.org/uniprot/Q9GZZ6>Commonly used antagonists(α8)~5~: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320> ≥ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> ≥ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347>(α9)~5~: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4005> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294>; α9α10: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294>α9α10: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294>Selective antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> ((α9)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4008> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3996> ((α9)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3996> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585> ((α9)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> ((α9)~5~), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> (α9α10)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3964> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4008> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3996> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585> (α9α10), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347> (α9α10)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3977> ((α8)~5~) (p*K* ~d~ 9.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3972> (native α8\*) (p*K* ~d~ 8.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3981> (native α8\*) (p*K* ~d~ 8.3)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3980> (Antagonist) (p*K* ~d~ 8.1), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3972> (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3981> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3980> (Antagonist) (p*K* ~d~ 8.1)Functional Characteristics--(α9)~5~: P~Ca~/P~Na~ = 9; α9α10: P~Ca~/P~Na~ = 9, *P* ~f~ = 22%α9α10: P~Ca~/P~Na~ = 9, *P* ~f~ = 22%

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=472><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=473><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=474><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=475><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=476><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=471> <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=477>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1961](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1961), <http://www.uniprot.org/uniprot/P11230>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1962](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1962), <http://www.uniprot.org/uniprot/P17787>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1963](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1963), <http://www.uniprot.org/uniprot/Q05901>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1964](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1964), <http://www.uniprot.org/uniprot/P30926>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1967), <http://www.uniprot.org/uniprot/P07510>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1965](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1965), <http://www.uniprot.org/uniprot/Q07001>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1966](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1966), <http://www.uniprot.org/uniprot/Q04844>Antagonists----------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8883> (pIC~50~ 6.2--6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11934578?dopt=AbstractPlus>\]--CommentsLigand interaction data for hetero‐oligomeric receptors containing the β1 subunit are listed under the α1 subunits

Comments {#bph14749-sec-0042}
--------

Commonly used agonists of nACh receptors that display limited discrimination in functional assays between receptor subtypes include <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5460>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5347>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3967>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5348>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585> and the natural transmitter, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294> (ACh). A summary of their profile across differing receptors is provided in \[<http://www.ncbi.nlm.nih.gov/pubmed/16876883?dopt=AbstractPlus>\] and quantitative data across numerous assay systems are summarized in \[<http://www.ncbi.nlm.nih.gov/pubmed/16033252?dopt=AbstractPlus>\]. Quantitative data presented in the table for commonly used antagonists and channel blockers for human receptors studied under voltage‐clamp are from \[<http://www.ncbi.nlm.nih.gov/pubmed/8987816?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8996215?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18448138?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11303054?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11867382?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16825297?dopt=AbstractPlus>\]. Type I PAMs increase peak agonist‐evoked responses but have little, or no, effect on the rate of desensitization of α7 nicotinic ACh receptors whereas type II PAMs also cause a large reduction in desensitization (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/21575610?dopt=AbstractPlus>\]).
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----------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=77> {#bph14749-sec-0044}
==========================================================================

Overview {#bph14749-sec-0045}
--------

P2X receptors (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on P2X Receptors** \[<http://www.ncbi.nlm.nih.gov/pubmed/18655795?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11171941?dopt=AbstractPlus>\]) have a trimeric topology \[<http://www.ncbi.nlm.nih.gov/pubmed/14523092?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19641588?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9606184?dopt=AbstractPlus>\] with two putative TM domains, gating primarily Na^+^, K^+^ and Ca^2+^, exceptionally Cl‐. The Nomenclature Subcommittee has recommended that for P2X receptors, structural criteria should be the initial criteria for nomenclature where possible. X‐ray crystallography indicates that functional P2X receptors are trimeric and three agonist molecules are required to bind to a single receptor in order to activate it \[<http://www.ncbi.nlm.nih.gov/pubmed/19641589?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22535247?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19641588?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27626375?dopt=AbstractPlus>\]. Native receptors may occur as either homotrimers (*e.g.* P2X1 in smooth muscle) or heterotrimers (*e.g.* P2X2:P2X3 in the nodose ganglion \[<http://www.ncbi.nlm.nih.gov/pubmed/9364478?dopt=AbstractPlus>\], P2X1:P2X5 in mouse cortical astrocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/18495881?dopt=AbstractPlus>\], and P2X2:P2X5 in mouse dorsal root ganglion, spinal cord and mid pons \[<http://www.ncbi.nlm.nih.gov/pubmed/22442090?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24391538?dopt=AbstractPlus>\]. P2X2, P2X4 and P2X7 receptors have been shown to form functional homopolymers which, in turn, activate pores permeable to low molecular weight solutes \[<http://www.ncbi.nlm.nih.gov/pubmed/18851707?dopt=AbstractPlus>\]. The hemi‐channel pannexin‐1 has been implicated in the pore formation induced by P2X7 \[<http://www.ncbi.nlm.nih.gov/pubmed/19212823?dopt=AbstractPlus>\], but not P2X2 \[<http://www.ncbi.nlm.nih.gov/pubmed/18689682?dopt=AbstractPlus>\], receptor activation.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=479><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=481><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=482><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=483><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8533](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8533), <http://www.uniprot.org/uniprot/P51575>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15459](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15459), <http://www.uniprot.org/uniprot/Q9UBL9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8534](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8534), <http://www.uniprot.org/uniprot/P56373>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8535](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8535), <http://www.uniprot.org/uniprot/Q99571>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8536](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8536), <http://www.uniprot.org/uniprot/Q93086>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8538](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8538), <http://www.uniprot.org/uniprot/O15547>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8537](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8537), <http://www.uniprot.org/uniprot/Q99572>Endogenous agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/18600475?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus>\]Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1757>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4236>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4236>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1757>--------Antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4324> (pIC~50~ ∼8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9614197?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4225> (pIC~50~ ∼8.5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4266> (pIC~50~ ∼6.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4267> (pIC~50~ ∼6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15072843?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9545> (pIC~50~ 7--8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9546> (pIC~50~ 7--8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9539> (pIC~50~ ∼7) \[<http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4324> (pIC~50~ ∼8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9614197?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9538> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9540> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4115> (pIC~50~ ∼7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12482951?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9541> (pIC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9543> (pIC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9542> (pIC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4790> (pIC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23253448?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9021> (p*K* ~d~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18071294?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4121> (pIC~50~ ∼8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4147> (pIC~50~ ∼8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10860929?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4122> (pIC~50~ ∼7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17471177?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19558545?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19464323?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4119> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16982702?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2459> (pA2 = 7.4) (p*A* ~2~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16487507?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4118> (pIC~50~ ∼6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17471177?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7722> (p*A* ~2~ 6.1) \[[36](#bph14749-bib-0036){ref-type="ref"}\]Selective antagonists------------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7538> (p*K* ~i~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/23889535?dopt=AbstractPlus>\]Allosteric modulators------------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9021> (Negative) \[<http://www.ncbi.nlm.nih.gov/pubmed/18071294?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9022> (Negative) \[<http://www.ncbi.nlm.nih.gov/pubmed/18071294?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18660826?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9022> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/18071294?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18660826?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5527> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1472](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1472), <http://www.uniprot.org/uniprot/P49913>) (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/18765670?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6063> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/21262970?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10338> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/15383600?dopt=AbstractPlus>\]Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6496> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/9632352?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2373> (Positive) (pEC~50~ ∼6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10460235?dopt=AbstractPlus>\] -- Rat----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953> (Negative) (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15210579?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4142> (Negative) \[<http://www.ncbi.nlm.nih.gov/pubmed/19309360?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17031385?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4235> (Negative) \[<http://www.ncbi.nlm.nih.gov/pubmed/9113369?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15210579?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2373> (Positive) \[<http://www.ncbi.nlm.nih.gov/pubmed/22506590?dopt=AbstractPlus>\]Comments------------Effects of the allosteric regulators at P2X7 receptors are species‐dependent.

Comments {#bph14749-sec-0046}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4115> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4298> also block the P2X2:P2X3 heteromultimer \[<http://www.ncbi.nlm.nih.gov/pubmed/16465177?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12482951?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4267>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4115> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4298> are more than 10‐fold selective for P2X1 and P2X3 receptors, respectively.

Agonists listed show selectivity within recombinant P2X receptors of *ca*. one order of magnitude. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4121>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4122>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4119> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4118> are at least 10‐fold selective for P2X7 receptors and show similar affinity across human and rodent receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/17471177?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19558545?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19464323?dopt=AbstractPlus>\]. Several P2X receptors (particularly P2X1 and P2X3) may be inhibited by desensitisation using stable agonists (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093>); <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1725> are non‐selective antagonists at rat and human P2X1‐3,5 and hP2X4, but not rP2X4,6,7 \[<http://www.ncbi.nlm.nih.gov/pubmed/8598206?dopt=AbstractPlus>\], and can also inhibit ATPase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/7889301?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4225> is inactive at rP2X2, an antagonist at rP2X3 (pIC~50~ 5.6) and enhances agonist responses at rP2X4 \[<http://www.ncbi.nlm.nih.gov/pubmed/10556935?dopt=AbstractPlus>\]. Antagonist potency of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4266> at recombinant P2X2, P2X3 and P2X5 is two orders of magnitude lower than that at P2X1 receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/10193905?dopt=AbstractPlus>\]. The P2X7 receptor may be inhibited in a non‐competitive manner by the protein kinase inhibitors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4235> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953> \[<http://www.ncbi.nlm.nih.gov/pubmed/15210579?dopt=AbstractPlus>\], while the p38 MAP kinase inhibitor <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4207> and the cyclic imide <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4142> show a species‐dependent non‐competitive action \[<http://www.ncbi.nlm.nih.gov/pubmed/14634045?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19309360?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17031382?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17031385?dopt=AbstractPlus>\].

The pH‐sensitive dye used in culture media, phenol red, is also reported to inhibit P2X1 and P2X3 containing channels \[<http://www.ncbi.nlm.nih.gov/pubmed/15778739?dopt=AbstractPlus>\]. Some recombinant P2X receptors expressed to high density bind <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5406> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5405>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5405>, although the latter can also bind to 5‐nucleotidase \[<http://www.ncbi.nlm.nih.gov/pubmed/8548175?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5407> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5408> have been used as high affinity antagonist radioligands for P2X3 (and P2X2/3) and P2X7 receptors, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/19558545?dopt=AbstractPlus>\]. Several high affinity radioligands for the P2X7 receptor have been recently synthesized \[<http://www.ncbi.nlm.nih.gov/pubmed/28374288?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26386289?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27765863?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9540> has shown clinical efficacy in reducing refractory chronic cough \[<http://www.ncbi.nlm.nih.gov/pubmed/25467586?dopt=AbstractPlus>\].

Further reading on P2X receptors {#bph14749-sec-0047}
--------------------------------

Di Virgilio F *et al.* (2017) The P2X7 Receptor in Infection and Inflammation. *Immunity* **47**: 15‐31 <https://www.ncbi.nlm.nih.gov/pubmed/28723547?dopt=AbstractPlus>

DiVirgilio F *etal*. (2018)TheElusive P2X7Macropore. *TrendsCellBiol.* **28**: 392‐404<https://www.ncbi.nlm.nih.gov/pubmed/29439897?dopt=AbstractPlus>

Habermacher C *et al.* (2016) Molecular structure and function of P2X receptors. *Neuropharmacology* **104**: 18‐30 <https://www.ncbi.nlm.nih.gov/pubmed/26231831?dopt=AbstractPlus>

Jacobson KA *et al.* (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. *Neuropharmacology* **104**: 31‐49 <https://www.ncbi.nlm.nih.gov/pubmed/26686393?dopt=AbstractPlus>

Khakh BS *et al.* (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. *Pharmacol. Rev.* **53**: 107‐18 <https://www.ncbi.nlm.nih.gov/pubmed/11171941?dopt=AbstractPlus>

North RA. (2016) P2X receptors. *Philos. Trans. R. Soc. Lond., B, Biol. Sci.* **371**: <https://www.ncbi.nlm.nih.gov/pubmed/27377721?dopt=AbstractPlus>

Stokes L *et al.* (2017) P2X4 Receptor Function in the Nervous System and Current Breakthroughs in Pharmacology. *Front Pharmacol* **8**: 291 <https://www.ncbi.nlm.nih.gov/pubmed/28588493?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=83> {#bph14749-sec-0048}
==========================================================================

Overview {#bph14749-sec-0049}
--------

The zinc‐activated channel (ZAC, **nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee for the Zinc Activated Channel**) is a member of the Cys‐loop family that includes the nicotinic ACh, 5‐HT~3~, GABA~A~ and strychnine‐sensitive glycine receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/12381728?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16083862?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]. The channel is likely to exist as a homopentamer of 4TM subunits that form an intrinsic cation selective channel equipermeable to Na^+^, K^+^ and Cs^+^, but impermeable to Ca^2+^ and Mg^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]. ZAC displays constitutive activity that can be blocked by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> and high concentrations of Ca^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]. Although denoted ZAC, the channel is more potently activated by protons and copper, with greater and lesser efficacy than zinc, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]. ZAC is present in the human, chimpanzee, dog, cow and opossum genomes, but is functionally absent from mouse, or rat, genomes \[<http://www.ncbi.nlm.nih.gov/pubmed/12381728?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16083862?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=587>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29504](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29504), <http://www.uniprot.org/uniprot/Q401N2>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> ^+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> \[<http://www.ncbi.nlm.nih.gov/pubmed/12381728?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]Antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12381728?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (pIC~50~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]Functional CharacteristicsOutwardly rectifying current (both constitutive and evoked by Zn^2+^)

Comments {#bph14749-sec-0050}
--------

The ZAC subunit does not appear to exist in the mouse or rat genomes \[<http://www.ncbi.nlm.nih.gov/pubmed/12381728?dopt=AbstractPlus>\]. Although tabulated as an antagonist, it is possible that <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2294> acts as a channel blocker. Antagonism by Ca^2+^ is voltage‐independent. ZAC is not activated (at 1 mM) by transition metals including Fe^2+^, Co^2+^, Ni^2+^, Cd^2+^, or Al^3+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\]. The concentration response relationship to Cu^2+^ is biphasic, with concentrations exceeding 30 *μ*M being associated with reduced activation \[<http://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>\].

Further reading on ZAC {#bph14749-sec-0051}
----------------------

Collingridge GL *et al.* (2009) A nomenclature for ligand‐gated ion channels. *Neuropharmacology* **56**: 2‐5 <https://www.ncbi.nlm.nih.gov/pubmed/18655795?dopt=AbstractPlus>

Peralta FA *et al.* (2016) Zinc as Allosteric Ion Channel Modulator: Ionotropic Receptors as Metalloproteins. *Int J Mol Sci* **17**: <https://www.ncbi.nlm.nih.gov/pubmed/27384555?dopt=AbstractPlus>

Trattnig SM *et al.* (2016) Copper and protons directly activate the zinc‐activated channel. *Biochem. Pharmacol.* **103**: 109‐17 <https://www.ncbi.nlm.nih.gov/pubmed/26872532?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=696> {#bph14749-sec-0052}
===========================================================================

Overview {#bph14749-sec-0053}
--------

The voltage‐gated ion channels and their structural relatives comprise a superfamily encoded by at least 143 genes in the human genome and are therefore one of the largest superfamilies of signal transduction proteins, following the G proteincoupled receptors and the protein kinases in number \[<http://www.ncbi.nlm.nih.gov/pubmed/16036917?dopt=AbstractPlus>\]. In addition to their prominence in signal transduction, these ion channels are also among the most common drug targets. As for other large protein superfamilies, understanding the molecular relationships among family members, developing a unified, rational nomenclature for the ion channel families and subfamilies, and assigning physiological functions and pharmacological significance to each family member has been an important challenge.

Further reading on Voltage‐gated ion channels {#bph14749-sec-0054}
---------------------------------------------

Catterall WA *et al.* (2005) Introduction to the IUPHAR Compendium of Voltage‐Gated Ion Channels 2005 *Pharmacological Reviews* **57**: 385

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=70> {#bph14749-sec-0055}
==========================================================================

Overview {#bph14749-sec-0056}
--------

CatSper channels (CatSper1‐4, **nomenclature as agreed by [NC‐IUPHAR]{.ul}** \[<http://www.ncbi.nlm.nih.gov/pubmed/16382101?dopt=AbstractPlus>\]) are putative 6TM, voltage‐gated, alkalinization‐activated calcium permeant channels that are presumed to assemble as a tetramer of α‐like subunits and mediate the current I~CatSper~ \[<http://www.ncbi.nlm.nih.gov/pubmed/16467839?dopt=AbstractPlus>\]. In mammals, CatSper subunits are structurally most closely related to individual domains of voltageactivated calcium channels (Cav) \[<http://www.ncbi.nlm.nih.gov/pubmed/11595941?dopt=AbstractPlus>\]. CatSper1 \[<http://www.ncbi.nlm.nih.gov/pubmed/11595941?dopt=AbstractPlus>\], CatSper2 \[<http://www.ncbi.nlm.nih.gov/pubmed/11675491?dopt=AbstractPlus>\] and CatSpers 3 and 4 \[<http://www.ncbi.nlm.nih.gov/pubmed/16107607?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12932298?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17227845?dopt=AbstractPlus>\], in common with a putative 2TM auxiliary CatSperβ protein \[<http://www.ncbi.nlm.nih.gov/pubmed/17478420?dopt=AbstractPlus>\] and two putative 1TM associated CatSperγ and CatSper*δ* proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/21224844?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19516020?dopt=AbstractPlus>\], are restricted to the testis and localised to the principle piece of sperm tail. The novel cross‐species CatSper channel inhibitor, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10266>, has been proposed as a useful tool to aid characterisation of native CatSper channels \[<http://www.ncbi.nlm.nih.gov/pubmed/29723408?dopt=AbstractPlus>\].

Two‐pore channels (TPCs) are structurally related to CatSpers, CaVs and NaVs. TPCs have a 2x6TM structure with twice the number of TMs of CatSpers and half that of CaVs. There are three animal TPCs (TPC1‐TPC3). Humans have TPC1 and TPC2, but not TPC3. TPC1 and TPC2 are localized in endosomes and lysosomes \[<http://www.ncbi.nlm.nih.gov/pubmed/19387438?dopt=AbstractPlus>\]. TPC3 is also found on the plasma membrane and forms a voltage‐activated, non‐inactivating Na^+^ channel \[<http://www.ncbi.nlm.nih.gov/pubmed/25256615?dopt=AbstractPlus>\]. All the three TPCs are Na^+^‐selective under whole‐cell or whole‐organelle patch clamp recording \[<http://www.ncbi.nlm.nih.gov/pubmed/24776928?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23394946?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19211808?dopt=AbstractPlus>\]. The channels may also conduct Ca^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/24277557?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=388><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=389><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=390><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=391>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17116](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17116), <http://www.uniprot.org/uniprot/Q8NEC5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18810](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18810), <http://www.uniprot.org/uniprot/Q96P56>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20819](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20819), <http://www.uniprot.org/uniprot/Q86XQ3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23220](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23220), <http://www.uniprot.org/uniprot/Q7RTX7>ActivatorsCatSper1 is constitutively active, weakly facilitated by membrane depolarisation, strongly augmented by intracellular alkalinisation. In human, but not mouse, progesterone (EC50 8 nM) also potentiates the CatSper current (I~CatSper~). \[<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21412338?dopt=AbstractPlus>\]------Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (Inhibition) (pIC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16467839?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4212> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19718436?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (Inhibition) (pIC~50~ 3.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16467839?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (Inhibition) (pIC~50~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16467839?dopt=AbstractPlus>\] -- Mouse------Selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4269> (Inhibition) (pIC~50~ 5.7) \[−80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21412338?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522> (Inhibition) (pIC~50~ 4.4--4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21412338?dopt=AbstractPlus>\]------Functional CharacteristicsCalcium selective ion channel (Ba^2+^\>Ca^2+^Mg^2+^Na^+^); quasilinear monovalent cation current in the absence of extracellular divalent cations; alkalinization shifts the voltage‐dependence of activation towards negative potentials \[V @ pH 6.0 = +87 mV (mouse); V @ pH 7.5 = +11mV (mouse) or pH 7.4 = +85 mV (human)\]; required for I~CatSper~ and male fertility (mouse and human)Required for I~CatSper~ and male fertility (mouse and human)Required for I~CatSper~ and male fertility (mouse)Required for I~CatSper~ and male fertility (mouse) Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=392><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=393>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18182](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18182), <http://www.uniprot.org/uniprot/Q9ULQ1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20820](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20820), <http://www.uniprot.org/uniprot/Q8NHX9>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794> (pEC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24776928?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794> (pEC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23063126?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (Inhibition) (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/24776928?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (Inhibition) (pIC~50~ 3.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24776928?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (Inhibition) (pIC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23063126?dopt=AbstractPlus>\]Functional CharacteristicsOrganelle voltage‐gated Na^+^‐selective channel (Na^+^K^+^Ca^2+^); Required for the generation of action potential‐like long depolarization in lysosomes. Voltage‐dependence of activation is sensitive to luminal pH (determined from lysosomal recordings). ^*ψ*^ ~1~/2 @ pH4.6 = +91 mV; ^*ψ*^ ~1~/2 @ pH6.5 = +2.6 mV. Maximum activity requires PI(3,5)P2 and reduced \[ATP\], or depletion of extracellular amino acids.Organelle voltage‐independent Na^+^‐selective channel (Na^+^K^+^Ca^2+^). Sensitive to the levels of PI(3,5)P2. Activated by decreases in \[ATP\] or depletion of extracellular amino acids

Comments {#bph14749-sec-0057}
--------

CatSper channel subunits expressed singly, or in combination, fail to functionally express in heterologous expression systems \[<http://www.ncbi.nlm.nih.gov/pubmed/11675491?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11595941?dopt=AbstractPlus>\]. The properties of CatSper1 tabulated above are derived from whole cell voltage‐clamp recordings comparing currents endogenous to spermatozoa isolated from the *corpus epididymis* of wild‐type and*Catsper1^(‐/‐)^* mice \[<http://www.ncbi.nlm.nih.gov/pubmed/16467839?dopt=AbstractPlus>\] and also mature human sperm \[<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21412338?dopt=AbstractPlus>\]. I~CatSper~ is also undetectable in the spermatozoa of *Catsper2^(−/−)^*, *Catsper3^(−/−)^*, *Catsper4^(−/−),^* or CatSper*δ* ^(−/−)^ mice, and CatSper 1 associates with CatSper 2, 3, 4, β, γ, and *δ* \[<http://www.ncbi.nlm.nih.gov/pubmed/21224844?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17478420?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17227845?dopt=AbstractPlus>\]. Moreover, targeted disruption of *Catsper1, 2, 3, 4*, or *δ* genes results in an identical phenotype in which spermatozoa fail to exhibit the hyperactive movement (whip‐like flagellar beats) necessary for penetration of the egg *cumulus* and *zona pellucida* and subsequent fertilization. Such disruptions are associated with a deficit in alkalinization and depolarization‐evoked Ca^2+^ entry into spermatozoa \[<http://www.ncbi.nlm.nih.gov/pubmed/16036917?dopt=AbstractPlus>,<http://www.ncbi.nlm.nih.gov/pubmed/16036917?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17227845?dopt=AbstractPlus>\]. Thus, it is likely that the CatSper pore is formed by a heterotetramer of CatSpers1‐4 \[<http://www.ncbi.nlm.nih.gov/pubmed/17227845?dopt=AbstractPlus>\] in association with the auxiliary subunits (β, γ, *δ*) that are also essential for function \[<http://www.ncbi.nlm.nih.gov/pubmed/21224844?dopt=AbstractPlus>\]. CatSper channels are required for the increase in intracellular Ca^2+^ concentration in sperm evoked by egg *zona pellucida* glycoproteins \[<http://www.ncbi.nlm.nih.gov/pubmed/19211808?dopt=AbstractPlus>\]. Mouse and human sperm swim against the fluid flow and Ca^2+^ signaling through CatSper is required for the rheotaxis \[<http://www.ncbi.nlm.nih.gov/pubmed/23453951?dopt=AbstractPlus>\]. *In vivo*, CatSper1‐null spermatozoa cannot ascend the female reproductive tracts efficiently \[<http://www.ncbi.nlm.nih.gov/pubmed/24813608?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19210926?dopt=AbstractPlus>\]. It has been shown that CatSper channels form four linear Ca^2+^ signaling domains along the flagella, which orchestrate capacitation‐associated tyrosine phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/24813608?dopt=AbstractPlus>\].The driving force for Ca^2+^ entry is principally determined by a mildly outwardly rectifying K^+^ channel (KSper) that, like CatSpers, is activated by intracellular alkalinization \[<http://www.ncbi.nlm.nih.gov/pubmed/17460039?dopt=AbstractPlus>\]. Mouse KSper is encoded by *mSlo3*, a protein detected only in testis \[<http://www.ncbi.nlm.nih.gov/pubmed/19338774?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17460039?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21427226?dopt=AbstractPlus>\]. In human sperm, such alkalinization may result from the activation of Hv1, a proton channel \[<http://www.ncbi.nlm.nih.gov/pubmed/20679352?dopt=AbstractPlus>\]. Mutations in CatSpers are associated with syndromic and non‐syndromic male infertility \[<http://www.ncbi.nlm.nih.gov/pubmed/20648059?dopt=AbstractPlus>\]. In human ejaculated spermatozoa, progesterone (*\<*50 nM) potentiates the CatSper current by a non‐genomic mechanism and acts synergistically with intracellular alkalinisation \[<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>\]. Spermcells frominfertile patients witha deletion inCatSper2gene lack I~CatSper~ and the progesterone response \[<http://www.ncbi.nlm.nih.gov/pubmed/23530196?dopt=AbstractPlus>\]. In addition, certain prostaglandins (*e.g.* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5412>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882>) also potentiate CatSper mediated currents \[<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>,<http://www.ncbi.nlm.nih.gov/pubmed/21412339?dopt=AbstractPlus>\].

In human sperm, CatSper channels are also activated by various small molecules including endocrine disrupting chemicals (EDC) and proposed as a polymodal sensor \[<http://www.ncbi.nlm.nih.gov/pubmed/22354039?dopt=AbstractPlus>\].

TPCs are the major Na^+^ conductance in lysosomes; knocking out TPC1 and TPC2 eliminates the Na^+^ conductance and renders the organelle\'s membrane potential insensitive to changes in \[Na^+^\] (31). The channels are regulated by luminal pH \[<http://www.ncbi.nlm.nih.gov/pubmed/24776928?dopt=AbstractPlus>\], PI(3,5)P2 \[<http://www.ncbi.nlm.nih.gov/pubmed/23063126?dopt=AbstractPlus>\], intracellular ATP and extracellular amino acids \[<http://www.ncbi.nlm.nih.gov/pubmed/23394946?dopt=AbstractPlus>\]. TPCs are also involved in the NAADP‐activated Ca^2+^ release from lysosomal Ca^2+^ stores \[<http://www.ncbi.nlm.nih.gov/pubmed/19387438?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24277557?dopt=AbstractPlus>\]. Mice lacking TPCs are viable but have phenotypes including compromised lysosomal pH stability, reduced physical endurance \[<http://www.ncbi.nlm.nih.gov/pubmed/23394946?dopt=AbstractPlus>\], resistance to Ebola viral infection \[<http://www.ncbi.nlm.nih.gov/pubmed/25722412?dopt=AbstractPlus>\] and fatty liver \[<http://www.ncbi.nlm.nih.gov/pubmed/25144390?dopt=AbstractPlus>\]. No major human diseaseassociated TPC mutation has been reported.

Further reading on CatSper and Two‐Pore channels {#bph14749-sec-0058}
------------------------------------------------

Clapham DE *et al.* (2005) International Union of Pharmacology. L. Nomenclature and structure‐Kintzer AF *et al.* (2018) On the structure and mechanism of two‐pore channels. *FEBS J.* **285**: 233‐243 function relationships of CatSper and two‐pore channels. *Pharmacol. Rev.* **57**: 451‐4 \[<https://www.ncbi.nlm.nih.gov/pubmed/28656706?dopt=AbstractPlus>\] \[<https://www.ncbi.nlm.nih.gov/pubmed/16382101?dopt=AbstractPlus>\]

Grimm C *et al.* (2017) Two‐Pore Channels: Catalyzers of Endolysosomal Transport and Function. *Front Pharmacol* **8**: 45 \[<https://www.ncbi.nlm.nih.gov/pubmed/28223936?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71> {#bph14749-sec-0059}
==========================================================================

Overview {#bph14749-sec-0060}
--------

**Cyclic nucleotide‐gated (CNG) channels** are responsible for signalling in the primary sensory cells of the vertebrate visual and olfactory systems.

CNG channels arevoltage‐independent cation channels formed as tetramers. Each subunit has 6TM, with the pore‐forming domain between TM5 and TM6. CNG channels were first found in rod photoreceptors \[<http://www.ncbi.nlm.nih.gov/pubmed/2578616?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/2481236?dopt=AbstractPlus>\], where light signals through rhodopsin and transducin to stimulate phosphodiesterase and reduce intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>level. This results ina closure ofCNG channels and a reduced 'dark current'. Similar channels were found in the cilia of olfactory neurons \[<http://www.ncbi.nlm.nih.gov/pubmed/3027574?dopt=AbstractPlus>\] and the pineal gland \[<http://www.ncbi.nlm.nih.gov/pubmed/1719422?dopt=AbstractPlus>\]. The cyclic nucleotides bind to a domain in the C terminus of the subunit protein: other channels directly binding cyclic nucleotides include HCN, eag and certain plant potassium channels.

**A standardised nomenclature for CNG and HCN channels has been proposed by the [NC‐IUPHAR subcommittee on voltage‐gated ion channels]{.ul}** \[<http://www.ncbi.nlm.nih.gov/pubmed/16382102?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=394><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=395><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=396><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=399>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2148](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2148), <http://www.uniprot.org/uniprot/P29973>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2149](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2149), <http://www.uniprot.org/uniprot/Q16280>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2150](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2150), <http://www.uniprot.org/uniprot/Q16281>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2153](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2153), <http://www.uniprot.org/uniprot/Q9NQW8>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> (EC~50~ 30 *μ*M) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> (EC50 1 *μ*M)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> (EC~50~ 30 *μ*M) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>--Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2349> (high affinity binding requires presence of CNGB subunits)--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2313> (Antagonist) (pIC~50~ 6.7) \[0mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12508052?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2349> (Antagonist) (p*K* ~i~ 4) \[−80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7682292?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2313> (Antagonist) (pIC~50~ 5.6) \[0mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14981138?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2349> (Antagonist) (pIC~50~ 5.5) \[0mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10662822?dopt=AbstractPlus>\] -- MouseFunctional Characteristicsγ = 25‐30 pS *P*Ca/*P*Na = 3.1γ = 35 pS *P*Ca/*P*Na = 6.8γ = 40 pS *P* ~Ca~/*P* ~Na~ = 10.9--

Comments {#bph14749-sec-0061}
--------

CNGA1, CNGA2 and CNGA3 express functional channels as homomers. Three additional subunits [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2152](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2152) (<http://www.uniprot.org/uniprot/Q8IV77>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2151](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2151) (<http://www.uniprot.org/uniprot/Q14028>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2153](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2153) (<http://www.uniprot.org/uniprot/Q9NQW8>) do not, and are referred to as auxiliary subunits. The subunit composition of the native channels is believed to be as follows. Rod: CNGA1~3~/CNGB1a; Cone: CNGA3~2~/CNGB3~2~; Olfactory neurons: CNGA2~2~/CNGA4/CNGB1b \[<http://www.ncbi.nlm.nih.gov/pubmed/15134637?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12467591?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12467592?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15134638?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12432397?dopt=AbstractPlus>\].

Hyperpolarisation‐activated, cyclic nucleotide‐gated (HCN) {#bph14749-sec-0062}
----------------------------------------------------------

The hyperpolarisation‐activated, cyclic nucleotide‐gated (HCN) channels are cation channels that are activated by hyperpolarisation at voltages negative to ˜‐50 mV. The cyclic nucleotides <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> directly activate the channels and shift the activation curves of HCN channels to more positive voltages, thereby enhancing channel activity. HCN channels underlie pacemaker currents found in many excitable cells including cardiac cells and neurons \[<http://www.ncbi.nlm.nih.gov/pubmed/7682045?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8815797?dopt=AbstractPlus>\]. In native cells, these currents have a variety of names, such as *I* ~h~, *I*q and*I* ~f~. The four known HCN channels have six transmembrane domains and form tetramers.

It is believed that the channels can form heteromers with each other, as has been shown for HCN1 and HCN4 \[<http://www.ncbi.nlm.nih.gov/pubmed/12702747?dopt=AbstractPlus>\]. High resolution structural studies of CNG and HCN channels has provided insight into the the gating processes of these channels \[<http://www.ncbi.nlm.nih.gov/pubmed/28086084?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28099415?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=400><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=401><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=402><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=403>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4845](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4845), <http://www.uniprot.org/uniprot/O60741>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4846](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4846), <http://www.uniprot.org/uniprot/Q9UL51>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19183](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19183), <http://www.uniprot.org/uniprot/Q9P1Z3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16882](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16882), <http://www.uniprot.org/uniprot/Q9Y3Q4>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> (both weak)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357> (Antagonist) (pIC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16387796?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359> (Antagonist) (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (pIC~50~ 3.7) \[−40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357> (Antagonist) (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16387796?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359> (Antagonist) (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (pIC~50~ 3.7) \[−40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357> (Antagonist) (pIC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16387796?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359> (Antagonist) (pIC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (pIC~50~ 3.8) \[−40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357> (Antagonist) (pIC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16387796?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359> (Antagonist) (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (pIC~50~ 3.8) \[−40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16043489?dopt=AbstractPlus>\]

Comments {#bph14749-sec-0063}
--------

HCN channels are permeable to both Na^+^ and K^+^ ions, with a Na^+^/K^+^ permeability ratio of about 0.2. Functionally, they differ from each other in terms of time constant of activation with HCN1 the fastest, HCN4 the slowest and HCN2 and HCN3 intermediate. The compounds <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2359> \[<http://www.ncbi.nlm.nih.gov/pubmed/7693281?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2357> \[<http://www.ncbi.nlm.nih.gov/pubmed/12084770?dopt=AbstractPlus>\] have proven useful in identifying and studying functional HCN channels in native cells. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2358> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2355> are also useful blocking agents.

Further reading on Cyclic nucleotide‐regulated channels {#bph14749-sec-0064}
-------------------------------------------------------

James ZM *et al.* (2018) Structural insights into the mechanisms of CNBD channel function. *J. Gen. Physiol.* **150**: 225--244 \[<https://www.ncbi.nlm.nih.gov/pubmed/29233886?dopt=AbstractPlus>\]

Michalakis S *et al.* (2018) Retinal Cyclic Nucleotide‐Gated Channels: From Pathophysiology to Ther‐ apy. *Int J Mol Sci* **19**: \[<https://www.ncbi.nlm.nih.gov/pubmed/29518895?dopt=AbstractPlus>\]

Podda MV *et al.* (2014) New perspectives in cyclic nucleotide‐mediated functions in the CNS: the emerging role of cyclic nucleotide‐gated (CNG) channels. *Pflugers Arch.* **466**: 1241‐57 \[<https://www.ncbi.nlm.nih.gov/pubmed/24142069?dopt=AbstractPlus>\]

Sartiani L *et al.* (2017) The Hyperpolarization‐Activated Cyclic Nucleotide‐Gated Channels: from Biophysics to Pharmacology of a Unique Family of Ion Channels. *Pharmacol. Rev.* **69**: 354‐395 \[<https://www.ncbi.nlm.nih.gov/pubmed/28878030?dopt=AbstractPlus>\]

Wahl‐Schott C *et al.* (2014) HCN channels: new roles in sinoatrial node function. *Curr Opin Pharmacol* **15**: 83‐90 \[<https://www.ncbi.nlm.nih.gov/pubmed/24441197?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=133> {#bph14749-sec-0065}
===========================================================================

Overview {#bph14749-sec-0066}
--------

Activation of potassium channels regulates excitability and can control the shape of the action potential waveform. They are present in all cells within the body and can influence processes asdiverse ascognition, muscle contraction and hormone secretion. Potassium channels aresubdivided into families, based on their structural and functional properties. The largest family consists of potassium channels that activated by membrane depolarization, with other families consisting of channels that are either activated by a riseof intracellular calcium ions orareconstitutively active. A standardised nomenclature for potassium channels has been proposed by the **NC‐IUPHAR subcommittees** on potassium channels \[<http://www.ncbi.nlm.nih.gov/pubmed/16382106?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16382104?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16382105?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16382103?dopt=AbstractPlus>\], which has placed cloned channels into groups based on gene family and structure of channels that exhibit 6, 4 or 2 transmembrane domains (TM).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=69> {#bph14749-sec-0067}
==========================================================================

Overview {#bph14749-sec-0068}
--------

Calcium‐ and sodium‐ activated potassium channels are members of the 6TM family of K channels which comprises the voltage‐gated KV subfamilies, including the KCNQ subfamily, the EAG subfamily (which includes herg channels), the Ca^2+^‐ activated Slo subfamily (actually with 6 or 7TM) and the Ca^2+^and Na^+^‐activated SK subfamily (**nomenclature as agreed by the [NC‐IUPHAR]{.ul} Subcommittee on Calcium‐ and sodiumactivated potassium channels** \[<http://www.ncbi.nlm.nih.gov/pubmed/28267675?dopt=AbstractPlus>\]). As for the 2TM family, the pore‐forming a subunits form tetramers and heteromeric channels may be formed within subfamilies (*e.g.* KV1.1 with KV1.2; KCNQ2 with KCNQ3). Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6284](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6284), <http://www.uniprot.org/uniprot/Q12791>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4271>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4272>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2309> (p*K* ~i~ 8.7) \[0mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8938726?dopt=AbstractPlus>\] -- MouseChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2328>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4218>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343>Functional CharacteristicsMaxi K~Ca~ Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=381><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=382><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=383>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6290](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6290), <http://www.uniprot.org/uniprot/Q92952>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6291](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6291), <http://www.uniprot.org/uniprot/Q9H2S1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6292](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6292), <http://www.uniprot.org/uniprot/Q9UGI6>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314> (Agonist) Concentration range: 2×10−^3^M \[−80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11134030?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317> (Agonist) Concentration range: 3×10−^8^M‐1×10−^7^M \[‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15471565?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317> (Agonist) (pEC~50~ 6.2) Concentration range: 3×10−^8^M‐1×10−^7^M \[<http://www.ncbi.nlm.nih.gov/pubmed/16239218?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15471565?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314> (Agonist) (pEC~50~ 3.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16239218?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314> (Agonist) (pEC~50~ 3) Concentration range: 2×10−^3^M \[<http://www.ncbi.nlm.nih.gov/pubmed/11181893?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11134030?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314> (Agonist) (pEC~50~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14978258?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317> (Agonist) Concentration range: 3×10−^8^M \[<http://www.ncbi.nlm.nih.gov/pubmed/15471565?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2320> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/10696100?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2311> (pIC~50~ 7.9--8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10683185?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15208027?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2320> (pIC~50~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11278890?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2311> (p*K* ~d~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10713270?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2311> (pIC~50~ 7.9--9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11369031?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14978258?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2320> (pIC~50~ 8--9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11278890?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 2.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 2.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 2.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\]Functional CharacteristicsSK~Ca~SK~Ca~SK~Ca~CommentsThe rat isoform does not form functional channels when expressed alone in cell lines. N‐ or C‐terminal chimeric constructs permit functional channels that are insensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2311> \[<http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\]. Heteromeric channels are formed between KCa2.1 and 2.2 subunits that show intermediate sensitivity to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2311> \[<http://www.ncbi.nlm.nih.gov/pubmed/25421315?dopt=AbstractPlus>\].---- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=384><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=385><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=386><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=387>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6293](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6293), <http://www.uniprot.org/uniprot/O15554>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18865](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18865), <http://www.uniprot.org/uniprot/Q5JUK3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18866](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18866), <http://www.uniprot.org/uniprot/Q6UVM3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18867](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18867), <http://www.uniprot.org/uniprot/A8MYU2>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2317> (Agonist) (pEC~50~ 8) \[‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15471565?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20359520?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8492> (Agonist) (pEC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24958817?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2314> (Agonist) (pEC~50~ 4.1--4.5) \[‐100mV -- ‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11134030?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10712246?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2338> (Agonist) (pEC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16876206?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8494> (Agonist) (pEC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22171093?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205> (Agonist) (pEC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22171093?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> (Agonist) (pEC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20176855?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22851714?dopt=AbstractPlus>\]--Inhibitors--------Gating inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2337> (pIC~50~ 5--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16876206?dopt=AbstractPlus>\] -- Rat----Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2328> (pIC~50~ 7.6--8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9730970?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9380751?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342> (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/14684870?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16876206?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Inhibition) (pIC~50~ 3) \[<http://www.ncbi.nlm.nih.gov/pubmed/14684870?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342> (Inhibition) Concentration range: 1×10−^3^M \[<http://www.ncbi.nlm.nih.gov/pubmed/14684870?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342> Concentration range: 2×10−^5^M \[<http://www.ncbi.nlm.nih.gov/pubmed/19934650?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26045093?dopt=AbstractPlus>\] -- MouseSelective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2336> (Inhibition) (p*K* ~d~ 7.6--8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12939222?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10884437?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2331> (Inhibition) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12433690?dopt=AbstractPlus>\]------Functional CharacteristicsIK~Ca~K~Na~K~Na~Sperm pH‐regulated K^+^ current, KSPER

Further reading on Calcium‐ and sodium‐activated potassium channels {#bph14749-sec-0069}
-------------------------------------------------------------------

Dopico AM *et al.* (2018) Calcium‐ and voltage‐gated BK channels in vascular smooth muscle. *Pflugers Arch.* **470**: 1271‐1289 \[<https://www.ncbi.nlm.nih.gov/pubmed/29748711?dopt=AbstractPlus>\]

Kaczmarek LK *et al.* (2017) International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium‐Activated and Sodium‐Activated Potassium Channels. *Pharmacol. Rev.* **69**: 1‐11 \[<https://www.ncbi.nlm.nih.gov/pubmed/28267675?dopt=AbstractPlus>\]

Kshatri AS *et al.* (2018) Physiological Roles and Therapeutic Potential of Ca^2+^ Activated Potassium Channels in the Nervous System. *Front Mol Neurosci* **11**: 258 \[<https://www.ncbi.nlm.nih.gov/pubmed/30104956?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=74> {#bph14749-sec-0070}
==========================================================================

Overview {#bph14749-sec-0071}
--------

The 2TM domain family of K channels are also known as the inward‐rectifier K channel family. This family includes the strong inward‐rectifier K channels (K~ir~2.x) that are constitutively active, the G‐protein‐activated inward‐rectifier K channels (K~ir~3.x) and the ATP‐sensitive K channels (K~ir~6.x, which combine with sulphonylurea receptors (SUR1‐3)). The pore‐forming α subunits form tetramers, and heteromeric channels may be formed within subfamilies (*e.g.* K~ir~3.2 with K~ir~3.3). Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=429>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6255](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6255), <http://www.uniprot.org/uniprot/P48048>Ion Selectivity and ConductanceNH~4~ ^+^ \[62pS\] \> K^+^ \[38. pS\] \> Tl^+^ \[21pS\] \> Rb^+^ \[15pS\] (Rat) \[<http://www.ncbi.nlm.nih.gov/pubmed/10736307?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7680431?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2383> (Inhibition) (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10572003?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (pIC~50~ 2.3--4.2) Concentration range: 1×10^−4^M \[*voltage dependent* 0mV -- ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7680431?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8997197?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (pIC~50~ 2.9) \[*voltage dependent* ‐120mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8997197?dopt=AbstractPlus>\] -- RatFunctional CharacteristicsK~ir~1.1 is weakly inwardly rectifying, as compared to classical (strong) inward rectifiers.Comments-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=430><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=431><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=432><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=433>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6263](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6263), <http://www.uniprot.org/uniprot/P63252>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6258](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6258), <http://www.uniprot.org/uniprot/Q14500>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6265](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6265), <http://www.uniprot.org/uniprot/P48050>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6260](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6260), <http://www.uniprot.org/uniprot/Q9UNX9>Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> (Agonist) Concentration range: 1×10^−5^M‐5×10^−5^M \[‐30mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9486652?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15980413?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11172809?dopt=AbstractPlus>\] -- Mouse----Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>Endogenous inhibitors--Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (pIC~50~ 5) \[40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8735700?dopt=AbstractPlus>\]----Gating inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) Concentration range: 5×10^−5^M \[‐150mV -- ‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8083233?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) Concentration range: 5×10^−6^M‐5×10^−5^M \[‐150mV -- ‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8083233?dopt=AbstractPlus>\] -- Mouse----Endogenous channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> (Antagonist) (p*K* ~d~ 9.1) \[*voltage dependent* 40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8866861?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7748552?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390> (Antagonist) (p*K* ~d~ 8.1) \[*voltage dependent* 40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7748552?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388> (Antagonist) (p*K* ~d~ 5.1) \[*voltage dependent* 40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8866861?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7748552?dopt=AbstractPlus>\] -- Mouse, Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (Antagonist) (p*K* ~d~ 4.8) \[*voltage dependent* 40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7748552?dopt=AbstractPlus>\] -- Mouse--Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (Antagonist) (p*K* ~d~ 5) \[*voltage dependent* 50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7969496?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388> (Antagonist) Concentration range: 5×10^−5^M‐1×10^−3^M \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7969496?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390> (Antagonist) Concentration range: 2.5×10^−5^M‐1×10^−3^M \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7969496?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> (Antagonist) Concentration range: 5×10^−5^M‐1×10^−3^M \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7969496?dopt=AbstractPlus>\]--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (p*K* ~d~ 3.9--5.6) Concentration range: 1×10^−6^M‐1×10^−4^M \[*voltage dependent* 0mV -- ‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11454958?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (p*K* ~d~ 1.3--4) Concentration range: 3×10^−5^M‐3×10^−4^M \[*voltage dependent* 0mV -- ‐102mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8799888?dopt=AbstractPlus>\] -- Mouse--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (pIC~50~ 5) Concentration range: 3×10^−6^M‐5×10^−4^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8051145?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12032359?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8034048?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (p*K* ~i~ 1.3--4.5) Concentration range: 3×10^−6^M‐3×10^−4^M \[0mV -- ‐130mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8051145?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (p*K* ~d~ 3--4.1) \[*voltage dependent* ‐60mV -- ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10942728?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (p*K* ~d~ 3.3) \[*voltage dependent* 0mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10942728?dopt=AbstractPlus>\]Functional CharacteristicsIK~1~ in heart, 'strong' inward‐rectifier currentIK~1~ in heart, 'strong' inward‐rectifier currentIK~1~ in heart, 'strong' inward‐rectifier currentIK~1~ in heart, 'strong' inward‐rectifier currentCommentsK~ir~2.1 is also inhibited by intracellular polyaminesK~ir~2.2 is also inhibited by intracellular polyaminesK~ir~2.3 is also inhibited by intracellular polyaminesK~ir~2.4 is also inhibited by intracellular polyamines Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=434><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=435><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=436><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=437>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6264](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6264), <http://www.uniprot.org/uniprot/P48549>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6267](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6267), <http://www.uniprot.org/uniprot/P48051>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6270](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6270), <http://www.uniprot.org/uniprot/Q92806>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6266](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6266), <http://www.uniprot.org/uniprot/P48544>Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> (Agonist) (p*K* ~d~ 6.3) Concentration range: 5×10^−5^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9486652?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> (Agonist) (p*K* ~d~ 6.3) Concentration range: 5×10^−5^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9486652?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> \[<http://www.ncbi.nlm.nih.gov/pubmed/8688080?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> \[<http://www.ncbi.nlm.nih.gov/pubmed/9804555?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8688080?dopt=AbstractPlus>\]Gating inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90> (Antagonist) (pEC~50~ 5.5) \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10780978?dopt=AbstractPlus>\] -- Mouse----Endogenous channel blockers----Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2383> (Antagonist) (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10572004?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8234283?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2399> (Antagonist) (pIC~50~ 4.4) \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15150531?dopt=AbstractPlus>\] -- Mouse--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2383> (Antagonist) (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10572004?dopt=AbstractPlus>\]Functional CharacteristicsG protein‐activated inward‐rectifier currentG protein‐activated inward‐rectifier currentG protein‐activated inward‐rectifier currentG protein‐activated inward‐rectifier currentCommentsK~ir~3.1 is also activated by G~βγ~. K~ir~3.1 is not functional alone. The functional expression of Kir3.1 in *Xenopus oocytes* requires coassembly with the endogenous *Xenopus* K~ir~3.5 subunit. The major functional assembly in the heart is the K~ir~3.1/3.4 heteromultimer, while in the brain it is K~ir~3.1/3.2, K~ir~3.1/3.3 and K~ir~3.2/3.3.K~ir~3.2 is also activated by G~βγ~. K~ir~3.2 forms functional heteromers with K~ir~3.1/3.3.K~ir~3.3 is also activated by G~βγ~K~ir~3.4 is also activated by G~βγ~ Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=438><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=439><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=440>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6256](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6256), <http://www.uniprot.org/uniprot/P78508>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6261](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6261), <http://www.uniprot.org/uniprot/Q99712>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6262](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6262), <http://www.uniprot.org/uniprot/Q9NPI9>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) Concentration range: 3×10^−6^M‐1×10^−3^M \[‐160mV -- 60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12456399?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7608203?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10856114?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) Concentration range: 3×10^−5^M‐3×10^−4^M \[‐160mV -- 50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7608203?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) Concentration range: 1×10^−5^M‐1×10^−4^M \[‐120mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9882736?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) Concentration range: 1×10^−5^M‐1×10^−4^M \[‐120mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9882736?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) Concentration range: 3×10^−3^M \[‐120mV -- 20mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11988170?dopt=AbstractPlus>\] -- RatFunctional CharacteristicsInward‐rectifier currentInward‐rectifier currentWeakly inwardly rectifyingCommentsK~ir~3.3 is also activated by G~βγ~K~ir~3.4 is also activated by G~βγ~-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=441><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=442><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=443>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6269](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6269), <http://www.uniprot.org/uniprot/Q15842>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6257](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6257), <http://www.uniprot.org/uniprot/Q14654>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6259](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6259), <http://www.uniprot.org/uniprot/O60928>Associated subunitsSUR1, SUR2A, SUR2BSUR1, SUR2A, SUR2B--Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2413>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2409> (Agonist) Concentration range: 2×10^−4^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9130167?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4254>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2411> (Agonist) Concentration range: 3×10^−4^M \[‐60mV -- 60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9130167?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2409> (Agonist) (pEC~50~ 4.2) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7502040?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2413> (Agonist) Concentration range: 3×10^−5^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8630239?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4254>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2411>--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6848><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6848>--Channel blockers----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344> (Antagonist) (p*K* ~i~ 3.2) \[*voltage dependent* ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9786970?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9620703?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11179389?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9738472?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2356> (Antagonist) (p*K* ~i~ 1.6) \[*voltage dependent* ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9786970?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9620703?dopt=AbstractPlus>,<http://www.ncbi.nlm.nih.gov/pubmed/9738472?dopt=AbstractPlus>\]Functional CharacteristicsATP‐sensitive, inward‐rectifier currentATP‐sensitive, inward‐rectifier currentInward‐rectifier current

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=79> {#bph14749-sec-0072}
==========================================================================

Overview {#bph14749-sec-0073}
--------

The 4TM family of K channels mediate many of the background potassium currents observed in native cells. They are open across the physiological voltage‐range and are regulated by a wide array of neurotransmitters and biochemical mediators. The pore‐forming α‐subunit contains two pore loop (P) domains and two subunits assemble to form one ion conduction pathway lined by four P domains. It is important to note that single channels do not have two pores but that each subunit has two P domains in its primary sequence; hence the name two P domain, or K~2~P channels (and not two‐pore channels). Some of the K~2P~ subunits can form heterodimers across subfamilies (*e.g.* K~2P~3.1 with K~2P~9.1). The nomenclature of 4TM K channels in the literature is still a mixture of IUPHAR and common names. The suggested division into subfamilies, described in the <http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=79>, is based on similarities in both structural and functional properties within subfamilies and this explains the "common abbreviation" nomenclature in the tables below.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=513><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=514><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=515><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=516>Common abbreviationTWIK1TREK1TASK1TRAAKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6272](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6272), <http://www.uniprot.org/uniprot/O00180>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6277](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6277), <http://www.uniprot.org/uniprot/O95069>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6278](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6278), <http://www.uniprot.org/uniprot/O14649>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6279](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6279), <http://www.uniprot.org/uniprot/Q9NYG8>Endogenous activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (studied at 1‐10 *μ*M) (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9687497?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (studied at 1‐10 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/9628867?dopt=AbstractPlus>\]Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10337> (pEC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/29150838?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10336> (pEC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/30089357?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2503> (studied at 1‐5 mM) Concentration range: 8×10−^3^M \[<http://www.ncbi.nlm.nih.gov/pubmed/10321245?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401> (studied at 1‐5 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/10321245?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2505> (studied at 1‐5 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/10321245?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401> (studied at 1‐10 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/20519544?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326> (studied at 1‐100 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/10779373?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=208> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/15685212?dopt=AbstractPlus>\]----Channel blockers----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2506> (pIC~50~ ∼6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11226154?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> (pIC~50~ ∼6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11226154?dopt=AbstractPlus>\]--Functional CharacteristicsBackground currentBackground currentBackground currentBackground currentCommentsK~2P~1.1 is inhibited by acid pH~o~ external acidification with a pK~a~ 6.7 \[<http://www.ncbi.nlm.nih.gov/pubmed/20498050?dopt=AbstractPlus>\]. K~2P~1 forms heterodimers with K~2P~3 and K~2P~9 \[<http://www.ncbi.nlm.nih.gov/pubmed/23169818?dopt=AbstractPlus>\].K~2P~2.1 is also activated by membrane stretch, heat and acid pH~i~ \[<http://www.ncbi.nlm.nih.gov/pubmed/10835347?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10480871?dopt=AbstractPlus>\]. \>K~2P~2 can heterodimerize with \>K~2P~4 \[<http://www.ncbi.nlm.nih.gov/pubmed/27035965?dopt=AbstractPlus>\] and K~2P~10 \[<http://www.ncbi.nlm.nih.gov/pubmed/27035963?dopt=AbstractPlus>\].Knock‐out of the *kcnk3* gene leads to a prolonged QT interval in mice \[<http://www.ncbi.nlm.nih.gov/pubmed/21865850?dopt=AbstractPlus>\] and disrupted development of the adrenal cortex \[<http://www.ncbi.nlm.nih.gov/pubmed/18034154?dopt=AbstractPlus>\]. \>K~2P~3.1 is inhibited by acid pH~o~ with a pK~a~ of 6.4 \[<http://www.ncbi.nlm.nih.gov/pubmed/10748056?dopt=AbstractPlus>\]. \>K~2P~3 forms heterodimers with K~2~P1 \[<http://www.ncbi.nlm.nih.gov/pubmed/23169818?dopt=AbstractPlus>\] and K~2~P9 \[<http://www.ncbi.nlm.nih.gov/pubmed/11733509?dopt=AbstractPlus>\].K~2P~4 is activated by membrane stretch \[<http://www.ncbi.nlm.nih.gov/pubmed/9880510?dopt=AbstractPlus>\], and increased temperature (12 to 20‐fold between 17 and 40°C \[<http://www.ncbi.nlm.nih.gov/pubmed/15677687?dopt=AbstractPlus>\]) and can heterodimerize with \>K~2P~2 \[<http://www.ncbi.nlm.nih.gov/pubmed/27035965?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=517><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=518><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=519><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=520><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=521>Common abbreviationTASK2TWIK2--TASK3TREK2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6280](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6280), <http://www.uniprot.org/uniprot/O95279>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6281](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6281), <http://www.uniprot.org/uniprot/Q9Y257>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6282](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6282), <http://www.uniprot.org/uniprot/Q9Y2U2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6283](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6283), <http://www.uniprot.org/uniprot/Q9NPC2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6273](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6273), <http://www.uniprot.org/uniprot/P57789>Endogenous activators--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (studied at 1‐10 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/10880510?dopt=AbstractPlus>\]Activators------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401> (studied at 1‐5 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/11886861?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10337> \[<http://www.ncbi.nlm.nih.gov/pubmed/29150838?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401> (studied at 1‐5 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/10880510?dopt=AbstractPlus>\]Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2506> (studied at 1‐10 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/10747866?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> (studied at 1‐10 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/10747866?dopt=AbstractPlus>\]--Functional CharacteristicsBackground currentUnknownUnknownBackground currentBackground currentCommentsK~2P~5.1 is activated by alkaline pH~o~ \[<http://www.ncbi.nlm.nih.gov/pubmed/9812978?dopt=AbstractPlus>\]. Knockout of the kcnk5 gene in mice is associated with metabolic acidosis, hyponatremia and hypotension due to impaired bicarbonate handling in the kidney \[<http://www.ncbi.nlm.nih.gov/pubmed/15141089?dopt=AbstractPlus>\], as well as deafness \[<http://www.ncbi.nlm.nih.gov/pubmed/26549439?dopt=AbstractPlus>\]. The T108P mutation is associated with Balkan Endemic Nephropathy in humans \[<http://www.ncbi.nlm.nih.gov/pubmed/24949484?dopt=AbstractPlus>\].----K~2P~9.1 is also inhibited by acid pH~o~ with a pK~a~ of 6 \[<http://www.ncbi.nlm.nih.gov/pubmed/10747866?dopt=AbstractPlus>\]. Imprinting of the *KCNK9* gene is associated with Birk Barel syndrome \[<http://www.ncbi.nlm.nih.gov/pubmed/18678320?dopt=AbstractPlus>\]. K~2P~9 can form heterodimers with \>K~2P~1 \[<http://www.ncbi.nlm.nih.gov/pubmed/23169818?dopt=AbstractPlus>\] or K~2P~3 \[<http://www.ncbi.nlm.nih.gov/pubmed/11733509?dopt=AbstractPlus>\].K~2P~10.1 is also activated by membrane stretch \[<http://www.ncbi.nlm.nih.gov/pubmed/10880510?dopt=AbstractPlus>\] and can heterodimerize with K~2P~2 \[<http://www.ncbi.nlm.nih.gov/pubmed/27035963?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=522><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=523><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=524><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=525><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=526><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=527>Common abbreviationTHIK2THIK1TASK5TALK1TALK2TRESKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6274](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6274), <http://www.uniprot.org/uniprot/Q9HB15>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6275](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6275), <http://www.uniprot.org/uniprot/Q9HB14>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13814](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13814), <http://www.uniprot.org/uniprot/Q9H427>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14464](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14464), <http://www.uniprot.org/uniprot/Q96T55>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14465](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14465), <http://www.uniprot.org/uniprot/Q96T54>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19439](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19439), <http://www.uniprot.org/uniprot/Q7Z418>Endogenous inhibitors----------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (studied at 10‐50 *μ*M) \[<http://www.ncbi.nlm.nih.gov/pubmed/12754259?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2401> (studied at 5 mM) \[<http://www.ncbi.nlm.nih.gov/pubmed/25148687?dopt=AbstractPlus>\]--------Functional CharacteristicsDoes not function as a homodimer \[<http://www.ncbi.nlm.nih.gov/pubmed/11060316?dopt=AbstractPlus>\] but can form a functional heterodimer with K~2P~13 \[<http://www.ncbi.nlm.nih.gov/pubmed/25148687?dopt=AbstractPlus>\].Background currentUnknownBackground currentBackground currentBackground currentComments--Forms a heterodimer with K~2P~12 \[<http://www.ncbi.nlm.nih.gov/pubmed/25148687?dopt=AbstractPlus>\].--K~2P~16.1 current is increased by alkaline pH~o~ with a pK~a~ of 7.8 \[<http://www.ncbi.nlm.nih.gov/pubmed/14985088?dopt=AbstractPlus>\].K~2P~17.1 current is increased by alkaline pH~o~ with a pK~a~ of 8.8 \[<http://www.ncbi.nlm.nih.gov/pubmed/14985088?dopt=AbstractPlus>\].A frame‐shift mutation (F139WfsX24) in the *KCNK18* gene, is associated with migraine with aura in humans \[<http://www.ncbi.nlm.nih.gov/pubmed/20871611?dopt=AbstractPlus>\].

Comments {#bph14749-sec-0074}
--------

The K~2P~6, K~2P~7.1, K~2P~15.1and K~2P~12.1 subtypes, when expressed in isolation, are nonfunctional. All 4TM channels are insensitive to the classical potassium channel blockers <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416>, but are blocked to varying degrees by Ba^2+^ ions.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=81> {#bph14749-sec-0075}
==========================================================================

Overview {#bph14749-sec-0076}
--------

The 6TM family of K channels comprises the voltage‐gated K~V~ subfamilies, the EAG subfamily (which includes hERG channels), the Ca^2+^‐activated Slo subfamily (actually with 7TM termed BK) and the Ca^2+^‐activated SK subfamily. These channels possess a pore‐forming α subunit that comprise tetramers of identical subunits (homomeric) or of different subunits (heteromeric). Heteromeric channels can only be formed within subfamilies (e.g. ‐ K~v~1.1 with K~v~1.2; K~v~7.2 with K~v~7.3). The pharmacology largely, reflects the subunit composition of the functional channel. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=538><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=539><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=540><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=541><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=543><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=544>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6218](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6218), <http://www.uniprot.org/uniprot/Q09470>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6220](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6220), <http://www.uniprot.org/uniprot/P16389>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6221](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6221), <http://www.uniprot.org/uniprot/P22001>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6222](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6222), <http://www.uniprot.org/uniprot/P22459>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6224](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6224), <http://www.uniprot.org/uniprot/P22460>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6225](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6225), <http://www.uniprot.org/uniprot/P17658>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6226](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6226), <http://www.uniprot.org/uniprot/Q96RP8>Associated subunitsK~v~1.2, K~v~1.4, K~v~β1 and K~v~β2 \[<http://www.ncbi.nlm.nih.gov/pubmed/10428084?dopt=AbstractPlus>\]K~v~1.1, K~v~1.4, K~v~ β1 and K~v~ β2 \[<http://www.ncbi.nlm.nih.gov/pubmed/10428084?dopt=AbstractPlus>\]K~v~1.1, K~v~1.2, K~v~1.4, K~v~1.6, K~v~ β1 and K~v~ β2 \[<http://www.ncbi.nlm.nih.gov/pubmed/10428084?dopt=AbstractPlus>\]K~v~1.1, K~v~1.2, K~v~β1 and K~v~β2 \[<http://www.ncbi.nlm.nih.gov/pubmed/10428084?dopt=AbstractPlus>\]K~v~ β1 and K~v~ β2K~v~ β1 and K~v~ β2K~v~ β1 and K~v~ β2Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2563> (pEC~50~ 7.7--9) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1921987?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2547> (Inhibition) (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24878374?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (Inhibition) (p*K* ~d~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2547> (Inhibition) (pIC~50~ 11.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/24878374?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2563> (pIC~50~ 7.8--9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1921987?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2552> (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2547> (pIC~50~ 10--10.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8360176?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10961988?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2552> (p*K* ~d~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2332> (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9792177?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (p*K* ~d~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 1.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/2555158?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8508531?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2563> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/2347305?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 2.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/2347305?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2552> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9488722?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 3.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/9488722?dopt=AbstractPlus>\] -- MouseSelective channel blockers----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2555> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/10213593?dopt=AbstractPlus>\]--------Functional CharacteristicsK~V~K~V~K~V~K~A~K~v~K~V~K~V~Comments----Resistant to dendrotoxinsResistant to dendrotoxinsResistant to external TEA---- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=545><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=546><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=547><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=548><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=549><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=551>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6219](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6219), <http://www.uniprot.org/uniprot/Q16322>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6231](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6231), <http://www.uniprot.org/uniprot/Q14721>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6232), <http://www.uniprot.org/uniprot/Q92953>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6233](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6233), <http://www.uniprot.org/uniprot/P48547>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6234](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6234), <http://www.uniprot.org/uniprot/Q96PR1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6235](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6235), <http://www.uniprot.org/uniprot/Q14003>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6236](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6236), <http://www.uniprot.org/uniprot/Q03721>Associated subunitsK~v~ β1 and K~v~ β2K~v~5.1, K~v~6.1‐6.4, K~v~8.1‐8.2 and K~v~9.1‐9.3K~v~5.1, K~v~6.1‐6.4, K~v~8.1‐8.2 and K~v~9.1‐9.3------MiRP2 is an associated subunit for K~v~3.4Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 2.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10836990?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (Pore blocker) (pIC~50~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16478442?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 2.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9612272?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 2.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/9612272?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 3.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/7517498?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11790809?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11790809?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 3.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/1381835?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/1378392?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1840526?dopt=AbstractPlus>\] -- RatSelective channel blockers------------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2578> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9506974?dopt=AbstractPlus>\] -- RatFunctional CharacteristicsK~V~K~V~--K~V~K~V~K~A~K~A~ Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=552><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=553><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=554>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6237](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6237), <http://www.uniprot.org/uniprot/Q9NSA2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6238](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6238), <http://www.uniprot.org/uniprot/Q9NZV8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6239](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6239), <http://www.uniprot.org/uniprot/Q9UK17>Associated subunitsKChIP 1‐4, DP66, DPP10KChIP 1‐4, DPP6, DPP10, K~v~β1, NCS‐1, Navβ1KChIP 1‐4, DPP6 and DPP10, MinK, MiRPsChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416> (pIC~50~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/10729221?dopt=AbstractPlus>\]----Functional CharacteristicsK~A~K~A~K~A~ Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=555><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=556><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=557><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=558><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=559>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6246](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6246), <http://www.uniprot.org/uniprot/Q9H3M0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6248](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6248), <http://www.uniprot.org/uniprot/Q9UIX4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6249](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6249), <http://www.uniprot.org/uniprot/Q9UJ96>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18306](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18306), <http://www.uniprot.org/uniprot/Q8TAE7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19697](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19697), <http://www.uniprot.org/uniprot/Q8TDN1> Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=560><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=561><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=562><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=563><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=564>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6294](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6294), <http://www.uniprot.org/uniprot/P51787>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6296](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6296), <http://www.uniprot.org/uniprot/O43526>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6297](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6297), <http://www.uniprot.org/uniprot/O43525>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6298](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6298), <http://www.uniprot.org/uniprot/P56696>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6299](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6299), <http://www.uniprot.org/uniprot/Q9NR82>Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601> (pEC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5483> (pEC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/30021858?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601> (pEC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601> (pEC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601> (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11890900?dopt=AbstractPlus>\]Selective activators--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5483> (pEC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/30021858?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596> (p*K* ~d~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/10825393?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/12690036?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11245603?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/11245603?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599> (p*K* ~d~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10787416?dopt=AbstractPlus>\]Sub/family‐selective inhibitors--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596> (pIC~50~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/10816588?dopt=AbstractPlus>\]Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 3.5--3.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10711337?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10953053?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343> (pIC~50~ 1.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18786918?dopt=AbstractPlus>\]--Functional Characteristicscardiac IK~5~M current as a heteromer between K~V~7.2 and K~V~7.3M current as heteromeric K~V~7.2/K~V~7.3 or K~V~7.3/K~V~7.5--M current as heteromeric K~V~7.3/K~V~7.5 Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=565><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=566><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=567><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=568><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=569><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=570><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=571>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18861](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18861), <http://www.uniprot.org/uniprot/Q6PIU1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19698](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19698), <http://www.uniprot.org/uniprot/Q8TDN2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6300](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6300), <http://www.uniprot.org/uniprot/Q96KK3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6301](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6301), <http://www.uniprot.org/uniprot/Q9ULS6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6302](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6302), <http://www.uniprot.org/uniprot/Q9BQ31>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6250](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6250), <http://www.uniprot.org/uniprot/O95259>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6254](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6254), <http://www.uniprot.org/uniprot/Q8NCM2> Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=573><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=574><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=575><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=576><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=577>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6251](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6251), <http://www.uniprot.org/uniprot/Q12809>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18862](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18862), <http://www.uniprot.org/uniprot/Q9H252>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18863](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18863), <http://www.uniprot.org/uniprot/Q9NS40>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18864](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18864), <http://www.uniprot.org/uniprot/Q96L42>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6252](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6252), <http://www.uniprot.org/uniprot/Q9ULD8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6253](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6253), <http://www.uniprot.org/uniprot/Q9UQ05>Associated subunitsminK (KCNE1) and MiRP1 (KCNE2)minK (KCNE1)minK (KCNE1)minK (KCNE1)minK (KCNE1) and MiRP2 (KCNE3)--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2603> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10376921?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9395068?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7167> (Inhibition) (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/12873512?dopt=AbstractPlus>\]----------Sub/family‐selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2605> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9449325?dopt=AbstractPlus>\]----------Selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2604> (Inhibition) (p*K*i 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17536794?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7200> (pIC~50~ 7.6--8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12873512?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15266014?dopt=AbstractPlus>\]----------Functional Characteristicscardiac IK~R~----------Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7657> is an activator of K~v~11.1 \[<http://www.ncbi.nlm.nih.gov/pubmed/15548764?dopt=AbstractPlus>\].----------

Further reading on Potassium channels {#bph14749-sec-0077}
-------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=125> {#bph14749-sec-0078}
===========================================================================

Overview {#bph14749-sec-0079}
--------

The ryanodine receptors (RyRs) are found on intracellular Ca^2+^ storage/release organelles. The family of RyR genes encodes three highly related Ca^2+^ release channels: RyR1, RyR2 and RyR3, which assemble as large tetrameric structures. These RyR channels are ubiquitously expressed in many types of cells and participate in a variety of important Ca^2+^ signaling phenomena (neurotransmission, secretion, *etc*.). In addition to the three mammalian isoforms described below, various nonmammalian isoforms of the ryanodine receptor have been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/8874493?dopt=AbstractPlus>\]. The function of the ryanodine receptor channels may also be influenced by closely associated proteins such as the tacrolimus (FK506)‐binding protein, calmodulin \[<http://www.ncbi.nlm.nih.gov/pubmed/12707260?dopt=AbstractPlus>\], triadin, calsequestrin, junctin and sorcin, and by protein kinases and phosphatases. Recent studies solving the structure of the ryanodine receptor have shed light on the structural basis of ryanodine receptor function \[see, for example, Samso (2017) \[<http://www.ncbi.nlm.nih.gov/pubmed/27671094?dopt=AbstractPlus>\] and Meissner (2017) \[<http://www.ncbi.nlm.nih.gov/pubmed/29122978?dopt=AbstractPlus>\]\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=747><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=748><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=749>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10483](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10483), <http://www.uniprot.org/uniprot/P21817>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10484](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10484), <http://www.uniprot.org/uniprot/Q92736>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10485](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10485), <http://www.uniprot.org/uniprot/Q15413>Endogenous activatorscytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> (endogenous; mM range), cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (endogenous; *μ*M range), luminal <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (endogenous)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> (endogenous; mM range), cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (endogenous; *μ*M range), luminal <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (endogenous)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> (endogenous; mM range), cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (endogenous; *μ*M range)Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407> (pharmacological; mM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4303> (pharmacological; nM ‐ *μ*M range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728> (pharmacological; *μ*M range)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407> (pharmacological; mM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4303> (pharmacological; nM ‐ *μ*M range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728> (pharmacological; *μ*M range)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407> (pharmacological; mM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4303> (pharmacological; nM ‐ *μ*M range)Endogenous antagonistscytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> Concentration range: \>1×10^−4^M, cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (mM range)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> Concentration range: \>1×10^−3^M, cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (mM range)cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> Concentration range: \>1×10^−3^M, cytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (mM range)Antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4172>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4172>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4291>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4303> Concentration range: \>1×10^−4^M<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4291>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4303> Concentration range: \>1×^10−4^M<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432>Functional CharacteristicsCa^2+^: (*P* ~Ca~/*P* ~K~6) single‐channel conductance: 90 pS (50mM Ca^2+^), 770 pS (200 mM K^+^)Ca^2+^: (*P* ~Ca~/*P* ~K~6) single‐channel conductance: 90 pS (50mM Ca^2+^), 720 pS (210 mM K^+^)Ca^2+^: (*P* ~Ca~/*P* ~K~6) single‐channel conductance: 140 pS (50mM Ca^2+^), 777 pS (250 mM K^+^)CommentsRyR1 is also activated by depolarisation *via* DHP receptor, calmodulin at low cytosolic Ca^2+^ concentrations, CaM kinase and PKA; antagonised by calmodulin at high cytosolic Ca^2+^ concentrationsRyR2 is also activated by CaM kinase and PKA; antagonised by calmodulin at high cytosolic Ca^2+^ concentrationsRyR3 is also activated by calmodulin at low cytosolic Ca^2+^ concentrations; antagonised by calmodulin at high cytosolic Ca^2+^ concentrations

Comments {#bph14749-sec-0080}
--------

The modulators of channel function included in this table are those most commonly used to identify ryanodine‐sensitive Ca^2+^ release pathways. Numerous other modulators of ryanodine receptor/channel function can be found in the reviews listed below. The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect. The potential role of cyclic ADP ribose as an endogenous regulator of ryanodine receptor channels is controversial. A region of RyR likely to be involved in ion translocation and selection has been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/10920015?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10473538?dopt=AbstractPlus>\].

Further reading on Ryanodine receptors {#bph14749-sec-0081}
--------------------------------------

Dulhunty AF *et al.* (2017) Physiology and Pharmacology of Ryanodine Receptor Calcium Release Channels. *Adv. Pharmacol.* **79**: 287‐324 <https://www.ncbi.nlm.nih.gov/pubmed/28528672?dopt=AbstractPlus>

Meissner G. (2017) The structural basis of ryanodine receptor ion channel function. *J. Gen. Physiol.* **149**: 1065‐1089 <https://www.ncbi.nlm.nih.gov/pubmed/29122978?dopt=AbstractPlus>

O\'Brien F *et al.* (2015) The ryanodine receptor provides high throughput Ca2+‐release but is precisely regulated by networks of associated proteins: a focus on proteins relevant to phosphorylation. *Biochem. Soc. Trans.* **43**: 426‐33 <https://www.ncbi.nlm.nih.gov/pubmed/26009186?dopt=AbstractPlus>

Samsó M. (2017) A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM. *Protein Sci.* **26**: 52‐68 \[<https://www.ncbi.nlm.nih.gov/pubmed/27671094?dopt=AbstractPlus>

Van Petegem F. (2015) Ryanodine receptors: allosteric ion channel giants. *J. Mol. Biol.* **427**: 31‐53 \[<https://www.ncbi.nlm.nih.gov/pubmed/25134758?dopt=AbstractPlus>

Zalk R *et al.* (2017) Ca^2+^ Release Channels Join the 'Resolution Revolution'. *Trends Biochem. Sci.* **42**: 543‐555 <https://www.ncbi.nlm.nih.gov/pubmed/28499500?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=78> {#bph14749-sec-0082}
==========================================================================

Overview {#bph14749-sec-0083}
--------

The TRP superfamily of channels (**nomenclature as agreed by [NC‐IUPHAR]{.ul}** \[<http://www.ncbi.nlm.nih.gov/pubmed/14657417?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716668?dopt=AbstractPlus>\]), whose founder member is the *Drosophila* Trp channel, exists in mammals as six families; TRPC, TRPM, TRPV, TRPA, TRPP and TRPML based on amino acid homologies. TRP subunits contain six putative transmembrane domains and assemble as homo‐ or hetero‐tetramers to form cation selective channels with diverse modes of activation and varied permeation properties (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/16460288?dopt=AbstractPlus>\]). Established, or potential, physiological functions of the individual members of the TRP families are discussed in detail in the recommended reviews and in a number of books \[<http://www.ncbi.nlm.nih.gov/pubmed/29356469?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21290328?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25296415?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22593967?dopt=AbstractPlus>\]. The established, or potential, involvement of TRP channels in disease is reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/17138610?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17368864?dopt=AbstractPlus>\] and \[<http://www.ncbi.nlm.nih.gov/pubmed/20127491?dopt=AbstractPlus>\], together with a special edition of *Biochemica et Biophysica Acta* on the subject \[<http://www.ncbi.nlm.nih.gov/pubmed/17368864?dopt=AbstractPlus>\]. Additional disease related reviews, for pain \[<http://www.ncbi.nlm.nih.gov/pubmed/28924972?dopt=AbstractPlus>\], stroke \[<http://www.ncbi.nlm.nih.gov/pubmed/25502473?dopt=AbstractPlus>\], sensation and inflammation \[<http://www.ncbi.nlm.nih.gov/pubmed/25361914?dopt=AbstractPlus>\], itch \[<http://www.ncbi.nlm.nih.gov/pubmed/24830011?dopt=AbstractPlus>\], and airway disease \[<http://www.ncbi.nlm.nih.gov/pubmed/24286227?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22820171?dopt=AbstractPlus>\], are available. The pharmacology of most TRP channels has been advanced in recent years. Broad spectrum agents are listed in the tables along with more selective, or recently recognised, ligands that are flagged by the inclusion of a primary reference. See Rubaiy (2019) for a review of pharmacological tools for TRPC1/C4/C5 channels \[<http://www.ncbi.nlm.nih.gov/pubmed/30656647?dopt=AbstractPlus>\]. Most TRP channels are regulated by phosphoinostides such as PtIns(4,5)P~2~ although the effects reported are often complex, occasionally contradictory, and likely to be dependent upon experimental conditions, such as intracellular ATP levels (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/18923420?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19376575?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17395625?dopt=AbstractPlus>\]). Such regulation is generally not included in the tables.When thermosensitivity is mentioned, it refers specifically to a high Q10 of gating, often in the range of 10‐ 30, but does not necessarily imply that the channel\'s function is to act as a 'hot' or 'cold' sensor. In general, the search for TRP activators has led to many claims for temperature sensing, mechanosensation, and lipid sensing. All proteins are of course sensitive to energies of binding, mechanical force, and temperature, but the issue is whether the proposed input is within a physiologically relevant range resulting in a response.

TRPA (ankyrin) family {#bph14749-sec-0084}
---------------------

TRPA1 is the sole mammalian member of this group (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/17217068?dopt=AbstractPlus>\]). TRPA1 activation of sensory neurons contribute to nociception \[<http://www.ncbi.nlm.nih.gov/pubmed/14712238?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17686976?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12654248?dopt=AbstractPlus>\]. Pungent chemicals such as mustard oil (AITC), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2419>, and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2423> activate TRPA1 by modification of free thiol groups of cysteine side chains, especially those located in its amino terminus \[<http://www.ncbi.nlm.nih.gov/pubmed/16564016?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17164327?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15916949?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17942735?dopt=AbstractPlus>\]. Alkenals with α, β‐unsaturated bonds, such as propenal (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2418>), butenal (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6288>), and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2417> can react with free thiols *via* Michael addition and can activate TRPA1. However, potency appears to weaken as carbon chain length increases \[<http://www.ncbi.nlm.nih.gov/pubmed/18568077?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16564016?dopt=AbstractPlus>\]. Covalent modification leads to sustained activation of TRPA1. Chemicals including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2497>, menthol, and local anesthetics reversibly activate TRPA1 by non‐covalent binding \[<http://www.ncbi.nlm.nih.gov/pubmed/17855602?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21861907?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16192383?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16617338?dopt=AbstractPlus>\]. TRPA1 is not mechanosensitive under physiological conditions, but can be activated by cold temperatures \[<http://www.ncbi.nlm.nih.gov/pubmed/21068322?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19144922?dopt=AbstractPlus>\]. The electron cryo‐EM structure of TRPA1 \[<http://www.ncbi.nlm.nih.gov/pubmed/25855297?dopt=AbstractPlus>\] indicates that it is a 6‐TM homotetramer. Each subunit of the channel contains two short 'pore helices' pointing into the ion selectivity filter, which is big enough to allow permeation of partially hydrated Ca^2+^ ions. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=485>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:497](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:497), <http://www.uniprot.org/uniprot/O75762>Chemical activatorsIsothiocyanates (covalent) and 1,4‐dihydropyridines (non‐covalent)Oxidative stress compounds4‐oxo‐nonenal: pEC~50~ 5.7, H2O2 : pEC~50~ 3.6 (Mouse) \[<http://www.ncbi.nlm.nih.gov/pubmed/18322093?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18364033?dopt=AbstractPlus>\]Physical activatorsCooling (*\<*17°C) (disputed) \[<http://www.ncbi.nlm.nih.gov/pubmed/14712238?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15843607?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29539642?dopt=AbstractPlus>\]Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10293> (pEC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18550530?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2418> (Agonist) (pEC~50~ 5.3) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16564016?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2419> (Agonist) (pEC~50~ 5.1) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16103371?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424>‐<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> (Agonist) (pEC~50~ 4.9) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14712238?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585> (non‐covalent) (pEC~50~ 4.8) \[‐75mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19749751?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2499> (non‐covalent) (pEC~50~ 4.7) Concentration range: 6.2×10^−6^M‐2.5×10^−5^M \[<http://www.ncbi.nlm.nih.gov/pubmed/18334983?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339> (Agonist) (pEC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/17314320?dopt=AbstractPlus>\], (‐)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> (Partial agonist) (pEC~50~ 4--4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17855602?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18815250?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2423> (Agonist) (pEC~50~ 4.2) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15046718?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2429> (Agonist) Concentration range: 1×10^−4^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12654248?dopt=AbstractPlus>\] -- MouseSelective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10275> (pEC~50~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/26630251?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4158> (covalent) (pEC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18501939?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10274> (pEC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/24291101?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4196> (covalent. This level of activity is also observed for rat TRPA1) (pEC~50~ 3.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17942735?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17686976?dopt=AbstractPlus>\] -- MouseChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4134> (Inhibition) (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18086313?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (Inhibition) (pIC~50~ 5.5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15843607?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4211> (Inhibition) (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17686976?dopt=AbstractPlus>\]Selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10276> (Antagonist) (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/26942860?dopt=AbstractPlus>\]Functional Characteristicsγ = 87--100 pS; conducts mono‐ and di‐valent cations non‐selectively (P~Ca~/PN~a~ = 0.84); outward rectification; activated by elevated intracellular Ca^2+^CommentsmiRNA‐711 is a selective activator of TRPA1 (pEC~50~ 5.0) \[<http://www.ncbi.nlm.nih.gov/pubmed/30033153?dopt=AbstractPlus>\].

Comments {#bph14749-sec-0085}
--------

Agents activating TRPA1 in a covalent manner are thiol reactive electrophiles that bind to cysteine and lysine residues within the cytoplasmic domain of the channel \[<http://www.ncbi.nlm.nih.gov/pubmed/17164327?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17237762?dopt=AbstractPlus>\]. TRPA1 is activated by a wide range of endogenous and exogenous compounds and only a few representative examples arementioned in the table: an exhaustive listing can be found in \[<http://www.ncbi.nlm.nih.gov/pubmed/20356305?dopt=AbstractPlus>\]. In addition, TRPA1 is potently activated by intracellular zinc (EC~50~ = 8 nM) \[<http://www.ncbi.nlm.nih.gov/pubmed/19416844?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19202543?dopt=AbstractPlus>\]. A gain‐of‐function mutation in TRPA1 was found to cause familial episodic pain syndrome \[<http://www.ncbi.nlm.nih.gov/pubmed/20547126?dopt=AbstractPlus>\].

TRPC (canonical) family {#bph14749-sec-0086}
-----------------------

Members of the TRPC subfamily (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/18940894?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17486362?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21624095?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19281310?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15975974?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19273053?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20490539?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16133266?dopt=AbstractPlus>\]) fall into the subgroups outlined below. TRPC2 is a pseudogene in humans. It is generally accepted that all TRPC channels are activated downstream of G~q/11~‐coupled receptors, or receptor tyrosine kinases (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/12765689?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17217081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20716668?dopt=AbstractPlus>\]). A comprehensive listing of G‐protein coupled receptors that activate TRPC channels is given in \[<http://www.ncbi.nlm.nih.gov/pubmed/18940894?dopt=AbstractPlus>\]. Hetero‐oligomeric complexes of TRPC channels and their association with proteins to form signalling complexes are detailed in \[<http://www.ncbi.nlm.nih.gov/pubmed/17486362?dopt=AbstractPlus>\] and \[<http://www.ncbi.nlm.nih.gov/pubmed/17217079?dopt=AbstractPlus>\]. TRPC channels have frequently been proposed to act as store‐operated channels (SOCs) (or compenents of mulimeric complexes that form SOCs), activated by depletion of intracellular calcium stores (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/17486362?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28900918?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21290310?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23890115?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28900914?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16098585?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18536932?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19061922?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19574740?dopt=AbstractPlus>\]). However, the weight of the evidence is that they are not directly gated by conventional store‐operated mechanisms, as established for Stim‐gated Orai channels. TRPC channels are not mechanically gated in physiologically relevant ranges of force. All members of the TRPC family are blocked by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441> \[<http://www.ncbi.nlm.nih.gov/pubmed/15843919?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20932261?dopt=AbstractPlus>\]. Activation of TRPC channels by lipids is discussed by \[<http://www.ncbi.nlm.nih.gov/pubmed/21624095?dopt=AbstractPlus>\]. Important progress has been recently made in TRPC pharmacology \[<http://www.ncbi.nlm.nih.gov/pubmed/23763262?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26030081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29865154?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/30656647?dopt=AbstractPlus>\]. TRPC channels regulate a variety of physiological functions and are implicated in many human diseases \[<http://www.ncbi.nlm.nih.gov/pubmed/23412755?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27289383?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23054893?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26648074?dopt=AbstractPlus>\].

TRPC1/C4/C5 subgroup {#bph14749-sec-0087}
--------------------

TRPC1 alone may not form a functional ion channel \[<http://www.ncbi.nlm.nih.gov/pubmed/25268281?dopt=AbstractPlus>\]. TRPC4/C5 may be distinguished from other TRP channels by their potentiation by micromolar concentrations of La^3+^. TRPC2 is a pseudogene in humans, but in other mammals appears to be an ion channel localized to microvilli of the vomeronasal organ. It is required for normal sexual behavior in response to pheromones in mice. It may also function in the main olfactory epithelia in mice \[[571](#bph14749-bib-0571){ref-type="ref"}, <http://www.ncbi.nlm.nih.gov/pubmed/25001287?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25701815?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12601176?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26157356?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20142439?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15971083?dopt=AbstractPlus>\].

TRPC3/C6/C7 subgroup {#bph14749-sec-0088}
--------------------

All members are activated by diacylglycerol independent of protein kinase C stimulation \[<http://www.ncbi.nlm.nih.gov/pubmed/20932261?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=486><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=487><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=488><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=489>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12333](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12333), <http://www.uniprot.org/uniprot/P48995>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12334](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12334), --[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12335](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12335), <http://www.uniprot.org/uniprot/Q13507>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12336](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12336), <http://www.uniprot.org/uniprot/Q9UBN4>Chemical activatorsNO‐mediated cysteine S‐nitrosylationDiacylglycerol (SAG, OAG, DOG): strongly inhibited by Ca^2+^/CaM once activated by DAG \[<http://www.ncbi.nlm.nih.gov/pubmed/19228965?dopt=AbstractPlus>\]diacylglycerolsNO‐mediated cysteine S‐nitrosylation, potentiation by extracellular protonsPhysical activators--DAG kinase; regulates DAG concentration in vomeronasal sensory neurons----Endogenous activatorsmembrane stretch (likely direct)Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707>----Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2435> (Agonist) Concentration range: 1×10^−4^M \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14642279?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2437> (Agonist) Concentration range: 1×10^−4^M \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14642279?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10281> (pEC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/28395140?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10278> (Agonist) (pEC~50~ 7.1) \[[1099](#bph14749-bib-1099){ref-type="ref"}\](‐)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8372> (Agonist) (pEC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/25707820?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10287> (pEC~50~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/29859013?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (*μ*M range)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11301024?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (Antagonist) Concentration range: 2×10^−5^M \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8663995?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) Concentration range: 1×10^−4^M \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11301024?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) Concentration range: 5×10^−5^M \[‐70mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14642279?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5283> (Antagonist) Concentration range: 1×10^−5^M -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10284> (pIC~50~ 7.7) \[80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/24453217?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10279> (Antagonist) (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23886683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (Antagonist) (pEC~50~ 7) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10970899?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10283> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25847402?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2438> (Antagonist) (pIC~50~ 6.5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15647288?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4293> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19289841?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10282> (Antagonist) (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22862290?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7091> (p*K* ~i~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22530015?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) (pIC~50~ 5.4) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10970899?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10285> (pIC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/25140002?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) (pIC~50~ 5) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15933213?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10286> (Antagonist) (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/29385160?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4255> (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21795696?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10288> (Inhibition) (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/25816897?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10285> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/25140002?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (mM range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> (Antagonist) Concentration range: 3×10^−5^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12388058?dopt=AbstractPlus>\] -- MouseFunctional CharacteristicsIt is not yet clear that TRPC1 forms a homomer. It does form heteromers with TRPC4 and TRPC5γ = 42 pS linear single channel conductance in 150 mM symmetrical Na^+^ in vomeronasal sensory neurons. P~Ca~/P~Na~ = 2.7; permeant to Na^+^, Cs^+^, Ca^2+^, but not NMDG \[<http://www.ncbi.nlm.nih.gov/pubmed/25001287?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26157356?dopt=AbstractPlus>\]γ = 66 pS; conducts mono and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 1.6); monovalent cation current suppressed by extracellular Ca^2+^; dual (inward and outward) rectificationγ = 30 --41 pS, conducts mono and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 1.1 -- 7.7); dual (inward and outward) rectification Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=492>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12337](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12337), <http://www.uniprot.org/uniprot/Q9UL62>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12338](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12338), <http://www.uniprot.org/uniprot/Q9Y210>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20754](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20754), <http://www.uniprot.org/uniprot/Q9HCX4>Chemical activatorsNO‐mediated cysteine S‐nitrosylation (disputed), potentiation by extracellular protonsDiacylglycerolsdiacylglycerolsPhysical activatorsMembrane stretchMembrane stretch--Endogenous activatorsintracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (at negative potentials) (pEC~50~ 6.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4103>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508>--Activators(‐)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8372> (Agonist) (pEC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/25707820?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10287> (pEC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/29859013?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10289> (pEC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/28807145?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2326> (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24117252?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7088> (pEC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/28807145?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056> (pEC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21406603?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> Concentration range: 1×10^−4^M, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (*μ*M range), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2525> Concentration range: 5×10^−6^M, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826> (independent of tyrosine kinase inhibition) \[<http://www.ncbi.nlm.nih.gov/pubmed/20233211?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10278> (Agonist) (pIC~50~ 6.4) \[[1099](#bph14749-bib-1099){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10281> (pEC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/28395140?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4191>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4101> \[<http://www.ncbi.nlm.nih.gov/pubmed/20008516?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2764> \[<http://www.ncbi.nlm.nih.gov/pubmed/17666455?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10281> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/28395140?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10291> (Inhibition) (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/28325835?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10286> (Antagonist) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/29385160?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10292> (Inhibition) (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26565375?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=410> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/26565375?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10285> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25140002?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232> (Inhibition) (pIC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17658472?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10288> (Inhibition) (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/25816897?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4255> (pIC~50~ ∼5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21795696?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) (pIC~50~ 4.7) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15806115?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) Concentration range: 5×10^−3^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12456670?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10284> (pIC~50~ 8.5) \[80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/24453217?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10283> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/25847402?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10295> (Inhibition) (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/26500253?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10279> (Antagonist) (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23886683?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10285> (pIC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/25140002?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (Antagonist) (pIC~50~ 5.7) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11179201?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441> (Antagonist) (pIC~50~ 5.4) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11179201?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7091> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22530015?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (pIC~50~ ∼5.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (Antagonist) (pIC~50~ 3.9) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11179201?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (Antagonist) (pIC~50~ 3.6) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11179201?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2443>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4206>, Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4232>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4256><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10283> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/25847402?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) Concentration range: 1×10^−4^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10488066?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2441> (Antagonist) Concentration range: 2.5×10^−5^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10488066?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421>Selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10290> (Inhibition) (pIC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/29217578?dopt=AbstractPlus>\]----Functional Characteristicsγ = 41‐63 pS; conducts mono‐and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 1.8 -- 9.5); dual rectification (inward and outward) as a homomer, outwardly rectifying when expressed with TRPC1 or TRPC4γ = 28‐37 pS; conducts mono and divalent cations with a preference for divalents (P~Ca~/P~Na~ = 4.5--5.0); monovalent cation current suppressed by extracellular Ca^2+^ and Mg^2+^, dual rectification (inward and outward), or inward rectificationγ = 25--75 pS; conducts mono and divalent cations with a preference for divalents (P~Ca~/ P~Cs~ = 5.9); modest outward rectification (monovalent cation current recorded in the absence of extracellular divalents); monovalent cation current suppressed by extracellular Ca^2+^ and Mg^2+^

TRPM (melastatin) family {#bph14749-sec-0089}
------------------------

Members of the TRPM subfamily (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/15530641?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15843919?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16098585?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20233227?dopt=AbstractPlus>\]) fall into the five subgroups outlined below.

TRPM1/M3 subgroup {#bph14749-sec-0090}
-----------------

In darkness, glutamate released by the photoreceptors and ON‐bipolar cells binds to the metabotropic glutamate receptor 6, leading to activation of Go . This results in the closure of TRPM1. When the photoreceptors are stimulated by light, glutamate release is reduced, and TRPM1 channels are more active, resulting in cell membrane depolarization. Human TRPM1 mutations are associated with congenital stationary night blindness (CSNB), whose patients lack rod function. TRPM1 is also found melanocytes. Isoforms of TRPM1 may present in melanocytes, melanoma, brain, and retina. In melanoma cells, TRPM1 is prevalent in highly dynamic intracellular vesicular structures \[<http://www.ncbi.nlm.nih.gov/pubmed/24756714?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19436059?dopt=AbstractPlus>\]. TRPM3 (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/17217062?dopt=AbstractPlus>\]) exists as multiple splice variants which differ significantly in their biophysical properties. TRPM3 is expressed in somatosensory neurons and may be important in development of heat hyperalgesia during inflammation (see review \[<http://www.ncbi.nlm.nih.gov/pubmed/28720517?dopt=AbstractPlus>\]). TRPM3 is frequently coexpressed with TRPA1 and TRPV1 in these neurons. TRPM3 is expressed in pancreatic beta cells as well as brain, pituitary gland, eye, kidney, and adipose tissue \[<http://www.ncbi.nlm.nih.gov/pubmed/24756716?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23511953?dopt=AbstractPlus>\]. TRPM3 may contribute to the detection of noxious heat \[<http://www.ncbi.nlm.nih.gov/pubmed/21555074?dopt=AbstractPlus>\].

TRPM2 {#bph14749-sec-0091}
-----

TRPM2 is activated under conditions of oxidative stress (respiratory burst of phagocytic cells) and ischemic conditions. However, the direct activators are ADPR(P) and calcium. As for many ion channels, PIP~2~ must also be present (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/20553742?dopt=AbstractPlus>\]). Numerous splice variants of TRPM2 exist which differ in their activation mechanisms \[<http://www.ncbi.nlm.nih.gov/pubmed/19372375?dopt=AbstractPlus>\]. The C‐terminal domain contains a TRP motif, a coiled‐coil region, and an enzymatic NUDT9 homologous domain. TRPM2 appears not to be activated by NAD, NAAD, or NAADP, but is directly activated by ADPRP (adenosine5′‐O‐disphosphoribose phosphate) \[<http://www.ncbi.nlm.nih.gov/pubmed/25918360?dopt=AbstractPlus>\]. TRPM2 is involved in warmth sensation \[<http://www.ncbi.nlm.nih.gov/pubmed/2955270?dopt=AbstractPlus>\], and contributes to neurological diseases \[<http://www.ncbi.nlm.nih.gov/pubmed/29671419?dopt=AbstractPlus>\]. Recent study shows that 2′‐deoxy‐ADPR is an endogenous TRPM2 superagonist \[<http://www.ncbi.nlm.nih.gov/pubmed/28671679?dopt=AbstractPlus>\].

TRPM4/5 subgroup {#bph14749-sec-0092}
----------------

TRPM4 and TRPM5 have the distinction within all TRP channels of being impermeable to Ca^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/20716668?dopt=AbstractPlus>\]. A splice variant of TRPM4 (*i.e.*TRPM4b) and TRPM5 are molecular candidates for endogenous calcium‐activated cation (CAN) channels \[<http://www.ncbi.nlm.nih.gov/pubmed/21290294?dopt=AbstractPlus>\]. TRPM4 is active in the late phase of repolarization of the cardiac ventricular action potential. TRPM4 deletion or knockout enhances beta adrenergic‐mediated inotropy \[<http://www.ncbi.nlm.nih.gov/pubmed/24226423?dopt=AbstractPlus>\]. Mutations are associated with conduction defects \[<http://www.ncbi.nlm.nih.gov/pubmed/25600961?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24226423?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21887725?dopt=AbstractPlus>\]. TRPM4 has been shown to be an important regulator of Ca^2+^ entry in to mast cells \[<http://www.ncbi.nlm.nih.gov/pubmed/17217063?dopt=AbstractPlus>\] and dendritic cell migration \[<http://www.ncbi.nlm.nih.gov/pubmed/18758465?dopt=AbstractPlus>\]. TRPM5 in taste receptor cells of the tongue appears essential for the transduction of sweet, amino acid and bitter stimuli \[<http://www.ncbi.nlm.nih.gov/pubmed/17217064?dopt=AbstractPlus>\] TRPM5 contributes to the slow afterdepolarization of layer 5 neurons in mouse prefrontal cortex \[<http://www.ncbi.nlm.nih.gov/pubmed/25237295?dopt=AbstractPlus>\]. Both TRPM4 and TRPM5 are required transduction of taste stimuli \[<http://www.ncbi.nlm.nih.gov/pubmed/29311301?dopt=AbstractPlus>\].

TRPM6/7 subgroup {#bph14749-sec-0093}
----------------

TRPM6 and 7 combine channel and enzymatic activities ('chanzymes'). These channels have the unusual property of permeation by divalent (Ca^2+^, Mg^2+^, Zn^2+^) and monovalent cations, high single channel conductances, but overall extremely small inward conductance when expressed to the plasma membrane. They are inhibited by internal Mg^2+^ at 0.6 mM, around the free level of Mg^2+^ in cells. Whether they contribute to Mg^2+^ homeostasis is a contentious issue. When either gene is deleted in mice, the result is embryonic lethality. The C‐terminal kinase region is cleaved under unknown stimuli, and the kinase phosphorylates nuclear histones. TRPM7 is responsible for oxidant‐ induced Zn^2+^ release from intracellular vesicles \[<http://www.ncbi.nlm.nih.gov/pubmed/28696294?dopt=AbstractPlus>\] and contributes to intestinal mineral absorption essential for postnatal survival \[<http://www.ncbi.nlm.nih.gov/pubmed/30770447?dopt=AbstractPlus>\].

TRPM8 {#bph14749-sec-0094}
-----

Is a channel activated by cooling and pharmacological agents evoking a 'cool' sensation and participates in the thermosensation of cold temperatures \[<http://www.ncbi.nlm.nih.gov/pubmed/17538622?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17481392?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17481391?dopt=AbstractPlus>\] reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/20932257?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21290296?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20932258?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17217067?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=493><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=494>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7146](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7146), <http://www.uniprot.org/uniprot/Q7Z4N2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12339](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12339), <http://www.uniprot.org/uniprot/O94759>Chemical activators--Agents producing reactive oxygen (e.g. H~2~O~2~) and nitrogen (e.g. GEA 3162) speciesPhysical activators--Heat 35°CEndogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> \[<http://www.ncbi.nlm.nih.gov/pubmed/21278253?dopt=AbstractPlus>\]intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2445> (Agonist) (pEC~50~ 5) \[‐80mV -- ‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16585058?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15808509?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16601673?dopt=AbstractPlus>\], intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2444> (Agonist) (pEC~50~ 3.9--4.4) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11385575?dopt=AbstractPlus>\], intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (perhaps *via* calmodulin), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448> (Agonist) Concentration range: 5×10^−7^M‐5×10^−5^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15302683?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11804595?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14512294?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12562896?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11960981?dopt=AbstractPlus>\], membrane <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> \[<http://www.ncbi.nlm.nih.gov/pubmed/22847436?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (Potentiation) Concentration range: 1×10^−5^M‐3×10^−5^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11804595?dopt=AbstractPlus>\]Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4200>Endogenous channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ 6)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ 6), extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346>Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) (pIC~50~ 6.1) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/18204483?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2443> (Antagonist) (pIC~50~ 5.8) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16604090?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330> (Antagonist) Concentration range: 3×10^−6^M‐3×10^−5^M \[‐60mV -- ‐15mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15549272?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2446> (Antagonist) Concentration range: 3×10^−6^M‐3×10^−5^M \[‐60mV -- ‐15mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15549272?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (Antagonist) Concentration range: 5×10^−5^M‐1×10^−3^M \[‐60mV -- ‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15275834?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18204483?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2449> (Antagonist) Concentration range: 1×10^−5^M \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/18204483?dopt=AbstractPlus>\]Functional CharacteristicsConducts mono‐ and di‐valent cations non‐selectively, dual rectification (inward and outward)γ = 52‐60 pS at negative potentials, 76 pS at positive potentials; conducts mono‐ and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 0.6‐0.7); non‐rectifying; inactivation at negative potentials; activated by oxidative stress probably *via* PARP‐1, PARP inhibitors reduce activation by oxidative stress, activation inhibited by suppression of APDR formation by glycohydrolase inhibitors.Comments--Additional endogenous activators include 2′‐deoxy‐ADPR, 3′‐deoxy‐ADPR, 2′‐phospho‐ADPR, 2‐F‐ADPR and ADP‐ribose‐2′‐phosphate (ADPRP) \[<http://www.ncbi.nlm.nih.gov/pubmed/28671679?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25918360?dopt=AbstractPlus>\]. 8‐Br‐cADPR acts as a gating inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/15808509?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=495><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=496>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17992](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17992), <http://www.uniprot.org/uniprot/Q9HCF6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17993](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17993), <http://www.uniprot.org/uniprot/Q8TD43>Other channel blockers--Intracellular nucleotides including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2456> with an IC~50~ range of 1.3‐1.9 *μ*MPhysical activatorsheat (Q~10~ = 7.2 between 15 ‐ 25°C), hypotonic cell swelling \[<http://www.ncbi.nlm.nih.gov/pubmed/12672799?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21555074?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29305649?dopt=AbstractPlus>\]Membrane depolarization (V~½~ = ‐20 mV to + 60 mV dependent upon conditions) in the presence of elevated \[Ca^2+^\]~i~, heat (Q~10~ = 8.5 @ +25 mV between 15 and 25°C)Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4290> (pEC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18978782?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> (Agonist) (pEC~50~ 4.9) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15550678?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> (Agonist) (pEC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15550678?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4188> \[<http://www.ncbi.nlm.nih.gov/pubmed/20735426?dopt=AbstractPlus>\]intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (Agonist) (pEC~50~ 3.9--6.3) \[‐100mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16424899?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15331675?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15590641?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16407466?dopt=AbstractPlus>\]Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10297> (pEC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/25733887?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28720517?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2438> (Agonist) (pEC~50~ 8.1) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16407466?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2459> (Agonist) (pEC~50~ 5.7) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15331675?dopt=AbstractPlus>\]Gating inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15806115?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (Antagonist) (pIC~50~ 5.6) \[100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15670874?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330> (Antagonist) Concentration range: 1×10^−6^M‐1×10^−5^M \[100mV\] \[[720](#bph14749-bib-0720){ref-type="ref"}\]Endogenous channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (Antagonist) (pIC~50~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15824111?dopt=AbstractPlus>\] -- Mouse, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2340> (TRPM3α2 only)--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10299> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006495?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5338> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/28106668?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2402> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/28106668?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/27433342?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8899> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006495?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10298> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006495?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23190005?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (Antagonist) (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/12672799?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12672827?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) (pIC~50~ 4) \[<http://www.ncbi.nlm.nih.gov/pubmed/12672799?dopt=AbstractPlus>,<http://www.ncbi.nlm.nih.gov/pubmed/12672827?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4114> (pIC~50~ 4.6--4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18297105?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> (Antagonist) (pIC~50~ 4.2) \[100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14758478?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> (pIC~50~ 3.2)Functional CharacteristicsTRPM3~1235~: γ = 83 pS (Na^+^ current), 65 pS (Ca^2+^ current); conducts mono and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 1.6) TRPM3α1: selective for monovalent cations (P~Ca~/P~Cs~0.1); TRPM3α2: conducts mono‐ and di‐valent cations non‐selectively (P~Ca~/P~Cs~ = 1‐10); In‐ and outwardly rectifying currents by co‐application of pregnenolone sulphate and clotrimazole or single application of CIM0216 \[<http://www.ncbi.nlm.nih.gov/pubmed/25733887?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24390427?dopt=AbstractPlus>\].γ = 23 pS (within the range 60 to +60 mV); permeable to monovalent cations; impermeable to Ca^2+^; strong outward rectification; slow activation at positive potentials, rapid deactivation at negative potentials, deactivation blocked by decavanadateCommentsG protein βγ subunits can act as endogenous inhibitors of TRPM3 channel activity \[<http://www.ncbi.nlm.nih.gov/pubmed/28829742?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28826482?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/28826490?dopt=AbstractPlus>\].-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=497><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=498>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14323](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14323), <http://www.uniprot.org/uniprot/Q9NZQ8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17995](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17995), <http://www.uniprot.org/uniprot/Q9BX84>EC number--[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)Other chemical activators--constitutively active, activated by reduction of intracellular Mg^2+^Physical activatorsmembrane depolarization (V~½~ = 0 to + 120 mV dependent upon conditions), heat (Q~10~ = 10.3 @ ‐75 mV between 15 and 25°C)--Endogenous activatorsintracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (Agonist) (pEC~50~ 4.5--6.2) \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12842017?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14657398?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15670874?dopt=AbstractPlus>\] -- Mouseextracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> (Potentiation), intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Agonist) (pEC~50~ 3.4--3.7) \[‐120mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16636202?dopt=AbstractPlus>\]Endogenous channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (inward current mediated by monovalent cations is blocked) (pIC~50~ 5.5--6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (inward current mediated by monovalent cations is blocked) (pIC~50~ 5.3--5.3)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (pIC~50~ 4.6), intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> (pIC~50~ 4.4), Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> (pIC~50~ 3.2)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (pIC~50~ 7) \[*voltage dependent* ‐120mV\]Functional Characteristicsγ = 15‐25 pS; conducts monovalent cations selectively (P~Ca~/P~Na~ = 0.05); strong outward rectification; slow activation at positive potentials, rapid inactivation at negative potentials; activated and subsequently desensitized by \[Ca^2+^\]~I~γ= 40--87 pS; permeable to mono‐ and di‐valent cations with a preference for divalents (Mg^2+^ \> Ca^2+^; P~Ca~/P~Na~ = 6.9), conductance sequence Zn^2+^ \> Ba^2+^ \> Mg^2+^= Ca^2+^ = Mn^2+^ \> Sr^2+^ \> Cd^2+^\> Ni^2+^; strong outward rectification abolished by removal of extracellular divalents, inhibited by intracellular Mg^2+^ (IC~50~ = 0.5 mM) and ATPCommentsTRPM5 is not blocked by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=499><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17994](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17994), <http://www.uniprot.org/uniprot/Q96QT4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17961](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17961), <http://www.uniprot.org/uniprot/Q7Z2W7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)--Chemical activators--agonist activities are temperature dependent and potentiated by coolingPhysical activators--depolarization (V~½~ +50 mV at 15°C), cooling (*\<* 22‐26°C)Endogenous activatorsExtracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> (Potentiation)--Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> Concentration range: \>1×10^−3^M \[<http://www.ncbi.nlm.nih.gov/pubmed/11385574?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640> \[<http://www.ncbi.nlm.nih.gov/pubmed/24633576?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2429> (Agonist) (pEC~50~ 6.7--6.9) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15190109?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14757700?dopt=AbstractPlus>\] -- Mouse, (‐)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> (inhibited by intracellular Ca^2+^) (pEC~50~ 4.6) \[‐120mV -- 160mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15306801?dopt=AbstractPlus>\]Selective activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4343> (Full agonist) (pEC~50~ 4.9) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/18930858?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20816009?dopt=AbstractPlus>\] -- RatChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710> (Inhibition) (p*K* ~i~ 5.6) \[‐110mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12149283?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Inhibition) (pIC~50~ 3.8) \[‐100mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16636202?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2497> (Inhibition) (pIC~50~ 3.5) \[‐100mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19135721?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> (Antagonist) (pIC~50~ 2.5) \[80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11385574?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> (Antagonist) Concentration range: 2×10^−3^M \[‐100mV -- 100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11161216?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2460> (Antagonist) (pIC~50~ 6.1) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14757700?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Antagonist) (pIC~50~ 4.9--5.1) \[100mV -- ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15194687?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21964764?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2461> (Antagonist) (pIC~50~ 4.7) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14757700?dopt=AbstractPlus>\] -- MouseSelective channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10300> (Antagonist) (pIC~50~ 7) \[*voltage dependent*\] \[<http://www.ncbi.nlm.nih.gov/pubmed/25893043?dopt=AbstractPlus>\]Functional Characteristicsγ = 40‐105 pS at negative and positive potentials respectively; conducts mono‐and di‐valent cations with a preference for monovalents (P~Ca~/P~Na~ = 0.34); conductance sequence Ni^2+^ \> Zn^2+^ \> Ba^2+^ = Mg^2+^ \> Ca^2+^ = Mn^2+^ \> Sr^2+^ \> Cd^2+^; outward rectification, decreased by removal of extracellular divalent cations; inhibited by intracellular Mg^2+^, Ba^2+^, Sr^2+^, Zn^2+^, Mn^2+^ and Mg.ATP (disputed); activated by and intracellular alkalinization; sensitive to osmotic gradientsγ = 40‐83 pS at positive potentials; conducts mono‐ and di‐valent cations non‐selectively (P~Ca~/P~Na~ = 1.0--3.3); pronounced outward rectification; demonstrates densensitization to chemical agonists and adaptation to a cold stimulus in the presence of Ca^2+^; modulated by lysophospholipids and PUFAsComments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> acts as a channel blocker in the *μ*M range. Recent study shows cAMP inhibits TRPM7‐mediated Ca^2+^ influx \[<http://www.ncbi.nlm.nih.gov/pubmed/30615643?dopt=AbstractPlus>\]. Waixenicin‐A specifically inhibits TRPM7 \[<http://www.ncbi.nlm.nih.gov/pubmed/21926172?dopt=AbstractPlus>\].<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4150> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> are examples of cannabinoid activators. TRPM8 is insensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2429> requires intracellular Ca^2+^ for full agonist activity.

Comments {#bph14749-sec-0095}
--------

Ca^2+^ activates all splice variants of TRPM2, but other activators listed are effective only at the full length isoform \[<http://www.ncbi.nlm.nih.gov/pubmed/19372375?dopt=AbstractPlus>\]. Inhibition of TRPM2 by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2449>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2446>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> is largely irreversible. Co‐application of pregnenolone sulphate and clotrimazole caused TRPM3 currents to acquire an inwardly rectifying component at negative voltages, resulting in a biphasic conductance‐voltage relationship. Evidence was presented that the inward current might reflect the permeation of cations through the opening of a non‐canonical pore \[<http://www.ncbi.nlm.nih.gov/pubmed/24390427?dopt=AbstractPlus>\]. TRPM3 activity is impaired in chronic fatigue syndrome/myalgic encephalomyelitis patients suggesting changes in intracellular Ca^2+^ concentration, which may impact natural killer cellular functions \[<http://www.ncbi.nlm.nih.gov/pubmed/30134818?dopt=AbstractPlus>\]. TRPM4 exists as multiple spice variants: data listed are for TRPM4b. The sensitivity of TRPM4b and TRPM5 to activation by \[Ca^2+^\]~i~ demonstrates a pronounced and time‐dependent reduction following excision of inside‐out membrane patches \[<http://www.ncbi.nlm.nih.gov/pubmed/15670874?dopt=AbstractPlus>\]. The V~½~ for activation of TRPM4 and TRPM5 demonstrates a pronounced negative shift with increasing temperature. Activation of TRPM8 by depolarization is strongly temperature‐dependent via a channel‐closing rate that decreases with decreasing temperature. The V~½~ is shifted in the hyperpolarizing direction both by decreasing temperature and by exogenous agonists, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> \[<http://www.ncbi.nlm.nih.gov/pubmed/15306801?dopt=AbstractPlus>\] whereas antagonists produce depolarizing shifts in V~½~ \[<http://www.ncbi.nlm.nih.gov/pubmed/17317754?dopt=AbstractPlus>\]. The V~½~ for the native channel is far more positive than that of heterologously expressed TRPM8 \[<http://www.ncbi.nlm.nih.gov/pubmed/17317754?dopt=AbstractPlus>\]. It should be noted that <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> and structurally related compounds can elicit release of Ca^2+^ from the endoplasmic reticulum independent of activation of TRPM8 \[<http://www.ncbi.nlm.nih.gov/pubmed/17142461?dopt=AbstractPlus>\]. Intracellular pH modulates activation of TRPM8 by cold and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2429>, but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> \[<http://www.ncbi.nlm.nih.gov/pubmed/15190109?dopt=AbstractPlus>\].

TRPML (mucolipin) family {#bph14749-sec-0096}
------------------------

The TRPML family \[<http://www.ncbi.nlm.nih.gov/pubmed/26336837?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19158345?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15971078?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25668017?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17306511?dopt=AbstractPlus>\] consists of three mammalian members (TRPML1‐3). TRPML channels are probably restricted to intracellular vesicles and mutations in the gene (*MCOLN1*) encoding TRPML1 (mucolipin‐1) cause the neurodegenerative disorder mucolipidosis type IV (MLIV) in man. TRPML1 is a cation selective ion channel that is important for sorting/transport of endosomes in the late endocytotic pathway and specifically, fission from late endosome‐lysosome hybrid vesicles and lysosomal exocytosis \[<http://www.ncbi.nlm.nih.gov/pubmed/23993788?dopt=AbstractPlus>\]. TRPML2 and TRPML3 show increased channel activity in low extracellular sodium and are activated by similar small molecules \[<http://www.ncbi.nlm.nih.gov/pubmed/22753890?dopt=AbstractPlus>\]. A naturally occurring gain of function mutation in TRPML3 (*i.e.* A419P) results in the varitint waddler (V*a*) mouse phenotype (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/17237345?dopt=AbstractPlus>,<http://www.ncbi.nlm.nih.gov/pubmed/15971078?dopt=AbstractPlus>\]). Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=501><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=502><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=503>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13356](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13356), <http://www.uniprot.org/uniprot/Q9GZU1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13357](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13357), <http://www.uniprot.org/uniprot/Q8IZK6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13358](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13358), <http://www.uniprot.org/uniprot/Q8TDD5>Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794> (Also activates other TRPMLs) (pEC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus>\]----Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386> (pEC~50~ 7.3) \[‐140mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9783> (pEC~50~ 7) \[‐200mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/25119295?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6389> (pEC~50~ 6.3) \[‐200mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/25119295?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6387> (pEC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\] TRPML1^Va^: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386> Concentration range: 1×10^−5^M \[‐140mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794> Concentration range: 1×10^−6^M \[‐140mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus>\] TRPML2^Va^: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386> Concentration range: 1×10^−5^M \[‐140mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794> Concentration range: 1×10^−6^M \[‐140mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus>\]Selective activators Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (Antagonist) (pIC~50~ 4.7) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/18162548?dopt=AbstractPlus>\] -- Mouse--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10301> (Agonist) (pEC~50~ 5.9) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/30479274?dopt=AbstractPlus>\]Functional CharacteristicsTRPML1^Va^: γ = 40 pS and 76‐86 pS at very negative holding potentials with Fe^2+^ and monovalent cations as charge carriers, respectively; conducts Na^+^≅ K^+^\>Cs^+^ and divalent cations (Ba^2+^\>Mn2^+^\>Fe^2+^\>Ca^2+^\> Mg^2+^ \> Ni^2+^ \> Co^2+^ \> Cd^2+^ \> Zn^2+^≫Cu^2+^); monovalent cation flux suppressed by divalent cations (*e.g.* Ca^2+^, Fe^2+^); inwardly rectifyingConducts Na^+^; monovalent cation flux suppressed by divalent cations; inwardly rectifyingTRPML3^Va^: γ = 49 pS at very negative holding potentials with monovalent cations as charge carrier; conducts Na^+^ \> K^+^ \> Cs^+^ with maintained current in the presence of Na^+^, conducts Ca^2+^ and Mg^2+^, but not Fe^2+^, impermeable to protons; inwardly rectifying Wild type TRPML3: γ = 59 pS at negative holding potentials with monovalent cations as charge carrier; conducts Na^+^ \> K^+^ \> Cs^+^ and Ca^2+^ (P~Ca~/P~K~ ^∼^ = 350), slowly inactivates in the continued presence of Na^+^ within the extracellular (extracytosolic) solution; outwardly rectifyingCommentsTRPML1 current is potentiated by acidic pH and sphingosine \[<http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\].--Current is activated by Na^+^‐free extracellular (extracytosolic) solution, and is inhibited by extracellular acidification (equivalent to intra‐lysosomal acidification). Channel blockers include the ML‐SI series of compounds (*e.g*. ML‐SI1; concentration range 5x10^‐5^ M; ‐120mV) \[<http://www.ncbi.nlm.nih.gov/pubmed/26027738?dopt=AbstractPlus>\].

Comments {#bph14749-sec-0097}
--------

Data in the table are for TRPML proteins mutated (*i.e* TRPML1^Va^, TRPML2^Va^ and TRPML3^Va^) at loci equivalent to TRPML3 A419P to allow plasma membrane expression when expressed in HEK‐293 cells and subsequent characterisation by patch‐clamp recording \[<http://www.ncbi.nlm.nih.gov/pubmed/18794901?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18048323?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17962195?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18162548?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17989217?dopt=AbstractPlus>\]. Data for wild type TRPML3 are also tabulated \[<http://www.ncbi.nlm.nih.gov/pubmed/17962195?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18369318?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18162548?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17989217?dopt=AbstractPlus>\]. It should be noted that alternative methodologies, particularly in the case of TRPML1, have resulted in channels with differing biophysical characteristics (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/19158345?dopt=AbstractPlus>\]). Initial functional characteristics of TRPML channels are performed on their Va mutations of TRPMLs at loci equivalent to TRPML3 A419P. Current pharmacological characterization of channel activators and blockers are conducted on wild‐type channel proteins using endolysosomal patch‐clamp \[<http://www.ncbi.nlm.nih.gov/pubmed/25119295?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/30479274?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus>\].

TRPP (polycystin) family {#bph14749-sec-0098}
------------------------

The TRPP family (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/15889307?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15336986?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16880824?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21290302?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17217069?dopt=AbstractPlus>\]) or PKD2 family is comprised of PKD2 (PC2), PKD2L1 (PC2L1), PKD2L2 (PC2L2), which have been renamed TRPP1, TRPP2 and TRPP3, respectively \[<http://www.ncbi.nlm.nih.gov/pubmed/20716668?dopt=AbstractPlus>\]. It should also be noted that the nomenclature of PC2 was TRPP2 in old literature. However, PC2 has been uniformed to be called TRPP2 \[<http://www.ncbi.nlm.nih.gov/pubmed/29149325?dopt=AbstractPlus>\]. PKD2 family channels are clearly distinct from the PKD1 family, whose function is unknown. PKD1 and PKD2 form a hetero‐oligomeric complex with a 1:3 ratio. \[<http://www.ncbi.nlm.nih.gov/pubmed/30093605?dopt=AbstractPlus>\]. Although still being sorted out, TRPP family members appear to be 6TM spanning nonselective cation channels. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=504><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=506>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9009), <http://www.uniprot.org/uniprot/Q13563>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9011](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9011), <http://www.uniprot.org/uniprot/Q9P0L9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9012](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9012), <http://www.uniprot.org/uniprot/Q9NZM6>Activators--Calmidazolium (in primary cilia): 10 *μ*M--Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4281> (pIC~50~ 6.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4145> (pIC~50~ 6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4186> (pIC~50~ 5), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2421> (pIC~50~ 3.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> Concentration range: 1×10^−4^M \[‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10517637?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> Concentration range: 1×10^−4^M \[‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10517637?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4191>--Functional CharacteristicsTRPP1 (PKD2) is a cation channel found in primary cilia of inner medullary collecting duct (IMCD) cells, but not at the plasma membrane; conducts K^+^\>Na^+^\>Ca^2+^ (1:0.4:0.025). PKD2 shows a large outward conductance (90‐117 pS) \[<http://www.ncbi.nlm.nih.gov/pubmed/29443690?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22760766?dopt=AbstractPlus>\]. Activators or channel blockers remain to be investigated.Currents have been measured directly from primary cilia and also when expressed on plasma membranes. Primary cilia appear to contain heteromeric TRPP2 + PKD1‐L1, underlying a gently outwardly rectifying nonselective conductance (P~Ca~/P~Na~ 6: PKD1‐L1 is a 12 TM protein of unknown topology). Primary cilia heteromeric channels have an inward single channel conductance of 80 pS and an outward single channel conductance of 95 pS. Presumed homomeric TRPP2 channels are gently outwardly rectifying. Single channel conductance is 120 pS inward, 200 pS outward \[<http://www.ncbi.nlm.nih.gov/pubmed/24336289?dopt=AbstractPlus>\]. TRPP2 (PKD2L1) displays calcium dependent activation. Calcium accumulation due to prolonged channel activity may lead to outward‐moving Ca^2+^ ions to close the channel \[<http://www.ncbi.nlm.nih.gov/pubmed/27348301?dopt=AbstractPlus>\].The functional characteristics of PKD2L2(PC2L2) has not been established yet.

Comments {#bph14749-sec-0099}
--------

Data in the table are extracted from \[<http://www.ncbi.nlm.nih.gov/pubmed/17804601?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15336986?dopt=AbstractPlus>\] and \[<http://www.ncbi.nlm.nih.gov/pubmed/18663466?dopt=AbstractPlus>\]. Broadly similar single channel conductance, mono‐ and di‐valent cation selectivity and sensitivity to blockers are observed for TRPP2 co‐expressed with TRPP1 \[<http://www.ncbi.nlm.nih.gov/pubmed/14766803?dopt=AbstractPlus>\]. Ca^2+^, Ba^2+^ and Sr^2+^ permeate TRPP3, but reduce inward currents carried by Na^+^. Mg^2^+ is largely impermeant and exerts a voltage dependent inhibition that increases with hyperpolarization.

TRPV (vanilloid) family {#bph14749-sec-0100}
-----------------------

Members of the TRPV family (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/18220815?dopt=AbstractPlus>\]) can broadly be divided into the non‐selective cation channels, TRPV1‐4 and the more calcium selective channels TRPV5 and TRPV6.

TRPV1‐V4 subfamily {#bph14749-sec-0101}
------------------

TRPV1 is involved in the development of thermal hyperalgesia following inflammation and may contribute to the detection of noxius heat (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/17217056?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17349697?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17464295?dopt=AbstractPlus>\]). Numerous splice variants of TRPV1 have been described, some of which modulate the activity of TRPV1, or act in a dominant negative manner when co‐expressed with TRPV1 \[<http://www.ncbi.nlm.nih.gov/pubmed/20515731?dopt=AbstractPlus>\]. The pharmacology of TRPV1 channels is discussed in detail in \[<http://www.ncbi.nlm.nih.gov/pubmed/19063991?dopt=AbstractPlus>\] and \[<http://www.ncbi.nlm.nih.gov/pubmed/19297520?dopt=AbstractPlus>\]. TRPV2 is probably not a thermosensor in man \[<http://www.ncbi.nlm.nih.gov/pubmed/21832173?dopt=AbstractPlus>\], but has recently been implicated in innate immunity \[<http://www.ncbi.nlm.nih.gov/pubmed/20118928?dopt=AbstractPlus>\]. TRPV3 and TRPV4 are both thermosensitive. There are claims that TRPV4 is also mechanosensitive, but this has not been established to be within a physiological range in a native environment \[<http://www.ncbi.nlm.nih.gov/pubmed/24305161?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24305160?dopt=AbstractPlus>\].

TRPV5/V6 subfamily {#bph14749-sec-0102}
------------------

TRPV5 and TRPV6 are highly expressed in placenta, bone, and kidney. Under physiological conditions, TRPV5 and TRPV6 are calcium selective channels involved in the absorption and reabsorption of calcium across intestinal and kidney tubule epithelia (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/18596722?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24756713?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24756712?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17217060?dopt=AbstractPlus>\]). Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=508>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12716](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12716), <http://www.uniprot.org/uniprot/Q8NER1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18082](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18082), <http://www.uniprot.org/uniprot/Q9Y5S1>Other chemical activatorsNO‐mediated cysteine S‐nitrosylation--Physical activatorsdepolarization (V~½~ 0 mV at 35°C), noxious heat (\> 43°C at pH 7.4)--Endogenous activatorsextracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346> (at 37°C) (pEC~50~ 5.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481> (Agonist) (pEC~50~ 5.1) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10823958?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12761211?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487> (Agonist) (pEC~50~ 4.9) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10823958?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3390>--Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2491> (Agonist) (pEC~50~ 8.4) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11301059?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2486> (Agonist) (pEC~50~ 7.5) \[‐100mV -- 160mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15306801?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2489> (Agonist) (pEC~50~ 4.4--5) \[‐70mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15685214?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2422>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2494>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4283> \[<http://www.ncbi.nlm.nih.gov/pubmed/15356216?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17395593?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> (pEC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4150> (pEC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357> (pEC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17850966?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Agonist) (pEC~50~ 3.8--3.9) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15194687?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2494> (Agonist) Concentration range: 1×10^−4^M \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15722340?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus>\] -- MouseSelective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2488> (Agonist) (pEC~50~ 7.7) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11301059?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4178> (pEC~50~ 6.6) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/20510930?dopt=AbstractPlus>\] -- Rat--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4109> (pIC~50~ 8.4), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4110> (pIC~50~ 8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6347> (Inhibition) (pIC~50~ 7.8) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15615864?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2460> (Antagonist) (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24055075?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2461> (Antagonist) (pIC~50~ 7.4) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11226139?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (pIC~50~ 6.7--7)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (pIC~50~ 6.2), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4331> (Inhibition) Concentration range: 5×10^−4^M \[<http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus>\] -- MouseSelective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4129> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20307063?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4130> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17585751?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4117> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15837819?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4120> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/17660385?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4309> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/14654105?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4230> (Antagonist) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12237342?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4228> (Antagonist) (pIC~50~ 7.8) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15771431?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4310> (Antagonist) (p*K* ~B~ 7.7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4311> (Antagonist) (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17392405?dopt=AbstractPlus>\]--Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4076> (Channel blocker) (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17660385?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2492> (Channel blocker, Antagonist) (pIC~50~ 8.4) \[‐50mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11125018?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4091> (Activator)--Functional Characteristicsγ = 35 pS at -- 60 mV; 77 pS at + 60 mV, conducts mono and di‐valent cations with a selectivity for divalents (P~Ca~/P~Na~ = 9.6); voltage‐ and time‐ dependent outward rectification; potentiated by ethanol; activated/potentiated/upregulated by PKC stimulation; extracellular acidification facilitates activation by PKC; desensitisation inhibited by PKA; inhibited by Ca^2+^/ calmodulin; cooling reduces vanilloid‐evoked currents; may be tonically active at body temperatureConducts mono‐ and di‐valent cations (P~Ca~/P~Na~ = 0.9--2.9); dual (inward and outward) rectification; current increases upon repetitive activation by heat; translocates to cell surface in response to IGF‐1 to induce a constitutively active conductance, translocates to the cell surface in response to membrane stretch Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=509><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=510>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18084](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18084), <http://www.uniprot.org/uniprot/Q8NET8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18083](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18083), <http://www.uniprot.org/uniprot/Q9HBA0>Other chemical activatorsNO‐mediated cysteine S‐nitrosylationEpoxyeicosatrieonic acids and NO‐mediated cysteine S‐nitrosylationPhysical activatorsdepolarization (V~½~ +80 mV, reduced to more negative values following heat stimuli), heat (23°C ‐ 39°C, temperature threshold reduces with repeated heat challenge)Constitutively active, heat (\> 24°C ‐ 32°C), mechanical stimuliActivators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4220> (pEC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18492727?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Full agonist) (pEC~50~ 4.6) \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15175387?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2494> (Full agonist) (pEC~50~ 4.1--4.2) \[*voltage dependent* ‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15722340?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2499> (Full agonist) (pEC~50~ 3.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/16617338?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2425> (Full agonist) (pEC~50~ 2.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16617338?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2422> (Full agonist) (pEC~50~ 2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15746429?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2430> (pEC~50~ 1.7) \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16829128?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2497> (Full agonist) Concentration range: 5×10^−4^M \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16617338?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341> (Agonist) (pEC~50~ 7.9) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12970074?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (pEC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12879072?dopt=AbstractPlus>\] -- MouseSelective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4111> (pEC~50~ 3.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17420775?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4205> (pEC~50~ 8.7) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/18499743?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4105> (pEC~50~ 7.1) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19361196?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2500> (Agonist) (pEC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12970074?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4295> (pEC~50~ 6.1) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19737537?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2502> (Agonist) (pEC~50~ 6) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/16899456?dopt=AbstractPlus>\] -- MouseChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (Inhibition) (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/12016205?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2498> (Antagonist) (pIC~50~ 5--5.2) \[‐80mV -- 80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15722340?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10303> (Inhibition) (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/30377214?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10302> (Inhibition) (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/30108138?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (Inhibition) (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12151520?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434>Selective channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4213> (Inhibition) (pIC~50~ 7.3) \[‐40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/20956320?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10304> (Antagonist) (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/26235950?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4294> (Inhibition) (pIC~50~ 5.6) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19737537?dopt=AbstractPlus>\]Functional Characteristicsγ = 197 pS at = +40 to +80 mV, 48 pS at negative potentials; conducts mono‐ and di‐valent cations; outward rectification; potentiated by arachidonic acidγ = 60 pS at --60 mV, 90‐100 pS at +60 mV; conducts mono‐ and di‐valent cations with a preference for divalents (P~Ca~/P~Na~ =6--10); dual (inward and outward) rectification; potentiated by intracellular Ca^2+^ *via* Ca^2+^/ calmodulin; inhibited by elevated intracellular Ca^2+^ *via* an unknown mechanism (IC~50~ = 0.4 *μ*M) Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=511><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=512>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3145](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3145), <http://www.uniprot.org/uniprot/Q9NQA5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14006](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14006), <http://www.uniprot.org/uniprot/Q9H1D0>Other channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2525> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4160> \> Fe^2^--Activatorsconstitutively active (with strong buffering of intracellular Ca^2+^)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433> (Potentiation) constitutively active (with strong buffering of intracellular Ca^2+^)Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (pIC~50~ 6.9), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432> (Antagonist) (pIC~50~ 5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11744752?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2434>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>Functional Characteristicsγ = 59--78 pS for monovalent ions at negative potentials, conducts mono‐ and di‐valents with high selectivity for divalents (P~Ca~/P~Na~ \> 107); voltage‐ and time‐ dependent inward rectification; inhibited by intracellular Ca^2+^ promoting fast inactivation and slow downregulation; feedback inhibition by Ca^2+^ reduced by calcium binding protein 80‐K‐H; inhibited by extracellular and intracellular acidosis; upregulated by 1,25‐dihydrovitamin D3γ = 58--79 pS for monovalent ions at negative potentials, conducts mono‐ and di‐valents with high selectivity for divalents (P~Ca~/P~Na~ \> 130); voltage‐ and time‐dependent inward rectification; inhibited by intracellular Ca^2+^ promoting fast and slow inactivation; gated by voltage‐dependent channel blockade by intracellular Mg^2+^; slow inactivation due to Ca^2+^‐dependent calmodulin binding; phosphorylation by PKC inhibits Ca^2+^‐calmodulin binding and slow inactivation; upregulated by 1,25‐dihydroxyvitamin D3

Comments {#bph14749-sec-0103}
--------

Activation of TRPV1 by depolarisation is strongly temperature‐dependent via a channel opening rate that increases with increasing temperature. The V~½~ is shifted in the hyperpolarizing direction both by increasing temperature and by exogenous agonists \[<http://www.ncbi.nlm.nih.gov/pubmed/15306801?dopt=AbstractPlus>\]. TRPV3 channel dysfunction caused by genetic gain‐of‐function mutations is implicated in the pathogenesis of skin inflammation, dermatitis, and chronic itch. In rodents, a sponateous gain‐of‐function matation of the TRPV3 gene causes the development of skin lesions with pruritus and dermatitis \[<http://www.ncbi.nlm.nih.gov/pubmed/16858425?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22405088?dopt=AbstractPlus>\]. In contrast to other thermoTRP channels, TRPV3 sensitizes rather than desensitizes, upon repeated stimulation with either heat or agonists \[<http://www.ncbi.nlm.nih.gov/pubmed/15175387?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22006988?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12077604?dopt=AbstractPlus>\]. The sensitivity of TRPV4 to heat, but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2500> is lost upon patch excision. TRPV4 is activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> following P450 epoxygenase‐dependent metabolism to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6304> (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/14707014?dopt=AbstractPlus>\]). Activation of TRPV4 by cell swelling, but not heat, or phorbol esters, is mediated via the formation of epoxyeicosatrieonic acids. Phorbol esters bind directly to TRPV4. Different TRPV4 mutations load to a broad spectrum of dominant skeletal dysplasias \[<http://www.ncbi.nlm.nih.gov/pubmed/19232556?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18587396?dopt=AbstractPlus>\] and spinal muscular atrophies and hereditary motor and sensory neuropathies \[<http://www.ncbi.nlm.nih.gov/pubmed/20037588?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20037587?dopt=AbstractPlus>\]. Similar mutations were also found in patients with Charcot‐Marie‐Tooth disease type 2C \[<http://www.ncbi.nlm.nih.gov/pubmed/20037586?dopt=AbstractPlus>\]. TRPV5 preferentially conducts Ca^2+^ under physiological conditions, but in the absence of extracellular Ca^2+^, conducts monovalent cations. Single channel conductances listed for TRPV5 and TRPV6 were determined in divalent cation‐free extracellular solution. Ca^2+^‐induced inactivation occurs at hyperpolarized potentials when Ca^2+^ is present extracellularly. Single channel events cannot be resolved (probably due to greatly reduced conductance) in the presence of extracellular divalent cations. Measurements of P~Ca~/P~Na~ for TRPV5 and TRPV6 are dependent upon ionic conditions due to anomalous mole fraction behaviour. Blockade of TRPV5 and TRPV6 by extracellular Mg^2+^ is voltage‐dependent. Intracellular Mg^2+^ also exerts a voltage dependent block that is alleviated by hyperpolarization and contributes to the time‐dependent activation and deactivation of TRPV6 mediated monovalent cation currents. TRPV5 and TRPV6 differ in their kinetics of Ca^2+^‐dependent inactivation and recovery from inactivation. TRPV5 and TRPV6 function as homo‐ and hetero‐tetramers.

Further reading on Transient Receptor Potential channels {#bph14749-sec-0104}
--------------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=80> {#bph14749-sec-0105}
==========================================================================

Overview {#bph14749-sec-0106}
--------

Calcium (Ca^2+^) channels are voltage‐gated ion channels present in the membrane of most excitable cells. The nomenclature for Ca^2+^channels was proposed by \[<http://www.ncbi.nlm.nih.gov/pubmed/10774722?dopt=AbstractPlus>\] and **approved by the [NC‐IUPHAR]{.ul} Subcommittee on Ca^2+^ channels**\[<http://www.ncbi.nlm.nih.gov/pubmed/16382099?dopt=AbstractPlus>\]. Ca^2+^ channels form hetero‐oligomeric complexes. The α1 subunit is pore‐forming and provides the binding site(s) for practically all agonists and antagonists. The 10 cloned α1‐subunits can be grouped into three families: (1) the high‐voltage activated dihydropyridine‐sensitive (L‐type, CaV1.x) channels; (2) the highvoltage activated dihydropyridine‐insensitive (CaV2.x) channels and (3) the low‐voltage‐activated (T‐type, CaV3.x) channels. Each α1 subunit has four homologous repeats (I--IV),each repeat having six transmembrane domains and a pore‐forming region between transmembrane domains S5 and S6. Gating is thought to be associated with the membrane‐spanning S4 segment, which contains highly conserved positive charges. Many of the α1‐subunit genes give rise to alternatively spliced products. At least for high‐voltage activated channels, it is likely that native channels comprise coassemblies of α1, β and α2--*δ* subunits. The γ subunits have not been proven to associate with channels other than the α1s skeletal muscle Cav1.1 channel. The α2--*δ*1 and α2--*δ*2 subunits bind <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5483> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5484>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=531>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1397](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1397), <http://www.uniprot.org/uniprot/Q13698>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1390](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1390), <http://www.uniprot.org/uniprot/Q13936>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1391](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1391), <http://www.uniprot.org/uniprot/Q01668>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1393](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1393), <http://www.uniprot.org/uniprot/O60840>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2518> (pEC~50~ ∼7.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4065> (pEC~50~ ∼7.8)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4065> (pEC~50~ ∼7.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2518> Concentration range: 1×10−^6^M‐5×10−^6^M \[<http://www.ncbi.nlm.nih.gov/pubmed/12842134?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2518> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4065> (pEC~50~ ∼7.8)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4065> (pEC~50~ ∼7.8)Gating inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (Antagonist) (pIC~50~ 6.3) Concentration range: 1×10−^7^M‐1×10−^4^M \[*voltage dependent* ‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/2451745?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> (Antagonist) (pIC~50~ ∼6) \[‐70mV\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2334> (Antagonist) (pIC~50~ 6) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/2458429?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4488> (arterial smooth muscle‐like activity) (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/28592699?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4488> (dopamine neuron neuron‐like activity) (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/28592699?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (Antagonist) (pIC~50~ 7.7) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11045961?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7506331?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> (Antagonist) (pIC~50~ 6.8) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11487617?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2334> (Inhibition) (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19029287?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4488> (dopamine neuron‐like activity; splice variant‐dependent) (pIC~50~ 7.8--8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/28592699?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (Antagonist) (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19029287?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> (Antagonist) (pIC~50~ 5.7--6.6) \[‐80mV -- ‐40mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11514547?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11487617?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> (Antagonist) (pIC~50~ 6) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14973233?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> (Antagonist) (pIC~50~ ∼6) \[‐70mV\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2334> (Antagonist) (pIC~50~ ∼6) \[‐70mV\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298> (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298> (Antagonist), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298> (pIC~50~ 4) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14744918?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> Concentration range: 1×10−^4^M \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/14744918?dopt=AbstractPlus>\] -- MouseSub/family‐selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4149> (Antagonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4149> (Antagonist)----Functional CharacteristicsL‐type calcium current: High voltage‐activated, slow voltage dependent inactivationL‐type calcium current: High voltage‐activated, slow voltage‐dependent inactivation, rapid calcium‐dependent inactivationL‐type calcium current: moderate‐voltage, slow voltage‐dependent inactivation, more rapid calcium‐dependent inactivationL‐type calcium current: Moderate voltage‐activated, slow voltage‐dependent inactivationComments----Ca~v~1.3 activates more negative potentials than Ca~v~1.2 and is about 5--10 fold less sensitive to dihydropyridine antagonists.Ca~v~1.4 is less sensitive to dihydropyridine antagonists than other Cav1 channels Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=532><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=533><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=534>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1388](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1388), <http://www.uniprot.org/uniprot/O00555>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1389](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1389), <http://www.uniprot.org/uniprot/Q00975>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1392](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1392), <http://www.uniprot.org/uniprot/Q15878>Gating inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7765> (pIC~50~ 7) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/19815411?dopt=AbstractPlus>\] -- Rat--Selective gating inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2529> (P current component: Kd =2nM, Q component Kd= \>100nM) (pIC~50~ 7--8.7) \[‐100mV -- ‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10321243?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1311418?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2530> (p*K* ~d~ 8.5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8232218?dopt=AbstractPlus>\] -- Rat--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4315> (Antagonist) (pIC~50~ 7.5--8) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9799496?dopt=AbstractPlus>\]Channel blockers----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (Antagonist) (pIC~50~ 4.6) \[‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8071363?dopt=AbstractPlus>\]Sub/family‐selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2537> (pIC~50~ 8.2--9.2) Concentration range: 2×10−^6^M‐5×10−^6^M \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10938268?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2535> (Antagonist) (pIC~50~ 10.4) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10938268?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2537> (Antagonist) (pIC~50~ 6.1--8.5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/1352986?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10938268?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8786437?dopt=AbstractPlus>\] -- Rat--Functional CharacteristicsP/Q‐type calcium current: Moderate voltage‐activated, moderate voltage‐dependent inactivationN‐type calcium current: High voltage‐activated, moderate voltage‐dependent inactivationR‐type calcium current: Moderate voltage‐activated, fast voltage‐dependent inactivation Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=535><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=537>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1394](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1394), <http://www.uniprot.org/uniprot/O43497>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1395](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1395), <http://www.uniprot.org/uniprot/O95180>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1396](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1396), <http://www.uniprot.org/uniprot/Q9P0X4>Gating inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2521> (Antagonist) (pIC~50~ 7.3--7.8) \[‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10196582?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11896142?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2521> (Antagonist) (pIC~50~ 7.3--7.6) \[‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10196582?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11896142?dopt=AbstractPlus>\] -- Rat--Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7718> (Pore blocker) (pIC~50~ 7.3) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/22344687?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7724> (Pore blocker) (pIC~50~ 7) \[‐75mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/23257507?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522> (Antagonist) (pIC~50~ 6--6.6) \[‐110mV -- ‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10991994?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (Antagonist) (pIC~50~ 3.6--3.8) \[*voltage dependent* ‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10585925?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7724> (Pore blocker) (pIC~50~ 8) \[‐75mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/23257507?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522> (Antagonist) (pIC~50~ 5.9--7.2) \[‐110mV -- ‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10991994?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7718> (Pore blocker) (pIC~50~ 6.8) \[‐75mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/22344687?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (Antagonist) (pIC~50~ 4.9--5.2) \[*voltage dependent* ‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10585925?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7724> (Pore blocker) (pIC~50~ 7.5) \[‐75mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/23257507?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522> (Antagonist) (pIC~50~ 5.8) \[‐110mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10991994?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2476> (Antagonist) (pIC~50~ 3.7--4.1) \[*voltage dependent* ‐90mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10585925?dopt=AbstractPlus>\] -- RatFunctional CharacteristicsT‐type calcium current: Low voltage‐activated, fast voltage‐dependent inactivationT‐type calcium current: Low voltage‐activated, fast voltage‐dependent inactivationT‐type calcium current: Low voltage‐activated, moderate voltage‐dependent inactivation

Comments {#bph14749-sec-0107}
--------

In many cell types, P and Q current components cannot be adequately separated and many researchers in the field have adopted the terminology 'P/Q‐type' current when referring to either component. Both of these physiologically defined current types are conducted by alternative forms of Cav2.1. Ziconotide (a synthetic peptide equivalent to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2536>) has been approved for the treatment of chronic pain \[<http://www.ncbi.nlm.nih.gov/pubmed/18518786?dopt=AbstractPlus>\].

Further reading on Voltage‐gated calcium channels {#bph14749-sec-0108}
-------------------------------------------------

Catterall WA *et al.* (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure‐function relationships of voltage‐gated calcium channels. *Pharmacol. Rev.* **57**: 411--25 \[<https://www.ncbi.nlm.nih.gov/pubmed/16382099?dopt=AbstractPlus>\]

Catterall WA *et al.* (2015) Structural basis for pharmacology of voltage‐gated sodium and calcium channels. *Mol. Pharmacol.* **88**: 141--50 \[<https://www.ncbi.nlm.nih.gov/pubmed/25848093?dopt=AbstractPlus>\]

Catterall WA *et al.* (2015) Deciphering voltage‐gated Na(+) and Ca(2+) channels by studying prokaryotic ancestors. *Trends Biochem. Sci.* **40**: 526--34 \[<https://www.ncbi.nlm.nih.gov/pubmed/26254514?dopt=AbstractPlus>\]

Dolphin AC. (2018) Voltage‐gated calcium channels: their discovery, function and importance as drug targets. *Brain Neurosci Adv* **2**: \[<https://www.ncbi.nlm.nih.gov/pubmed/30320224?dopt=AbstractPlus>\]

Flucher BE *et al.* (2017) How and why are calcium currents curtailed in the skeletal muscle voltagegated calcium channels? *J. Physiol. (Lond.)* **595**: 1451--1463 \[<https://www.ncbi.nlm.nih.gov/pubmed/27896815?dopt=AbstractPlus>\]

Huang J *et al.* (2017) Regulation of voltage gated calcium channels by GPCRs and post‐translational modification. *Curr Opin Pharmacol* **32**: 1--8 \[<https://www.ncbi.nlm.nih.gov/pubmed/27768908?dopt=AbstractPlus>\]

Nanou E *et al.* (2018) Calcium Channels, Synaptic Plasticity, and Neuropsychiatric Disease. *Neuron* **98**: 466--481 \[<https://www.ncbi.nlm.nih.gov/pubmed/29723500?dopt=AbstractPlus>\]

Ortner NJ *et al.* (2016) L‐type calcium channels as drug targets in CNS disorders. *Channels (Austin)* **10**: 7--13 \[<https://www.ncbi.nlm.nih.gov/pubmed/26039257?dopt=AbstractPlus>\]

Rougier JS *et al.* (2016) Cardiac voltage‐gated calcium channel macromolecular complexes. *Biochim. Biophys. Acta* **1863**: 1806--12 \[<https://www.ncbi.nlm.nih.gov/pubmed/26707467?dopt=AbstractPlus>\]

Zamponi GW. (2016) Targeting voltage‐gated calcium channels in neurological and psychiatric diseases. *Nat Rev Drug Discov* **15**: 19--34 \[<https://www.ncbi.nlm.nih.gov/pubmed/26542451?dopt=AbstractPlus>\]

Zamponi GW *et al.* (2015) The Physiology, Pathology, and Pharmacology of Voltage‐Gated Calcium Channels and Their Future Therapeutic Potential. *Pharmacol. Rev.* **67**: 821--70 \[<https://www.ncbi.nlm.nih.gov/pubmed/26362469?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=124> {#bph14749-sec-0109}
===========================================================================

Overview {#bph14749-sec-0110}
--------

The voltage‐gated proton channel (provisionally denoted Hv1) is a putative 4TM proton‐selective channel gated by membrane depolarization and which is sensitive to the transmembrane pH gradient \[<http://www.ncbi.nlm.nih.gov/pubmed/20961760?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18463791?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18801839?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16554753?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16556803?dopt=AbstractPlus>\]. The structure of Hv1 is homologous to the voltage sensing domain (VSD) of the superfamily of voltage‐gated ion channels (*i.e*. segments S1 to S4) and contains no discernable pore region \[<http://www.ncbi.nlm.nih.gov/pubmed/16554753?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16556803?dopt=AbstractPlus>\]. Proton flux through Hv1 is instead most likely mediated by a water wire completed in a crevice of the protein whenthe voltage‐sensing S4 helix moves in response to a change in transmembrane potential \[<http://www.ncbi.nlm.nih.gov/pubmed/20543828?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21843503?dopt=AbstractPlus>\]. Hv1 expresses largely as a dimer mediated by intracellular C‐terminal coiled‐coil interactions \[<http://www.ncbi.nlm.nih.gov/pubmed/20147290?dopt=AbstractPlus>\] but individual promoters nonetheless support gated H^+^ flux via separate conduction pathways \[<http://www.ncbi.nlm.nih.gov/pubmed/18583477?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18509058?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21124855?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18498736?dopt=AbstractPlus>\]. Within dimeric structures, the two protomers do not function independently, but display co‐operative interactions during gating resulting in increased voltage sensitivity, but slower activation, of the dimeric,*versus* monomeric, complexes \[<http://www.ncbi.nlm.nih.gov/pubmed/20023639?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20023640?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=746>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28240](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28240), <http://www.uniprot.org/uniprot/Q96D96>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ ∼5.7--6.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (pIC~50~ ∼5)Functional CharacteristicsActivated by membrane depolarization mediating macroscopic currents with time‐, voltage‐ and pH‐dependence; outwardly rectifying; voltage dependent kinetics with relatively slow current activation sensitive to extracellular pH and temperature, relatively fast deactivation; voltage threshold for current activation determined by pH gradient (ΔpH = pH~o~ ‐pH~i~) across the membrane

Comments {#bph14749-sec-0111}
--------

The voltage threshold (V~thr~) for activation of Hv1 is not fixed but is set by the pH gradient across the membrane such that V~thr~ is positive to the Nernst potential for H^+^, which ensures that only outwardly directed flux of H^+^ occurs under physiological conditions \[<http://www.ncbi.nlm.nih.gov/pubmed/20961760?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18463791?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18801839?dopt=AbstractPlus>\]. Phosphorylation of Hv1 within the N‐terminal domain by PKC enhances the gating of the channel \[<http://www.ncbi.nlm.nih.gov/pubmed/20037153?dopt=AbstractPlus>\]. Tabulated IC~50~ values for Zn^2^+ and Cd^2+^ are for heterologously expressed human and mouse Hv1 \[<http://www.ncbi.nlm.nih.gov/pubmed/16554753?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16556803?dopt=AbstractPlus>\]. Zn^2+^ is not a conventional pore blocker, but is coordinated by two, or more, external protonation sites involving <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> residues \[<http://www.ncbi.nlm.nih.gov/pubmed/16554753?dopt=AbstractPlus>\]. Zn^2+^ binding may occur at the dimer interface between pairs of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204> residues from both monomers where it may interfere with channel opening \[<http://www.ncbi.nlm.nih.gov/pubmed/20231140?dopt=AbstractPlus>\]. Mouse knockout studies demonstrate that Hv1 participates in charge compensation in granulocytes during the respiratory burst of NADPH oxidasedependent reactive oxygen species production that assists in the clearance of bacterial pathogens \[<http://www.ncbi.nlm.nih.gov/pubmed/19372380?dopt=AbstractPlus>\]. Additional physiological functions of Hv1 are reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/20961760?dopt=AbstractPlus>\].

Further reading on Voltage‐gated proton channel {#bph14749-sec-0112}
-----------------------------------------------

Castillo K *et al.* (2015) Voltage‐gated proton (H(v)1) channels, a singular voltage sensing domain. *FEBS Lett.* **589**: 3471--8 \[<https://www.ncbi.nlm.nih.gov/pubmed/26296320?dopt=AbstractPlus>\]

DeCoursey TE. (2018) Gating currents indicate complex gating of voltage‐gated proton channels. *Proc. Natl. Acad. Sci. U.S.A.* **115**: 9057--9059 \[<https://www.ncbi.nlm.nih.gov/pubmed/30135099?dopt=AbstractPlus>\]

DeCoursey TE. (2018) Voltage and pH sensing by the voltage‐gated proton channel, HV1. *J R Soc Interface* **15**: \[<https://www.ncbi.nlm.nih.gov/pubmed/29643227?dopt=AbstractPlus>\]

Fernández A *et al.* (2016) Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives. *Mol. Pharmacol.* **90**: 385--402 \[<https://www.ncbi.nlm.nih.gov/pubmed/27260771?dopt=AbstractPlus>\]

Okamura Y *et al.* (2015) Gating mechanisms of voltage‐gated proton channels. *Annu. Rev. Biochem.* **84**: 685--709 \[<https://www.ncbi.nlm.nih.gov/pubmed/26034892?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=82> {#bph14749-sec-0113}
==========================================================================

Overview {#bph14749-sec-0114}
--------

Sodium channels are voltage‐gated sodium‐selective ion channels present in the membrane of most excitable cells. Sodium channels comprise of one pore‐forming α subunit, which may be associated with either one or two β subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/11486343?dopt=AbstractPlus>\]. α‐Subunits consist of four homologous domains (I‐IV), each containing six transmembrane segments (S1‐S6) and a pore‐forming loop. The positively charged fourth transmembrane segment (S4) acts as a voltage sensor and is involved in channel gating. The crystal structure of the bacterial NavAb channel has revealed a number of novel structural features compared to earlier potassium channel structures including a short selectivity filter with ion selectivity determined by interactions with glutamate side chains \[<http://www.ncbi.nlm.nih.gov/pubmed/21743477?dopt=AbstractPlus>\]. Interestingly, the pore region is penetrated by fatty acyl chains that extend into the central cavity which may allow the entry of small, hydrophobic pore‐blocking drugs \[<http://www.ncbi.nlm.nih.gov/pubmed/21743477?dopt=AbstractPlus>\]. Auxiliary β1, β2, β3 and β4 subunits consist of a large extracellular N‐terminal domain, a single transmembrane segment and a shorter cytoplasmic domain.

**The nomenclature for sodium channels was proposed by Goldin *et al.*, (2000)** \[<http://www.ncbi.nlm.nih.gov/pubmed/11144347?dopt=AbstractPlus>\] **and approved by the [NC‐IUPHAR]{.ul} Subcommittee on sodium channels (Catterall *et al.*, 2005,** \[<http://www.ncbi.nlm.nih.gov/pubmed/16382098?dopt=AbstractPlus>\]) .

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=578><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=579><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=581>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10585](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10585), <http://www.uniprot.org/uniprot/P35498>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10588](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10588), <http://www.uniprot.org/uniprot/Q99250>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10590](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10590), <http://www.uniprot.org/uniprot/Q9NY46>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10591](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10591), <http://www.uniprot.org/uniprot/P35499>Sub/family‐selective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619> (Agonist) (p*K* ~d~ 9.1) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9811906?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626> (Partial agonist) (p*K* ~d~ 5.2) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/6114956?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619> (Full agonist) Concentration range: 5×10−^6^M \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9482942?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626> (Partial agonist) Concentration range: 2×10−^4^M \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9482942?dopt=AbstractPlus>\] -- RatChannel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (p*K* ~d~ 8) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9437003?dopt=AbstractPlus>\] -- Rat------Sub/family‐selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9553> \[<http://www.ncbi.nlm.nih.gov/pubmed/27281198?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker) (pIC~50~ 8.8) \[‐120mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15815630?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 8) \[‐120mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/15815630?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7472> (Antagonist) (pIC~50~ 4.5) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/24065921?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11122339?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker) (pIC~50~ 8.4) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/11159437?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 7.6) \[‐120mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8058462?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2630> (Pore blocker) (pIC~50~ 5.9) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8058462?dopt=AbstractPlus>\]Functional CharacteristicsActivation V0.5 = ‐20 mV. Fast inactivation (*τ* = 0.7 ms for peak sodium current).Activation V0.5 = ‐24 mV. Fast inactivation (*τ* = 0.8 ms for peak sodium current).Activation V0.5 = ‐24 mV. Fast inactivation (0.8 ms)Activation V0.5 = ‐30 mV. Fast inactivation (0.6 ms) Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=582><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=583><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=585><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=586>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10593](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10593), <http://www.uniprot.org/uniprot/Q14524>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10596](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10596), <http://www.uniprot.org/uniprot/Q9UQD0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10597](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10597), <http://www.uniprot.org/uniprot/Q15858>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10582](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10582), <http://www.uniprot.org/uniprot/Q9Y5Y9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10583](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10583), <http://www.uniprot.org/uniprot/Q9UI33>Sub/family‐selective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619> (Full agonist) (p*K* ~d~ 7.6) \[physiological voltage\] \[<http://www.ncbi.nlm.nih.gov/pubmed/2431264?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626> (Partial agonist) (pEC~50~ 6.3) \[‐30mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/2154667?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2619>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2626>----Sub/family‐selective channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (p*K* ~d~ 5.8) \[‐80mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/2175715?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8967455?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 9) \[‐130mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/9603190?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 7.6) \[‐100mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/7720699?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2625> (Pore blocker) (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23077250?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 4.2) \[‐60mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/8538791?dopt=AbstractPlus>\] -- Rat<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Pore blocker) (pIC~50~ 4.4) \[‐120mV\] \[<http://www.ncbi.nlm.nih.gov/pubmed/10594087?dopt=AbstractPlus>\] -- RatSelective channel blockers------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8521> (Pore blocker) (pIC~50~ 6.7) \[*voltage dependent*\] \[<http://www.ncbi.nlm.nih.gov/pubmed/25625641?dopt=AbstractPlus>\]--Functional CharacteristicsActivation V~0.5~ = ‐26 mV. Fast inactivation (*τ* = 1 ms for peak sodium current).Activation V~0.5~ = ‐29 mV. Fast inactivation (1 ms)Activation V~0.5~ = ‐27 mV. Fast inactivation (0.5 ms)Activation V~0.5~ = ‐16 mV. Inactivation (6 ms)Activation V~0.5~ = ‐32 mV. Slow inactivation (16 ms)

Comments {#bph14749-sec-0115}
--------

Sodium channels are also blocked by local anaesthetic agents, antiarrythmic drugs and antiepileptic drugs. In general, these drugs are not highly selective among channel subtypes. There are two clear functional fingerprints for distinguishing different subtypes. These are sensitivity to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (Na~V~1.5, Na~V~1.8 and Na~V~1.9 are much less sensitive to block) and rate of fast inactivation (Na~V~1.8 and particularly Na~V~1.9 inactivate more slowly). All sodium channels also have a slow inactivation process that is engaged during long depolarizations (\>100 msec) or repetitive trains of stimuli. All sodium channel subtypes are blocked by intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2405>.

Further reading on Voltage‐gated sodium channels {#bph14749-sec-0116}
------------------------------------------------

Catterall WA *et al.* (2005) International Union of Pharmacology. XLVII. Nomenclature and structure‐function relationships of voltage‐gated sodium channels. *Pharmacol. Rev.* **57**: 397409 \[<https://www.ncbi.nlm.nih.gov/pubmed/16382098?dopt=AbstractPlus>\]

Catterall WA *et al.* (2017) The chemical basis for electrical signaling. *Nat. Chem. Biol.* **13**: 455--463 \[<https://www.ncbi.nlm.nih.gov/pubmed/28406893?dopt=AbstractPlus>\]

Deuis JR *et al.* (2017) The pharmacology of voltage‐gated sodium channel activators. *Neuropharmacology* **127**: 87--108 \[<https://www.ncbi.nlm.nih.gov/pubmed/28416444?dopt=AbstractPlus>\]

Jiang D *et al.* (2018) Structural basis for gating pore current in periodic paralysis. *Nature* **557**: 590--594 \[<https://www.ncbi.nlm.nih.gov/pubmed/29769724?dopt=AbstractPlus>\]

Kanellopoulos AH *et al.* (2016) Voltage‐gated sodium channels and pain‐related disorders. *Clin. Sci.* **130**: 2257--2265 \[<https://www.ncbi.nlm.nih.gov/pubmed/27815510?dopt=AbstractPlus>\]

Shen H *et al.* (2018) Structural basis for the modulation of voltage‐gated sodium channels by animal toxins. *Science* **362**: \[<https://www.ncbi.nlm.nih.gov/pubmed/30049784?dopt=AbstractPlus>\]

Terragni B *et al.* (2018) Post‐translational dysfunctions in channelopathies of the nervous system. *Neuropharmacology* **132**: 31--42 \[<https://www.ncbi.nlm.nih.gov/pubmed/28571716?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=119> {#bph14749-sec-0117}
===========================================================================

A number of ion channels in the human genome do not fit readily into the classification of either ligand‐gated or voltage‐gated ion channels. These are identified below.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=119> {#bph14749-sec-0118}
===========================================================================

Overview {#bph14749-sec-0119}
--------

Aquaporins and aquaglyceroporins are membrane channels that allow the permeation of water and certain other small solutes across the cell membrane, or in the case of AQP6, AQP11 and AQP12A, intracellular membranes, such as vesicles and the endoplasmic reticulum membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/26342685?dopt=AbstractPlus>\]. Since the isolation and cloning of the first aquaporin (AQP1)\[<http://www.ncbi.nlm.nih.gov/pubmed/1373524?dopt=AbstractPlus>\], 12 additional mammalian membersof thefamily havebeenidentified, although little is known about the functional properties of one of these ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19941); <http://www.uniprot.org/uniprot/Q8IXF9>) and it is thus not tabulated. The other 12 aquaporins can be broadly divided into three families: orthodox aquaporins (AQP0,‐1,‐2,‐4,‐5,‐6 and ‐8) permeable mainly to water, but for some additional solutes \[<http://www.ncbi.nlm.nih.gov/pubmed/24090884?dopt=AbstractPlus>\]; aquaglyceroporins (AQP3,‐7 ‐9 and ‐10), additionally permeableto glycerol and for some isoforms urea \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\], and superaquaporins (AQP11 and 12) located within cells \[<http://www.ncbi.nlm.nih.gov/pubmed/24189537?dopt=AbstractPlus>\]. Some aquaporins also conduct ammonia and/or H~2~O~2~ giving rise to the terms 'ammoniaporins' ('aquaammoniaporins') and 'peroxiporins', respectively. Aquaporins are impermeable to protons and other inorganic and organic cations, with the possible exception of AQP1 \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\]. One or more members of this family of proteins have been found to be expressed in almost all tissues of the body \[reviewed in Yang (2017) \[1104\]\]. AQPs are involved in numerous processes that include systemic water homeostasis, adipocyte metabolism, brain oedema, cell migration and fluid secretion by epithelia and loss of function mutations of some human AQPs, or their disruption by autoantibodies further underscore their importance \[reviewed by Verkman *et al.* (2014) \[<http://www.ncbi.nlm.nih.gov/pubmed/24625825?dopt=AbstractPlus>\], Kitchen *et al.* (2105) \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\]\].

Functional AQPs exist as homotetramers that are the water conducting units wherein individual AQP subunits (each a protomer) have six transmembrane helices and two half helices that constitute a seventh 'pseudotransmembrane domain' that surrounds a narrow water conducting channel \[<http://www.ncbi.nlm.nih.gov/pubmed/26342685?dopt=AbstractPlus>\]. In addition to the four pores contributed by the protomers, an additional hydrophobic pore exists within the center of the complex \[<http://www.ncbi.nlm.nih.gov/pubmed/26342685?dopt=AbstractPlus>\] that may mediate the transport of gases (*e.g.* O~2~, CO~2~, NO) and cations (the central pore is the proposed transport pathway for cations through AQP1) by some AQPs \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24141139?dopt=AbstractPlus>\]. Although numerous small molecule inhibitors of aquaporins, particularly APQ1, have been reported primarily from *Xenopus* oocyte swelling assays, the activity of most has subsequently been disputed upon retesting using assays of water transport that are less prone to various artifacts \[<http://www.ncbi.nlm.nih.gov/pubmed/26993802?dopt=AbstractPlus>\] and they are therefore excluded from the tables \[see Tradtrantip *et al.* (2017) \[<http://www.ncbi.nlm.nih.gov/pubmed/28258578?dopt=AbstractPlus>\] for a review\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=687><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=688><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=689>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7103](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7103), <http://www.uniprot.org/uniprot/P30301>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:633](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:633), <http://www.uniprot.org/uniprot/P29972>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:634](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:634), <http://www.uniprot.org/uniprot/P41181>Endogenous activatorAQP0 is gated by calmodulin \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\]cGMP (see comment)--Permeabilitywater (rat single channel permeability 0.25 × 10^−14^cm^3^s^−1^) (Rat) \[<http://www.ncbi.nlm.nih.gov/pubmed/9195910?dopt=AbstractPlus>\]water (rat single channel permeability 6.0 × 10^−14^cm^3^s^−1^), ammonia, H~2~O~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9195910?dopt=AbstractPlus>\]water (rat single channel permeability 3.3 × 10--14cm3s‐1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9388476?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4126>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1773><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>CommentsAQP0 appears permeable to CO~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\].Human, but not mouse, AQP1 appears permeable to CO~2~, probably through the central pore of the tetrameric complex \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\]. NO also appears permeable \[<http://www.ncbi.nlm.nih.gov/pubmed/16682607?dopt=AbstractPlus>\]. Permeability to H~2~0~2~ has been demonstrated for rat, but not human, AQP1 \[<http://www.ncbi.nlm.nih.gov/pubmed/24060746?dopt=AbstractPlus>\]. Numerous small molecule inhibitors of AQP1 have been proposed, but re‐evaluation indicates that they have no significant effect upon water permeability at concentrations in excess of their originally reported IC~50~ values \[<http://www.ncbi.nlm.nih.gov/pubmed/26313002?dopt=AbstractPlus>\]. A fifth pore located at the central axis of the tetrameric complex has, controversially, been described as a cation conductance activated by cGMP and phosphorylation by protein kinases A and C. Evidence in support and against this proposal is discussed in detail by Kitchen *et al.* (2015) \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\].-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=690><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=691><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=692><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=693>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:636](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:636), <http://www.uniprot.org/uniprot/Q92482>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:637](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:637), <http://www.uniprot.org/uniprot/P55087>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:638](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:638), <http://www.uniprot.org/uniprot/P55064>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:639](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:639), <http://www.uniprot.org/uniprot/Q13520>Permeabilitywater (rat single channel permeability 2.1 × 10^−14^cm^3^s^−1^), glycerol, ammonia, H~2~O~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/24060746?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9195910?dopt=AbstractPlus>\]water (rat single channel permeability 24 × 10--14cm3s‐1 \[<http://www.ncbi.nlm.nih.gov/pubmed/9195910?dopt=AbstractPlus>\]water (rat single channel permeability 5.0 × 10--14cm3s‐1), H~2~O~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/24141139?dopt=AbstractPlus>\]water (zero, or very low basal, permeability is enhanced by low pH and in mouse and rat by Hg^2+^), glycerol, ammonia, urea, anions \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14985982?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25225485?dopt=AbstractPlus>\]Activators------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10188> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22624030?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10189> (pIC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22624030?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>--CommentsAQP3 is also inhibited by acid pH: permeability to urea is controversial \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\].AQP4 is inhibited by PKC activation (although this is probably due to phosphorylation‐dependent protein localisation rather than inhibition of the channel *per se*), but not by HgCl~2~. An isoform of AQP4 (AQP4M23 *vs*. AQPM1) may conduct CO~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\]. AQP4 is predicted to be permeable to NO \[<http://www.ncbi.nlm.nih.gov/pubmed/19842162?dopt=AbstractPlus>\].AQP5 may conduct CO~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\].AQP6 is an intracellular channel that localises to acid secreting intercalated cells of the renal collecting ducts. Notably, AQP6 is activated by Hg^2+^ and by low pH and is unusually permeable to anions (with the permeability sequence NO~3~ ^‐^\>I^‐^ *\>\>*Br^‐^\>Cl^‐^ *\>\>*Fl^‐^) as well as water, both through the monomeric pore \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25225485?dopt=AbstractPlus>\]. AQP6 may also conduct CO~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\]. Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=694><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=695><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=696><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=697>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:640](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:640), <http://www.uniprot.org/uniprot/O14520>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:642](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:642), <http://www.uniprot.org/uniprot/O94778>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:643](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:643), <http://www.uniprot.org/uniprot/O43315>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16029), <http://www.uniprot.org/uniprot/Q96PS8>Permeabilitywater (high), glycerol, ammonia, urea \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9252401?dopt=AbstractPlus>\]water (mouse single channel permeability 8.2 × 10^−14^cm^3^s^−1^), ammonia, H~2~0~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/24060746?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9388476?dopt=AbstractPlus>\]water (low), glycerol, ammonia, urea, H202, monocarboxylates \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15988592?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25225485?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26837049?dopt=AbstractPlus>\]water (low), glycerol, urea \[<http://www.ncbi.nlm.nih.gov/pubmed/12084581?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10188> (Effective at 15 *μ*M), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4215>CommentsAQP7 also transports silicon \[<http://www.ncbi.nlm.nih.gov/pubmed/26313002?dopt=AbstractPlus>\].Permeability to urea is controversial, but might be explained by differences between mouse and human caused by a pore‐lining amino acid residue that differs between species \[<http://www.ncbi.nlm.nih.gov/pubmed/26365508?dopt=AbstractPlus>\].AQP9 may conduct CO2 \[<http://www.ncbi.nlm.nih.gov/pubmed/23485707?dopt=AbstractPlus>\] and also transport silicon \[<http://www.ncbi.nlm.nih.gov/pubmed/26313002?dopt=AbstractPlus>\].It is not known if AQP10 is permeable to ammonia. Permeability to silicon has been described \[<http://www.ncbi.nlm.nih.gov/pubmed/26313002?dopt=AbstractPlus>\].

Further reading on Aquaporins {#bph14749-sec-0120}
-----------------------------
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Carbrey JM *et al.* (2009) Discovery of the aquaporins and development of the field. *Handb Exp Pharmacol* 3--28 \[<https://www.ncbi.nlm.nih.gov/pubmed/19096770?dopt=AbstractPlus>\]
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=120> {#bph14749-sec-0121}
===========================================================================

Overview {#bph14749-sec-0122}
--------

Chloride channels are a functionally and structurally diverse group of anion selective channels involved in processes including the regulation of the excitability of neurones, skeletal, cardiac and smooth muscle, cell volume regulation, transepithelial salt transport, the acidification of internal and extracellular compartments, the cell cycle and apoptosis (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/19827947?dopt=AbstractPlus>\]). Excluding the transmittergated GABA~A~ and glycine receptors (see separate tables), well characterised chloride channels can be classified as certain members of the voltage‐sensitive ClC subfamily, calcium‐activated channels, high (maxi) conductance channels, the cystic fibrosis transmembrane conductance regulator (CFTR) and volume regulated channels \[<http://www.ncbi.nlm.nih.gov/pubmed/19153558?dopt=AbstractPlus>\]. No official recommendation exists regarding the classification of chloride channels. Functional chloride channels that have been cloned from, or characterised within, mammalian tissues are listed with the exception of several classes of intracellular channels (*e.g.* CLIC) that are reviewed by in \[<http://www.ncbi.nlm.nih.gov/pubmed/20100480?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=128> {#bph14749-sec-0123}
===========================================================================

Overview {#bph14749-sec-0124}
--------

The mammalian ClC family (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/20188062?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15709979?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19827947?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17452037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18307107?dopt=AbstractPlus>\]) contains 9 members that fall, on the basis of sequence homology, into three groups; ClC‐1, ClC‐2, hClC‐Ka (rClC‐K1) and hClC‐Kb (rClC‐K2); ClC‐3 to ClC‐5, and ClC‐6 and ‐7. ClC‐1 and ClC‐2 are plasma membrane chloride channels. ClC‐Ka and ClC‐Kb are also plasma membrane channels (largely expressed in the kidney and inner ear) when associated with barttin ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16512](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16512), <http://www.uniprot.org/uniprot/Q8WZ55>), a 320 amino acid 2TM protein \[<http://www.ncbi.nlm.nih.gov/pubmed/11734858?dopt=AbstractPlus>\]. The localisation of the remaining members of the ClC family is likely to be predominantly intracellular *in vivo*, although they may traffic to the plasma membrane in overexpression systems. Numerous recent reports indicate that ClC‐4, ClC‐5, ClC‐6 and ClC‐7 (and by inference ClC‐3) function as Cl^‐^/H^+^ antiporters (secondary active transport), rather than classical Cl^−^ channels \[<http://www.ncbi.nlm.nih.gov/pubmed/18449189?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21527911?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20466723?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034421?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034422?dopt=AbstractPlus>\]; reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/20188062?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16179405?dopt=AbstractPlus>\]). It has recently been reported that the activity of ClC‐5 as a Cl‐/H^+^ exchanger is important for renal endocytosis \[<http://www.ncbi.nlm.nih.gov/pubmed/20430975?dopt=AbstractPlus>\]. Alternative splicing increases the structural diversity within the ClC family. The crystal structure of two bacterial ClC proteins has been described \[<http://www.ncbi.nlm.nih.gov/pubmed/11796999?dopt=AbstractPlus>\] and a eukaryotic ClC transporter (CmCLC) has recently been described at 3.5 Å resolution \[<http://www.ncbi.nlm.nih.gov/pubmed/20929736?dopt=AbstractPlus>\]. Each ClC subunit, with a complex topology of 18 intramembrane segments, contributes a single pore to a dimeric 'double‐barrelled' ClC channel that contains two independently gatedpores, confirming the predictions of previous functional and structural investigations (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/15709979?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17452037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18307107?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16179405?dopt=AbstractPlus>\]). As found for ClC‐4, ClC‐5, ClC‐6 and ClC‐7, the prokaryotic ClC homologue (ClC‐ec1) and CmCLC function as H^+^/Cl antiporters, rather than as ion channels \[<http://www.ncbi.nlm.nih.gov/pubmed/14985752?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20929736?dopt=AbstractPlus>\]. The generation of monomers from dimeric ClC‐ec1 has firmly established that each ClC subunit is afunctional unit fortransport and thatcross‐subunit interaction is not required for Cl^‐^/H^+^ exchange in ClC transporters \[<http://www.ncbi.nlm.nih.gov/pubmed/21048711?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=699>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2019](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2019), <http://www.uniprot.org/uniprot/P35523>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2020](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2020), <http://www.uniprot.org/uniprot/P51788>Endogenous activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4242>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4279>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4097>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4098>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2662>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4199> (p*K* ~d~ 10.8) \[*voltage dependent* ‐100mV\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4182>Functional Characteristicsγ = 1--1.5 pS; voltage‐activated (depolarization) (by fast gating of single protopores and a slower common gate allowing both pores to open simultaneously); inwardly rectifying; incomplete deactivation upon repolarization, ATP binding to cytoplasmic cystathionine β‐synthetase related (CBS) domains inhibits ClC‐1 (by closure of the common gate), depending on its redox statusγ = 2--3 pS; voltage‐activated by membrane hyperpolarization by fast protopore and slow cooperative gating; channels only open negative to E~Cl~ resulting in steady‐state inward rectification; voltage dependence modulated by permeant anions; activated by cell swelling, PKA, and weak extracellular acidosis; potentiated by SGK1; inhibited by phosphorylation by p34(cdc2)/cyclin B; cell surface expression and activity increased by association with Hsp90CommentsCIC‐1 is constitutively activeCIC‐2 is also activated by amidation Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=700><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=701><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=702><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=703>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2026](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2026), <http://www.uniprot.org/uniprot/P51800>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2027](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2027), <http://www.uniprot.org/uniprot/P51801>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2021](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2021), <http://www.uniprot.org/uniprot/P51790>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2022](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2022), <http://www.uniprot.org/uniprot/P51793>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> (pEC~50~ 3--5)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> (pEC~50~ 3--5)----Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4104>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4104>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4285> (pIC~50~ 4.5)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18658230?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (pIC~50~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18658230?dopt=AbstractPlus>\]Functional Characteristicsγ = 26 pS; linear current‐voltage relationship except at very negative potentials; no time dependence; inhibited by extracellular protons (p*K* = 7.1); potentiated by extracellular Ca^2+^Bidirectional rectification; no time dependence; inhibited by extracellular protons; potentiated by extracellular Ca^2+^Cl‐/H^+^ antiporter \[<http://www.ncbi.nlm.nih.gov/pubmed/17977943?dopt=AbstractPlus>\]; pronounced outward rectification; slow activation, fast deactivation; activity enhanced by CaM kinase II; inhibited by intracellular Ins(3,4,5,6)P4 and extracellular acidosisCl‐/H^+^ antiporter (2Cl‐:1H^+^) \[<http://www.ncbi.nlm.nih.gov/pubmed/19364886?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034421?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034422?dopt=AbstractPlus>\]; extreme outward rectification; voltage‐dependent gating with midpoint of activation at +73 mV \[<http://www.ncbi.nlm.nih.gov/pubmed/21354396?dopt=AbstractPlus>\]; rapid activation and deactivation; inhibited by extracellular acidosis; non‐hydrolytic nucleotide binding required for full activityCommentsCIC‐Ka is constitutively active (when co‐expressed with barttin), and can be blocked by benzofuran derivativesCIC‐Kb is constitutively active (when co‐expressed with barttin), and can be blocked by benzofuran derivativesinsensitive to the channel blockers <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> (10 *μ*M)-- Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=704><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=705><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=706>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2023), <http://www.uniprot.org/uniprot/P51795>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2024), <http://www.uniprot.org/uniprot/P51797>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2025](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2025), <http://www.uniprot.org/uniprot/P51798>Channel blockers--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> (pIC~50~ 3)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4275> (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270> (pIC~50~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\]Functional CharacteristicsCl‐/H^+^ antiporter (2Cl‐:1H^+^) \[<http://www.ncbi.nlm.nih.gov/pubmed/16034421?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034422?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20501796?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19131966?dopt=AbstractPlus>\]; extreme outward rectification; voltage‐dependent gating with midpoint of activation of 116.0 mV; rapid activation and deactivation; potentiated and inhibited by intracellular and extracellular acidosis, respectively; ATP binding to cytoplasmic cystathionine β‐synthetase related (CBS) domains activates ClC‐5Cl‐/H^+^ antiporter (2Cl‐:1H^+^) \[<http://www.ncbi.nlm.nih.gov/pubmed/20466723?dopt=AbstractPlus>\]; outward rectification, rapid activation and deactivationCl‐/H^+^ antiporter (2Cl‐:1H^+^) \[<http://www.ncbi.nlm.nih.gov/pubmed/18449189?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21527911?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\]; strong outward rectification; voltage‐dependent gating with a threshold more positive than + 20 mV; very slow activation and deactivationCommentsInsensitive to the channel blockers <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> (1 mM), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4182> (1 mM), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113> (2 mM), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270> (0.5 mM) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> (1 mM)--active when co‐expressed with Ostm1

Comments {#bph14749-sec-0125}
--------

ClC channels display the permeability sequence Cl^−^\> Br^−^ \> I^−^ (at physiological pH). ClC‐1 has significant opening probability at resting membrane potential, accounting for 75% of the membrane conductance at rest in skeletal muscle, and is important for stabilization of the membrane potential. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4098>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439> act intracellularly and exhibit a strongly voltage‐dependent block with strong inhibition at negative voltages and relief of block at depolarized potentials (\[<http://www.ncbi.nlm.nih.gov/pubmed/17128287?dopt=AbstractPlus>\] and reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/12512775?dopt=AbstractPlus>\]). Inhibition of ClC‐2 by the peptide <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4199>, from *Leiurus quinquestriatus herbareus* venom, is likely to occur through inhibition of channel gating, rather than direct open channel blockade \[<http://www.ncbi.nlm.nih.gov/pubmed/19574231?dopt=AbstractPlus>\]. Although ClC‐2 can be activated by cell swelling, it does not correspond to the VRAC channel (see below). Alternative potential physiological functions for ClC‐2 are reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/19708126?dopt=AbstractPlus>\]. Functional expression of human ClC‐Ka and ClC‐Kb requires the presence of barttin \[<http://www.ncbi.nlm.nih.gov/pubmed/11734858?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16849430?dopt=AbstractPlus>\] reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/21423394?dopt=AbstractPlus>\]. The properties of ClC‐Ka/barttin and ClC‐Kb/barttin tabulated are those observed in mammalian expression systems: in oocytes the channels display time‐ and voltage‐dependent gating. The rodent homologue (ClC‐K1) of ClC‐Ka demonstrates limited expression as a homomer, but its function is enhanced by barttin which increases both channel opening probablility in the physiological range of potentials \[<http://www.ncbi.nlm.nih.gov/pubmed/11734858?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20538786?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16849430?dopt=AbstractPlus>\] reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/21423394?dopt=AbstractPlus>\]). ClC‐Ka is approximately 5 to 6‐fold more sensitive to block by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4104> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> than ClC‐Kb, while newly synthesized benzofuran derivatives showed the same blocking affinity (*\<*10 *μ*M) on both CLC‐K isoforms \[<http://www.ncbi.nlm.nih.gov/pubmed/18216243?dopt=AbstractPlus>\]. The biophysical and pharmacological properties of ClC‐3, and the relationship of the protein to the endogenous volume‐regulated anion channel(s) VRAC \[<http://www.ncbi.nlm.nih.gov/pubmed/19036336?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16697056?dopt=AbstractPlus>\] are controversial and further complicated by the possibility that ClC‐3 may function as both a Cl‐/H^+^ exchanger and an ion channel \[<http://www.ncbi.nlm.nih.gov/pubmed/19036336?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16034421?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17046694?dopt=AbstractPlus>\]. The functional properties tabulated are those most consistent with the close structural relationship between ClC‐3, ClC‐4 and ClC‐5. Activation of heterologously expressed ClC‐3 by cell swelling in response to hypotonic solutions is disputed, as are many other aspects of its regulation. Dependent upon the predominant extracellular anion (*e.g.* SCN^−^ versus Cl‐), CIC‐4 can operate in two transport modes: a slippage mode in which behaves as an ion channel and an exchanger mode in which unitary transport rate is 10‐fold lower \[<http://www.ncbi.nlm.nih.gov/pubmed/19364886?dopt=AbstractPlus>\]. Similar findings have been made for ClC‐5 \[<http://www.ncbi.nlm.nih.gov/pubmed/18063579?dopt=AbstractPlus>\]. ClC‐7 associates with a β subunit, Ostm1, which increases the stability of the former \[<http://www.ncbi.nlm.nih.gov/pubmed/16525474?dopt=AbstractPlus>\] and is essential for its function \[<http://www.ncbi.nlm.nih.gov/pubmed/21527911?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=129> {#bph14749-sec-0126}
===========================================================================

Overview {#bph14749-sec-0127}
--------

CFTR, a 12TM, ABC transporter‐type protein, is a cAMP‐regulated epithelial cell membrane Cl^−^ channel involved in normal fluid transport across various epithelia. Of the 1700 mutations identified in CFTR, the most common is the deletion mutant F508 (a class 2 mutation) which results in impaired trafficking of CFTR and reduces its incorporation into the plasma membrane causing cystic fibrosis (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/21108631?dopt=AbstractPlus>\]). Channels carrying the F508 mutation that do traffic to the plasma membrane demonstrate gating defects. Thus, pharmacological restoration of the function of the ΔF508 mutant would require a compound that embodies 'corrector' (*i.e.* facilitates folding and trafficking to the cell surface) and 'potentiator' (*i.e.* promotes opening of channels at the cell surface) activities \[<http://www.ncbi.nlm.nih.gov/pubmed/21108631?dopt=AbstractPlus>\]. In addition to acting as an anion channel *per se*, CFTR may act as a regulator of several other conductances including inhibition of the epithelial Na channel (ENaC), calcium activated chloride channels (CaCC) and volume regulated anion channel (VRAC), activation of the outwardly rectifying chloride channel (ORCC), and enhancementof the sulphonylurea sensitivity of therenalouter medullary potassium channel (ROMK2), (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/12558550?dopt=AbstractPlus>\]). CFTR also regulates TRPV4, which provides the Ca^2+^ signal for regulatory volume decrease in airway epithelia \[<http://www.ncbi.nlm.nih.gov/pubmed/15489228?dopt=AbstractPlus>\]. The activities of CFTR and the chloride‐bicarbonate exchangers SLC26A3 (DRA) and SLC26A6 (PAT1) are mutually enhanced by a physical association between the regulatory (R) domain of CFTR and the STAS domain of the SCL26 transporters, an effect facilitated by PKA‐mediated phosphorylation of the R domain of CFTR \[<http://www.ncbi.nlm.nih.gov/pubmed/15048129?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1884](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1884), <http://www.uniprot.org/uniprot/P13569>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4190> (Potentiation) (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17452495?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4152> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4271> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4335> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4337> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4338> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4136> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2486> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4342> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4284> (Potentiation), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4313> (Potentiation)Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7453> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19808995?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414> (p*K* ~i~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/1281220?dopt=AbstractPlus>\], intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4153> (intracellular application prolongs mean closed time), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4198>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4202>Functional Characteristicsγ = 6--10 pS; permeability sequence = Br^−^ ≥ Cl^−^ \> I^−^ \> F^‐^, (P~I~/P~Cl~ = 0.1--0.85); slight outward rectification; phosphorylation necessary for activation by ATP binding at binding nucleotide binding domains (NBD)1 and 2; positively regulated by PKC and PKGII (tissue specific); regulated by several interacting proteins including syntaxin 1A, Munc18 and PDZ domain proteins such as NHERF (EBP50) and CAP70Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4337>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4335>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4136> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826> are examples of flavones. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4338> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4271> are examples of benzimidazolones. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4152> is an example of a benzoquinoline. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4190> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523> are examples of 1,4‐dihydropyridines. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4284> is an example of a phenylglycine. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4313> is an example of a sulfonamide. Malonic acid hydrazide conjugates are also CFTR channel blockers (see Verkman and Galietta, 2009 \[<http://www.ncbi.nlm.nih.gov/pubmed/19153558?dopt=AbstractPlus>\])

Comments {#bph14749-sec-0128}
--------

In addition to the agents listed in the table, the novel small molecule, ataluren, induces translational read through of nonsense mutations in CFTR (reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/20829696?dopt=AbstractPlus>\]). Corrector compounds that aid the folding of DF508CFTR to increase the amount of protein expressed and potentially delivered to the cell surface include VX‐532 (which is also a potentiator), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4340>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4234>, Corr‐3a and Corr‐4a see \[<http://www.ncbi.nlm.nih.gov/pubmed/19153558?dopt=AbstractPlus>\] for details and structures of Corr3a and Corr‐4a). Inhibition of CFTR by intracellular application of the peptide <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4198>, from *Leiurus quinquestriatus herbareus* venom, occurs preferentially for the closed state of the channel \[<http://www.ncbi.nlm.nih.gov/pubmed/17951250?dopt=AbstractPlus>\]. CFTR contains two cytoplasmic nucleotide binding domains (NBDs) that bind <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>. A single open‐closing cycle is hypothesised to involve, in sequence: binding of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> at the Nterminal NBD1, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> binding to the C‐terminal NBD2 leading to the formation of an intramolecular NBD1‐NBD2 dimer associated with the open state, and subsequent <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> hydrolysis at NBD2 facilitating dissociation of the dimer and channel closing, and the initiation of a new gating cycle \[<http://www.ncbi.nlm.nih.gov/pubmed/17021796?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18957373?dopt=AbstractPlus>\]. Phosphorylation by PKA at sites within a cytoplasmic regulatory (R) domain facilitates the interaction of the two NBD domains. PKC (and PKGII within intestinal epithelial cells via guanylinstimulated <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> formation) positively regulate CFTR activity.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=130> {#bph14749-sec-0129}
===========================================================================

Overview {#bph14749-sec-0130}
--------

Chloride channels activated by intracellular calcium (CaCC) are widely expressed in excitable and non‐excitable cells where they perform diverse functions \[<http://www.ncbi.nlm.nih.gov/pubmed/15709976?dopt=AbstractPlus>\]. The molecular nature of CaCC has been uncertain with both *CLCA*, *TWEETY* and *BEST* genes having been considered as likely candidates \[<http://www.ncbi.nlm.nih.gov/pubmed/19827947?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18391176?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15987802?dopt=AbstractPlus>\]. It is now accepted that CLCA expression products are unlikely to form channels *per se* and probably function as cell adhesion proteins, or are secreted \[<http://www.ncbi.nlm.nih.gov/pubmed/18954282?dopt=AbstractPlus>\]. Similarly, *TWEETY* gene products do not recapictulate the properties of endogenous CaCC. The bestrophins encoded by genes *BEST1‐4* have a topology more consistent with ion channels \[<http://www.ncbi.nlm.nih.gov/pubmed/18391176?dopt=AbstractPlus>\] and form chloride channels that are activated by physiological concentrations of Ca^2+^, but whether such activation is direct is not known \[<http://www.ncbi.nlm.nih.gov/pubmed/18391176?dopt=AbstractPlus>\]. However, currents generated by bestrophin over‐expression do not resemble native CaCC currents. The evidence for and against bestrophin proteins forming CaCC is critically reviewed by Duran *et al.* \[<http://www.ncbi.nlm.nih.gov/pubmed/19827947?dopt=AbstractPlus>\]. Recently, a new gene family, TMEM16 (anoctamin) consisting of 10 members (TMEM16A‐K; anoctamin 1--10) has been identified and there is firm evidence that some of these members form chloride channels \[<http://www.ncbi.nlm.nih.gov/pubmed/21642943?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21607626?dopt=AbstractPlus>\]. TMEM16A (anoctamin 1; Ano 1) produces Ca^2+^‐activated Cl^−^ currents with kinetics similar to native CaCC currents recorded from different cell types \[<http://www.ncbi.nlm.nih.gov/pubmed/18772398?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19363029?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18805094?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18724360?dopt=AbstractPlus>\]. Knockdown of TMEM16A greatly reduces currents mediated by calcium‐activated chloride channels in submandibular gland cells \[<http://www.ncbi.nlm.nih.gov/pubmed/18724360?dopt=AbstractPlus>\] and smooth muscle cells from pulmonary artery \[<http://www.ncbi.nlm.nih.gov/pubmed/20421283?dopt=AbstractPlus>\]. In TMEM16A^(‐/‐)^ mice secretion of Ca^2+^‐dependent Cl^−^ secretion by several epithelia is reduced \[<http://www.ncbi.nlm.nih.gov/pubmed/19679661?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19363029?dopt=AbstractPlus>\]. Alternative splicing regulates the voltage‐ and Ca^2+^‐ dependence of TMEM16A and such processing may be tissue‐specific manner and thus contribute to functional diversity \[<http://www.ncbi.nlm.nih.gov/pubmed/19819874?dopt=AbstractPlus>\]. There are also reports that TMEM16B (anoctamin 2; Ano 2) supports CaCC activity (*e.g*.\[<http://www.ncbi.nlm.nih.gov/pubmed/19475416?dopt=AbstractPlus>\]) and in TMEM16B^(‐/‐)^ mice Ca‐activated Cl^−^ currents in the main olfactory epithelium (MOE) and in the vomeronasal organ are virtually absent \[<http://www.ncbi.nlm.nih.gov/pubmed/21516098?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21625](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21625), <http://www.uniprot.org/uniprot/Q5XXA6>Endogenous activatorsintracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7453> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19808995?dopt=AbstractPlus>\]Endogenous channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4224>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4173>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=203>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4319>Functional Characteristicsγ = 0.5--5 pS; permeability sequence, SCN^−^ \> NO~3~ ^−^\> I^−^ \> Br^−^ \> Cl^−^ \> F^−^; relative permeability of SCN^−^:Cl^−^ 8. I‐:Cl^−^ 3, aspartate:Cl^−^ 0.15, outward rectification (decreased by increasing \[Ca^2+^\]~i~); sensitivity to activation by \[Ca^2+^\]~i~ decreased at hyperpolarized potentials; slow activation at positive potentials (accelerated by increasing \[Ca^2+^\]~i~); rapid deactivation at negative potentials, deactivation kinetics modulated by anions binding to an external site; modulated by redox status

Comments {#bph14749-sec-0131}
--------

Blockade of I~Cl(Ca)~ by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113> is voltage‐dependent whereas block by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270> is voltage‐independent \[<http://www.ncbi.nlm.nih.gov/pubmed/15709976?dopt=AbstractPlus>\]. Extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2439>; <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4173> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113> (but not <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>) exert a complex effect upon I~Cl(Ca)~ in vascular smooth muscle, enhancing and inhibiting inwardly and outwardly directed currents in a manner dependent upon \[Ca^2+^\]~i~ (see \[<http://www.ncbi.nlm.nih.gov/pubmed/16091780?dopt=AbstractPlus>\] for summary). Considerable crossover in pharmacology with large conductance Ca^2+^‐activated K^+^ channels also exists (see \[<http://www.ncbi.nlm.nih.gov/pubmed/17150263?dopt=AbstractPlus>\] for overview). Two novel compounds, CaCC~inh~‐A01 and CaCC~inh~‐B01 have recently been identified as blockers of calcium‐activated chloride channels in T84 human intestinal epithelial cells \[<http://www.ncbi.nlm.nih.gov/pubmed/18083779?dopt=AbstractPlus>\] for structures). Significantly, other novel compounds totally block currents mediated by TMEM116A, but have only a modest effect upon total current mediated by CaCC native to T84 cells or human bronchial epithelial cells, suggesting that TMEM16A is not the predominant CaCC in such cells \[<http://www.ncbi.nlm.nih.gov/pubmed/21084298?dopt=AbstractPlus>\]. CaMKII modulates CaCC in a tissue dependent manner (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/15709976?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16091780?dopt=AbstractPlus>\]). CaMKII inhibitors block activation of I~Cl(Ca)~ in T84 cells but have no effect in parotid acinar cells. In tracheal and arterial smooth muscle cells, but not portal vein myocytes, inhibition of CaMKII reduces inactivation of I~Cl(Ca)~. Intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4224> may act as an endogenous negative regulator of CaCC channels activated by Ca^2+^, or CaMKII. Smooth muscle CaCC are also regulated positively by Ca^2+^‐dependent phosphatase, calcineurin (see \[<http://www.ncbi.nlm.nih.gov/pubmed/16091780?dopt=AbstractPlus>\] for summary).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=131> {#bph14749-sec-0132}
===========================================================================

Overview {#bph14749-sec-0133}
--------

Maxi Cl^‐^ channels are high conductance, anion selective, channels initially characterised in skeletal muscle and subsequently found in many cell types including neurones, glia, cardiac muscle, lymphocytes, secreting and absorbing epithelia, macula densa cells of the kidney and human placenta syncytiotrophoblasts \[<http://www.ncbi.nlm.nih.gov/pubmed/19340557?dopt=AbstractPlus>\]. The physiological significance of the maxi Cl^‐^ channel is uncertain, but roles in cell volume regulation and apoptosis have been claimed. Evidence suggests a role for maxi Clchannels as a conductive pathway in the swelling‐induced release of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> from mouse mammary C127i cells that may be important for autocrine and paracrine signalling by purines \[<http://www.ncbi.nlm.nih.gov/pubmed/12154180?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11524456?dopt=AbstractPlus>\]. A similar channel mediates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> release from macula densa cells within the thick ascending of the loop of Henle in response to changes in luminal NaCl concentration \[<http://www.ncbi.nlm.nih.gov/pubmed/12655045?dopt=AbstractPlus>\]. A family of human high conductance Cl^‐^ channels (TTYH1‐3) that resemble Maxi Cl^‐^ channels has been cloned \[<http://www.ncbi.nlm.nih.gov/pubmed/15010458?dopt=AbstractPlus>\], but alternatively, Maxi Cl^‐^ channels have also been suggested to correspond to the voltage‐dependent anion channel, VDAC, expressed at the plasma membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/12794078?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15477379?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709>Activatorscytosolic <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4207>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=83>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4325>, extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4330>Endogenous channel blockersintracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\], extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566> (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18658230?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270> (pIC~50~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20830208?dopt=AbstractPlus>\], extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4182>Functional Characteristicsγ = 280--430 pS (main state); permeability sequence, I \> Br \> Cl \> F \> gluconate (PCIP~Cl~ = 1.5); ATP is a voltage dependent permeant blocker of single channel activity (PATP/P~Cl~ = 0.08‐0.1); channel activity increased by patch‐excision; channel opening probability (at steady‐state) maximal within approximately ± 20 mV of 0 mV, opening probability decreased at more negative and (commonly) positive potentials yielding a bell‐shaped curve; channel conductance and opening probability regulated by annexin 6CommentsMaxi Cl^‐^ is also activated by G protein‐coupled receptors and cell swelling. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4325> are examples of triphenylethylene anti‐oestrogens

Comments {#bph14749-sec-0134}
--------

Differing ionic conditions may contribute to variable estimates of γ reported in the literature. Inhibition by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> (and cis‐unsaturated fatty acids) is voltageindependent, occurs at an intracellular site, and involves both channel shut down (K*d* = 4‐5 *μ*M) and a reduction of γ (K*d* = 1314 *μ*M). Blockade of channel activity by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4314>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>, Gd^3+^ and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> is paralleled by decreased swelling‐induced release of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> \[<http://www.ncbi.nlm.nih.gov/pubmed/12154180?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11524456?dopt=AbstractPlus>\]. Channel activation by anti‐oestrogens in whole cell recordings requires the presence of intracellular nucleotides and is prevented by pre‐treatment with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5485>, or intracellular dialysis with GDPβS \[<http://www.ncbi.nlm.nih.gov/pubmed/11579158?dopt=AbstractPlus>\]. Activation by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> is suppressed by low concentrations of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5349>, suggesting that a dephosphorylation event by protein phosphatase PP2A occurs in the activation pathway \[<http://www.ncbi.nlm.nih.gov/pubmed/11579158?dopt=AbstractPlus>\]. In contrast, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016> appear to directly inhibit the maxi Cl^‐^ channel of human placenta reconstituted into giant liposomes and recorded in excised patches \[<http://www.ncbi.nlm.nih.gov/pubmed/19604577?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=132> {#bph14749-sec-0135}
===========================================================================

Overview {#bph14749-sec-0136}
--------

Volume activated chloride channels (also termed VSOAC, volume‐sensitive organic osmolyte/anion channel; VRC, volume regulated channel and VSOR, volume expansion‐sensing outwardly rectifying anion channel) participate in regulatory volumedecrease(RVD) inresponse tocell swelling. VRAC may also be important for several other processes including the regulation of membrane excitability, transcellular Cl^‐^ transport, angiogenesis, cell proliferation, necrosis, apoptosis, glutamate release from astrocytes, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6081](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6081), <http://www.uniprot.org/uniprot/P01308>) release from pancreatic β cells and resistance to the anti‐cancer drug, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5343> (reviewed by \[<http://www.ncbi.nlm.nih.gov/pubmed/21099297?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17047222?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12558550?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19171657?dopt=AbstractPlus>\]). VRAC may not be a single entity, but may instead represent a number of different channels that are expressed to a variable extent in different tissues and are differentially activated by cell swelling. In addition to ClC‐3 expression products (see above) several former VRAC candidates including *MDR1* (ABCB1 P‐glycoprotein), Icln, Band 3 anion exchanger and phospholemman are also no longer considered likely to fulfil this function (see reviews \[<http://www.ncbi.nlm.nih.gov/pubmed/12558550?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14729152?dopt=AbstractPlus>\]).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710>Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4207>Endogenous channel blockersintracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4100>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4113>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4174>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4177>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4217>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4270>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4273>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4159>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4176>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4204>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4252>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2522>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4263>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4265>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016>Functional Characteristicsγ = 10--20 pS (negative potentials), 50--90 pS (positive potentials); permeability sequence SCN \> I \> NO~3~ ^‐^ \>Br^‐^ \> Cl^‐^ \> F^‐^ \> gluconate; outward rectification due to voltage dependence of γ; inactivates at positive potentials in many, but not all, cell types; time dependent inactivation at positive potentials; intracellular ionic strength modulates sensitivity to cell swelling and rate of channel activation; rate of swelling‐induced activation is modulated by intracellular ATP concentration; ATP dependence is independent of hydrolysis and modulated by rate of cell swelling; inhibited by increased intracellular free Mg^2+^ concentration; swelling induced activation of several intracellular signalling cascades may be permissive of, but not essential to, the activation of VRAC including: the Rho‐Rho kinase‐MLCK; Ras‐Raf‐MEK‐ERK; PIK3‐NOX‐H~2~O~2~ and Src‐PLCγ‐Ca^2+^ pathways; regulation by PKCα required for optimal activity; cholesterol depletion enhances activity; activated by direct stretch of β1‐integrinCommentsVRAC is also activated by cell swelling and low intracellular ionic strength. VRAC is also blocked by chromones, extracellular nucleotides and nucleoside analogues

Comments {#bph14749-sec-0137}
--------

In addition to conducting monovalent anions, in many cell types the activation of VRAC by a hypotonic stimulus can allow the efflux of organic osmolytes such as amino acids and polyols that may contribute to RVD.

Comments on Chloride channels: Other chloride channels {#bph14749-sec-0138}
------------------------------------------------------

In addition to some intracellular chloride channels that are not considered here, plasma membrane channels other than those listed have been functionally described. Many cells and tissues contain outwardly rectifying chloride channels (ORCC) that may correspond to VRAC active under isotonic conditions. A <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>‐activated Cl^‐^ channel that does not correspond to CFTR has been described in intestinal Paneth cells \[<http://www.ncbi.nlm.nih.gov/pubmed/9769420?dopt=AbstractPlus>\]. A Cl channel activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> with a dependence on raised intracellular Ca^2+^ has been recorded in various vascular smooth muscle cells types, which has a pharmacology and biophysical characteristics very different from the 'conventional' CaCC \[<http://www.ncbi.nlm.nih.gov/pubmed/14718479?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14724180?dopt=AbstractPlus>\]. It has been proposed that <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5377> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17105](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17105), <http://www.uniprot.org/uniprot/Q8N1M1>) is an essential component of the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>‐activated channel \[<http://www.ncbi.nlm.nih.gov/pubmed/18776041?dopt=AbstractPlus>\]. A proton‐activated, outwardly rectifying anion channel has also been described \[<http://www.ncbi.nlm.nih.gov/pubmed/15961423?dopt=AbstractPlus>\].

Further reading on Chloride channels {#bph14749-sec-0139}
------------------------------------

Adkins GB *et al.* (2015) Potential role of cardiac chloride channels and transporters as novel therapeutic targets. *Pharmacol. Ther.* **145**: 67--75 \[<https://www.ncbi.nlm.nih.gov/pubmed/25160469?dopt=AbstractPlus>\]

Huang F *et al.* (2012) International Union of Basic and Clinical Pharmacology. LXXXV: calciumactivated chloride channels. *Pharmacol. Rev.* **64**: 1--15 \[<https://www.ncbi.nlm.nih.gov/pubmed/22090471?dopt=AbstractPlus>\]

KamaleddinMA.(2018)Molecular, biophysical, and pharmacological properties of calcium‐activated chloride channels. *J. Cell. Physiol.* **233**: 787--798 \[<https://www.ncbi.nlm.nih.gov/pubmed/28121009?dopt=AbstractPlus>\]

Kunzelmann K. (2015) TMEM16, LRRC8A, bestrophin: chloride channels controlled by Ca(2+) and cell volume. *Trends Biochem. Sci.* **40**: 535--43 \[<https://www.ncbi.nlm.nih.gov/pubmed/26254230?dopt=AbstractPlus>\]

Pedersen SF *et al.* (2016) Biophysics and Physiology of the Volume‐Regulated Anion Channel (VRAC)/Volume‐Sensitive Outwardly Rectifying Anion Channel (VSOR). *Pflugers Arch.* **468**: 371--83 \[<https://www.ncbi.nlm.nih.gov/pubmed/26739710?dopt=AbstractPlus>\]

Peretti M *et al.* (2015) Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. *Biochim. Biophys. Acta* **1848**: 2523--31 \[<https://www.ncbi.nlm.nih.gov/pubmed/25546839?dopt=AbstractPlus>\]

Sabirov RZ *et al.* (2016) The properties, functions, and pathophysiology of maxi‐anion channels. *Pflugers Arch.* **468**: 405--20 \[<https://www.ncbi.nlm.nih.gov/pubmed/26733413?dopt=AbstractPlus>\]

Zegarra‐Moran O *et al.* (2017) CFTR pharmacology. *Cell. Mol. Life Sci.* **74**: 117--128 \[<https://www.ncbi.nlm.nih.gov/pubmed/27704174?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=121> {#bph14749-sec-0140}
===========================================================================

Overview {#bph14749-sec-0141}
--------

Gap junctions are essential for many physiological processes including cardiac and smooth muscle contraction, regulation of neuronal excitability and epithelial electrolyte transport \[<http://www.ncbi.nlm.nih.gov/pubmed/14597722?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15217338?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12126230?dopt=AbstractPlus>\]. Gap junction channels allow the passive diffusion of molecules of up to 1,000 Daltons which can include nutrients, metabolites and second messengers (such as IP~3~) as well as cations and anions. 21 connexin genes and 3 pannexin genes which are structurally related to the invertebrate innexin genes) code for gap junction proteins in humans. Each connexin gap junction comprises 2 hemichannels or 'connexons' which are themselves formed from 6 connexin molecules. The various connexins have been observed to combine into both homomeric and heteromeric combinations, each of which may exhibit different functional properties. Itis also suggested that individual hemichannels formed by a number of different connexins might be functional in at least some cells \[<http://www.ncbi.nlm.nih.gov/pubmed/17507078?dopt=AbstractPlus>\]. Connexins have a common topology, with four α‐helical transmembrane domains, two extracellular loops, a cytoplasmic loop, and N‐ and C‐termini located on the cytoplasmic membrane face. In mice, the most abundant connexins in electrical synapses in the brain seem to be Cx36, Cx45 and Cx57 \[<http://www.ncbi.nlm.nih.gov/pubmed/15738956?dopt=AbstractPlus>\]. Mutations in connexin genes are associated with the occurrence of a number of pathologies, such as peripheral neuropathies, cardiovascular diseases and hereditary deafness. The pannexin genes Px1 and Px2 are widely expressed in the mammalian brain \[<http://www.ncbi.nlm.nih.gov/pubmed/16143426?dopt=AbstractPlus>\]. Like the connexins, at least some of the pannexins can form hemichannels \[<http://www.ncbi.nlm.nih.gov/pubmed/14597722?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17121814?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=714><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=715><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=716><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=717><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=718><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=719><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=720>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:33251](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33251), <http://www.uniprot.org/uniprot/A6NN92>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16690](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16690), <http://www.uniprot.org/uniprot/Q6PEY0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4284](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4284), <http://www.uniprot.org/uniprot/P29033>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4288](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4288), <http://www.uniprot.org/uniprot/O95452>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17495](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17495), <http://www.uniprot.org/uniprot/Q8NFK1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4286](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4286), <http://www.uniprot.org/uniprot/Q9NTQ9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4285](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4285), <http://www.uniprot.org/uniprot/O75712>Endogenous inhibitors extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (blocked by raising external Ca^2+^)Inhibitors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278> Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=721><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=722><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=723><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=724><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=725><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=726><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=727>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4287](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4287), <http://www.uniprot.org/uniprot/O95377>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19147](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19147), <http://www.uniprot.org/uniprot/Q8N144>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4283](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4283), <http://www.uniprot.org/uniprot/P08034>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19154](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19154), <http://www.uniprot.org/uniprot/Q9UKL4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4278](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4278), <http://www.uniprot.org/uniprot/P35212>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4279](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4279), <http://www.uniprot.org/uniprot/P36382>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23296](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23296), <http://www.uniprot.org/uniprot/Q96KN9>Endogenous inhibitors extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (blocked by raising external Ca^2+^)Inhibitors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278> Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=728><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=729><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=730><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=731><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=732><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=733><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=734>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4274](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4274), <http://www.uniprot.org/uniprot/P17302>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4280](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4280), <http://www.uniprot.org/uniprot/P36383>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4277](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4277), <http://www.uniprot.org/uniprot/Q9Y6H8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17494](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17494), <http://www.uniprot.org/uniprot/Q5T442>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4281](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4281), <http://www.uniprot.org/uniprot/P48165>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19155](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19155), <http://www.uniprot.org/uniprot/P57773>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16995](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16995), <http://www.uniprot.org/uniprot/Q969M2>Endogenous inhibitors extracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> (blocked by raising external Ca^2+^)Inhibitors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4278> Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=735><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=736><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=737>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8599](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8599), <http://www.uniprot.org/uniprot/Q96RD7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8600](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8600), <http://www.uniprot.org/uniprot/Q96RD6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20573](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20573), <http://www.uniprot.org/uniprot/Q96QZ0>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (little block by flufenamic acid)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (little block by flufenamic acid)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> (little block by flufenamic acid)CommentsUnaffected by raising external Ca^2+^Unaffected by raising external Ca^2+^Unaffected by raising external Ca^2+^

Comments {#bph14749-sec-0142}
--------

Connexins are most commonly named according to their molecular weights, so, for example, Cx23 is the connexin protein of 23 kDa. This can cause confusion when comparing between species -- for example, the mouse connexin Cx57 is orthologous to the human connexin Cx62. No natural toxin or specific inhibitor of junctional channels has been identified yet however two compounds often used experimentally to block connexins are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> \[<http://www.ncbi.nlm.nih.gov/pubmed/16216217?dopt=AbstractPlus>\]. At least some pannexin hemichannels are more sensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4151> than connexins but much less sensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447> \[<http://www.ncbi.nlm.nih.gov/pubmed/15715654?dopt=AbstractPlus>\]. It has been suggested that 2‐aminoethoxydiphenyl borate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433>) may be a more effective blocker of some connexin channel subtypes (Cx26, Cx30, Cx36, Cx40, Cx45, Cx50) compared to others (Cx32, Cx43, Cx46, \[<http://www.ncbi.nlm.nih.gov/pubmed/16985167?dopt=AbstractPlus>\]).

Further reading on Connexins and Pannexins {#bph14749-sec-0143}
------------------------------------------

Decrock E *et al.* (2015) Connexin and pannexin signaling pathways, an architectural blueprint for CNS physiology and pathology? *Cell. Mol. Life Sci.* **72**: 2823--51 \[<https://www.ncbi.nlm.nih.gov/pubmed/26118660?dopt=AbstractPlus>\]

Esseltine JL *et al.* (2016) Next‐Generation Connexin and Pannexin Cell Biology. *Trends Cell Biol.* **26**: 944--955 \[<https://www.ncbi.nlm.nih.gov/pubmed/27339936?dopt=AbstractPlus>\]

Freund‐Michel V *et al.* (2016) Expression and role of connexin‐based gap junctions in pulmonary inflammatory diseases. *Pharmacol. Ther.* **164**: 105--19 \[<https://www.ncbi.nlm.nih.gov/pubmed/27126473?dopt=AbstractPlus>\]

Harris AL. (2018) Electrical coupling and its channels. *J. Gen. Physiol.* **150**: 1606--1639 \[<https://www.ncbi.nlm.nih.gov/pubmed/30389716?dopt=AbstractPlus>\]

Sáez JC *et al.* (2015) Regulation of pannexin and connexin channels and their functional role in skeletal muscles. *Cell. Mol. Life Sci.* **72**: 2929--35 \[<https://www.ncbi.nlm.nih.gov/pubmed/26084874?dopt=AbstractPlus>\]

Willebrords J *et al.* (2017) Inhibitors of connexin and pannexin channels as potential therapeutics. *Pharmacol. Ther.* **180**: 144--160 \[<https://www.ncbi.nlm.nih.gov/pubmed/28720428?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=967> {#bph14749-sec-0144}
===========================================================================

Overview {#bph14749-sec-0145}
--------

Piezo proteins are the pore‐forming subunits of trimeric mechanosensitive ion channels that open in response to mechanical stimuli such as shear stress and membrane stretch, allowing positively charged ions, including calcium, to flow into the cell. Piezo orthologs have thus far been identified in numerous eukaryotes. Most vertebrates have two channel isoforms, Piezol and Piezo2. Across species, Piezos are very large proteins (2521 and 2752 amino acids for human Piezo1 and human Piezo2, respectively) with numerous (\>14) predicted transmembrane (TM) domains per subunit and, strikingly, no homology to other known proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/27743844?dopt=AbstractPlus>\]. Piezo channels play a critical role in sensory neuron transduction \[<http://www.ncbi.nlm.nih.gov/pubmed/30305457?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/30361375?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2945><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2946>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28993](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28993), <http://www.uniprot.org/uniprot/Q92508>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26270](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26270), <http://www.uniprot.org/uniprot/Q9H5I5>Selective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9817> (pEC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26001275?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10111> (pEC~50~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/29610524?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10249> \[<http://www.ncbi.nlm.nih.gov/pubmed/29610524?dopt=AbstractPlus>\] -- Mouse--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10112> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/29498036?dopt=AbstractPlus>\]--Functional CharacteristicsMechano‐activatedMechano‐activated

Comments {#bph14749-sec-0146}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9817> is a Piezo1 channel activator \[<http://www.ncbi.nlm.nih.gov/pubmed/29498036?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/27797339?dopt=AbstractPlus>\].

Further reading on Piezo channels {#bph14749-sec-0147}
---------------------------------

Chesler AT *et al.* (2018) Portraits of a pressure sensor. *Elife* **7**: \[<https://www.ncbi.nlm.nih.gov/pubmed/29376828?dopt=AbstractPlus>\]

Ehmke H. (2018) The mechanotransduction of blood pressure. *Science* **362**: 398--399 \[<https://www.ncbi.nlm.nih.gov/pubmed/30361358?dopt=AbstractPlus>\]

Gottlieb PA*etal*. (2012)Piezo1: propertiesof a cation selective mechanical channel. *Channels(Austin)* **6**: 214--9 \[<https://www.ncbi.nlm.nih.gov/pubmed/22790400?dopt=AbstractPlus>\]

Parpaite T *et al.* (2017) Piezo channels. *Curr. Biol.* **27**: R250‐R252 \[<https://www.ncbi.nlm.nih.gov/pubmed/28376327?dopt=AbstractPlus>\]

Volkers L *et al.* (2015) Piezo channels: from structure to function. *Pflugers Arch.* **467**: 95--9 \[<https://www.ncbi.nlm.nih.gov/pubmed/25037583?dopt=AbstractPlus>\]

Wu J *et al.* (2017) Touch, Tension, and Transduction ‐ The Function and Regulation of Piezo Ion Channels. *Trends Biochem. Sci.* **42**: 57--71 \[<https://www.ncbi.nlm.nih.gov/pubmed/27743844?dopt=AbstractPlus>\]

Zeng WZ *etal*. (2018)PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex. *Science* **362**: 464--467 \[<https://www.ncbi.nlm.nih.gov/pubmed/30361375?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=126> {#bph14749-sec-0148}
===========================================================================

Overview {#bph14749-sec-0149}
--------

The sodium leak channel, non selective (**[NC‐IUPHAR]{.ul} tentatively recommends the nomenclature Na~Vi~2.1, W.A. Catterall, personal communication**) is structurally a member of the family of voltage‐gated sodium channel family (Na~v~1.1‐Na~v~1.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10094463?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15467096?dopt=AbstractPlus>\]. In contrast to the latter, Na~Vi~2.1, is voltage‐insensitive (denoted in the subscript 'vi' in the tentative nomenclature) and possesses distinctive ion selectivity and pharmacological properties. Na~Vi~2.1, which is insensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616> (10 *μ*M), has been proposed to mediate the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2616>‐resistant and voltage‐insensitive Na^+^ leak current (I~L~‐Na) observed in many types of neurone \[<http://www.ncbi.nlm.nih.gov/pubmed/17448995?dopt=AbstractPlus>\]. However, whether Na~Vi~2.1 is constitutively active has been challenged \[<http://www.ncbi.nlm.nih.gov/pubmed/19575010?dopt=AbstractPlus>\]. Na~Vi~2.1 is widely distributed within the central nervous system and is also expressed in the heart and pancreas specifically, in rodents, within the islets of Langerhans \[<http://www.ncbi.nlm.nih.gov/pubmed/10094463?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17448995?dopt=AbstractPlus>\]. Recently, Na~Vi~2.1 has been proposed to be a core effector for the action of inhibitory G proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/30556810?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=750>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19082](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19082), <http://www.uniprot.org/uniprot/Q8IZF0>ActivatorsConstitutively active (Lu *et al*., 2007), or activated downstream of Src family tyrosine kinases (SFKs) (Lu *et al*.,2009; Swayne *et al*., 2009); positively modulated by decreased extracellular Ca^2+^ concentration (Lu *et al*., 2010) \[<http://www.ncbi.nlm.nih.gov/pubmed/17448995?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19092807?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21040849?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19575010?dopt=AbstractPlus>\]Channel blockers<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426> (pIC~50~ 5.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2440> (pIC~50~ 3.8), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4160> (pIC~50~ 3.6), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406> (pIC~50~ 3.4)Functional Characteristicsγ = 27 pS (by fluctuation analysis), *P* ~Na~/*P* ~Cs~ = 1.3, *P* ~K~/*P* ~Cs~ = 1.2, *P* ~Ca~/*P* ~Cs~ = 0.5, linear current voltage‐relationship, voltage‐independent and non‐inactivating

Comments {#bph14749-sec-0150}
--------

In native and recombinant expression systems Na~Vi~2.1 can be activated by stimulation of NK~1~ (in hippocampal neurones), neurotensin (in ventral tegmental area neurones) and M3 muscarinic acetylcholine receptors (in MIN6 pancreatic β‐cells) and in a manner that is independent of signalling through G proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/19092807?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19575010?dopt=AbstractPlus>\]. Pharmacological and molecular biological evidence indicates such modulation to occur though a pathway that involves the activation of Src family tyrosine kinases. It is suggested that Na~Vi~2.1 exists as a macromolecular complex with M3 receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/19575010?dopt=AbstractPlus>\] and peptide receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/19092807?dopt=AbstractPlus>\], in the latter instance in association with the protein UNC‐80, which recruits Src to the channel complex \[<http://www.ncbi.nlm.nih.gov/pubmed/19092807?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19535918?dopt=AbstractPlus>\]. By contrast, stimulation of Na~Vi~2.1 by decreased extracellular Ca^2+^ concentration is G protein dependent and involves a Ca^2+^‐sensing G protein‐coupled receptor and UNC80 which links Na~Vi~2.1 to the protein UNC79 in the same complex \[<http://www.ncbi.nlm.nih.gov/pubmed/21040849?dopt=AbstractPlus>\]. Na~Vi~2.1 null mutant mice have severe disturbances in respiratory rhythm and die within 24 hours of birth \[<http://www.ncbi.nlm.nih.gov/pubmed/17448995?dopt=AbstractPlus>\]. Na~Vi~2.1 heterozygous knockout mice display increased serum sodium concentrations in comparison to wildtype littermates and a role for the channel in osmoregulation has been postulated \[<http://www.ncbi.nlm.nih.gov/pubmed/21177381?dopt=AbstractPlus>\].

Further reading on Sodium leak channel, non‐selective {#bph14749-sec-0151}
-----------------------------------------------------

Cochet‐Bissuel M *et al*. (2014) The sodium leak channel, NALCN, in health and disease. *Front Cell Neurosci* **8**: 132 \[<https://www.ncbi.nlm.nih.gov/pubmed/24904279?dopt=AbstractPlus>\]

Lu TZ *et al*. (2012) NALCN: a regulator of pacemaker activity. *Mol. Neurobiol*. **45**: 415‐23 \[<https://www.ncbi.nlm.nih.gov/pubmed/22476981?dopt=AbstractPlus>\]

Philippart F *et al*. (2018) G_i/o protein‐coupled receptors in dopamine neurons inhibit the sodium leak channel NALCN. *Elife* **7**: \[<https://www.ncbi.nlm.nih.gov/pubmed/30556810?dopt=AbstractPlus>\]

Waxman SG *et al*. (2014) Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat. Neurosci*. **17**: 153‐63 \[<https://www.ncbi.nlm.nih.gov/pubmed/24473263?dopt=AbstractPlus>\]
